{
  "paragraphs": [
    {
      "text": "%python\nfrom neo4j import GraphDatabase\nimport pandas as pd\nimport numpy as np\nimport json\nfrom googletrans import Translator\nimport itertools\nimport requests",
      "user": "anonymous",
      "dateUpdated": "2019-02-04 08:07:27.819",
      "config": {
        "colWidth": 12.0,
        "fontSize": 9.0,
        "enabled": true,
        "results": {},
        "editorSetting": {
          "language": "python",
          "editOnDblClick": false,
          "completionKey": "TAB",
          "completionSupport": true
        },
        "editorMode": "ace/mode/python"
      },
      "settings": {
        "params": {},
        "forms": {}
      },
      "results": {
        "code": "SUCCESS",
        "msg": []
      },
      "apps": [],
      "jobName": "paragraph_1548502568445_-1771772463",
      "id": "20190126-093608_2129981658",
      "dateCreated": "2019-01-26 09:36:08.445",
      "dateStarted": "2019-02-04 08:07:28.527",
      "dateFinished": "2019-02-04 08:08:16.566",
      "status": "FINISHED",
      "progressUpdateIntervalMs": 500
    },
    {
      "text": "%python\n\n\ndef get_proxy_list():\n    url_proxy \u003d \u0027https://free-proxy-list.net/\u0027\n    response \u003d requests.get(url_proxy)\n    df \u003d pd.read_html(response.text)\n    df_proxies \u003d df[0]\n    df_proxies.columns \u003d [\u0027ip_address\u0027, \u0027port\u0027, \u0027code\u0027, \u0027country\u0027, \u0027anonymity\u0027,\u0027google\u0027, \u0027https\u0027, \u0027last_checked\u0027]\n    df_proxies[\u0027port\u0027] \u003d df_proxies[\u0027port\u0027].astype(str).str[:-2]\n    df_proxies[\u0027address\u0027] \u003d df_proxies[\u0027ip_address\u0027]+\u0027:\u0027+df_proxies[\u0027port\u0027]\n    \n    \n    proxy_ips \u003d df_proxies[(df_proxies.anonymity \u003d\u003d \u0027elite proxy\u0027) \u0026 (df_proxies.https \u003d\u003d \u0027yes\u0027)][\u0027address\u0027]\n    \n    return proxy_ips\n    \n    \n#get_proxy_list()",
      "user": "anonymous",
      "dateUpdated": "2019-02-05 22:38:55.260",
      "config": {
        "colWidth": 12.0,
        "fontSize": 9.0,
        "enabled": true,
        "results": {},
        "editorSetting": {
          "language": "python",
          "editOnDblClick": false,
          "completionKey": "TAB",
          "completionSupport": true
        },
        "editorMode": "ace/mode/python"
      },
      "settings": {
        "params": {},
        "forms": {}
      },
      "results": {
        "code": "SUCCESS",
        "msg": []
      },
      "apps": [],
      "jobName": "paragraph_1549207505727_1137322793",
      "id": "20190203-132505_544218281",
      "dateCreated": "2019-02-03 13:25:05.727",
      "dateStarted": "2019-02-05 22:38:55.333",
      "dateFinished": "2019-02-05 22:38:55.419",
      "status": "FINISHED",
      "progressUpdateIntervalMs": 500
    },
    {
      "text": "%python\n\ndef translate(text,src,dest):\n    \n    for proxy in get_proxy_list():\n        try:\n            translator \u003d Translator(proxies\u003d{\u0027https\u0027:proxy},timeout\u003d5)\n            t \u003d translator.translate(text, dest\u003ddest, src\u003dsrc)\n            if t.text !\u003d \u0027\u0027:\n                return t.text.strip()\n        except Exception as err:\n            print(err)",
      "user": "anonymous",
      "dateUpdated": "2019-02-04 08:08:08.266",
      "config": {
        "colWidth": 12.0,
        "fontSize": 9.0,
        "enabled": true,
        "results": {},
        "editorSetting": {
          "language": "python",
          "editOnDblClick": false,
          "completionKey": "TAB",
          "completionSupport": true
        },
        "editorMode": "ace/mode/python"
      },
      "settings": {
        "params": {},
        "forms": {}
      },
      "results": {
        "code": "SUCCESS",
        "msg": []
      },
      "apps": [],
      "jobName": "paragraph_1549195408342_1526899720",
      "id": "20190203-100328_1643559974",
      "dateCreated": "2019-02-03 10:03:28.343",
      "dateStarted": "2019-02-04 08:08:17.292",
      "dateFinished": "2019-02-04 08:08:19.793",
      "status": "FINISHED",
      "progressUpdateIntervalMs": 500
    },
    {
      "text": "%python\n\nuri \u003d \"bolt://172.17.0.3:7687\"\nuser\u003d\u0027neo4j\u0027\npassword\u003d\u0027neo4j2018\u0027\n\nbulas_df  \u003d pd.read_csv(\"/home/altieris/datascience/data/bulario/cleansed/bulas-tagged.csv\",sep\u003d\u0027;\u0027)\n\ndrugbank_df \u003d pd.read_csv(\u0027/home/altieris/datascience/data/bulario/drugbank/drugbank.tsv\u0027, sep\u003d\u0027\\t\u0027)\ndrugbank_df[\u0027lower_name\u0027] \u003d drugbank_df[\u0027name\u0027].map(lambda x : x.lower())\n\n\ninterations_df \u003d pd.read_csv(\u0027/home/altieris/datascience/data/bulario/drugbank/drugbank_interations_df.tsv\u0027, sep\u003d\u0027\\t\u0027)\n",
      "user": "anonymous",
      "dateUpdated": "2019-02-04 08:08:11.587",
      "config": {
        "colWidth": 12.0,
        "fontSize": 9.0,
        "enabled": true,
        "results": {},
        "editorSetting": {
          "language": "python",
          "editOnDblClick": false,
          "completionKey": "TAB",
          "completionSupport": true
        },
        "editorMode": "ace/mode/python"
      },
      "settings": {
        "params": {},
        "forms": {}
      },
      "results": {
        "code": "SUCCESS",
        "msg": []
      },
      "apps": [],
      "jobName": "paragraph_1548502281381_1713775657",
      "id": "20190126-093121_1304408655",
      "dateCreated": "2019-01-26 09:31:21.381",
      "dateStarted": "2019-02-04 08:08:20.129",
      "dateFinished": "2019-02-04 08:08:52.643",
      "status": "FINISHED",
      "progressUpdateIntervalMs": 500
    },
    {
      "text": "%python\ndf_translated \u003d pd.read_csv(\"/home/altieris/datascience/data/bulario/drugbank/drugbank_translated.csv\",sep\u003d\u0027\\t\u0027, names\u003d[\u0027drugbank_id\u0027,\u0027name\u0027,\u0027name_pt_br\u0027])\n#df_translated[\u0027lower_name\u0027] \u003d df_translated[\u0027name_pt_br\u0027].map(lambda x : x.lower())",
      "user": "anonymous",
      "dateUpdated": "2019-02-05 21:54:25.839",
      "config": {
        "colWidth": 12.0,
        "fontSize": 9.0,
        "enabled": true,
        "results": {},
        "editorSetting": {
          "language": "python",
          "editOnDblClick": false,
          "completionKey": "TAB",
          "completionSupport": true
        },
        "editorMode": "ace/mode/python"
      },
      "settings": {
        "params": {},
        "forms": {}
      },
      "results": {
        "code": "SUCCESS",
        "msg": []
      },
      "apps": [],
      "jobName": "paragraph_1549202137221_1915312622",
      "id": "20190203-115537_482673414",
      "dateCreated": "2019-02-03 11:55:37.221",
      "dateStarted": "2019-02-05 21:54:25.911",
      "dateFinished": "2019-02-05 21:54:26.121",
      "status": "FINISHED",
      "progressUpdateIntervalMs": 500
    },
    {
      "text": "%python\ndf_translated[\u0027lower_name\u0027] \u003d df_translated[\u0027name_pt_br\u0027].map(lambda x : str(x).lower())",
      "user": "anonymous",
      "dateUpdated": "2019-02-05 21:55:11.079",
      "config": {
        "colWidth": 12.0,
        "fontSize": 9.0,
        "enabled": true,
        "results": {},
        "editorSetting": {
          "language": "python",
          "editOnDblClick": false,
          "completionKey": "TAB",
          "completionSupport": true
        },
        "editorMode": "ace/mode/python"
      },
      "settings": {
        "params": {},
        "forms": {}
      },
      "results": {
        "code": "SUCCESS",
        "msg": []
      },
      "apps": [],
      "jobName": "paragraph_1549410873791_-1792633194",
      "id": "20190205-215433_861779203",
      "dateCreated": "2019-02-05 21:54:33.791",
      "dateStarted": "2019-02-05 21:55:11.158",
      "dateFinished": "2019-02-05 21:55:11.296",
      "status": "FINISHED",
      "progressUpdateIntervalMs": 500
    },
    {
      "text": "%python\nz.show(df_translated[(df_translated[\u0027name\u0027] \u003d\u003d \u0027Acebrophilin\u0027 )].head(50))\n#disease_df \u003d bulas_df[(bulas_df[\u0027indicacao_keywords\u0027].str.contains(disease)\u003d\u003dTrue) \u0026 (bulas_df[\u0027contraindicacao_keywords\u0027].str.contains(disease)\u003d\u003dFalse)]",
      "user": "anonymous",
      "dateUpdated": "2019-02-05 22:22:38.921",
      "config": {
        "colWidth": 12.0,
        "fontSize": 9.0,
        "enabled": true,
        "results": {
          "0": {
            "graph": {
              "mode": "table",
              "height": 300.0,
              "optionOpen": false,
              "setting": {
                "table": {
                  "tableGridState": {},
                  "tableColumnTypeState": {
                    "names": {
                      "drugbank_id": "string",
                      "name": "string",
                      "name_pt_br": "string",
                      "lower_name": "string"
                    },
                    "updated": false
                  },
                  "tableOptionSpecHash": "[{\"name\":\"useFilter\",\"valueType\":\"boolean\",\"defaultValue\":false,\"widget\":\"checkbox\",\"description\":\"Enable filter for columns\"},{\"name\":\"showPagination\",\"valueType\":\"boolean\",\"defaultValue\":false,\"widget\":\"checkbox\",\"description\":\"Enable pagination for better navigation\"},{\"name\":\"showAggregationFooter\",\"valueType\":\"boolean\",\"defaultValue\":false,\"widget\":\"checkbox\",\"description\":\"Enable a footer for displaying aggregated values\"}]",
                  "tableOptionValue": {
                    "useFilter": false,
                    "showPagination": false,
                    "showAggregationFooter": false
                  },
                  "updated": false,
                  "initialized": false
                }
              },
              "commonSetting": {}
            }
          }
        },
        "editorSetting": {
          "language": "python",
          "editOnDblClick": false,
          "completionKey": "TAB",
          "completionSupport": true
        },
        "editorMode": "ace/mode/python"
      },
      "settings": {
        "params": {},
        "forms": {}
      },
      "results": {
        "code": "SUCCESS",
        "msg": [
          {
            "type": "TABLE",
            "data": "drugbank_id\tname\tname_pt_br\tlower_name\n"
          }
        ]
      },
      "apps": [],
      "jobName": "paragraph_1549202309344_1390834201",
      "id": "20190203-115829_780735162",
      "dateCreated": "2019-02-03 11:58:29.344",
      "dateStarted": "2019-02-05 22:22:38.986",
      "dateFinished": "2019-02-05 22:22:39.091",
      "status": "FINISHED",
      "progressUpdateIntervalMs": 500
    },
    {
      "text": "%python\n\ndf_translated \u003d pd.read_csv(\"/home/altieris/datascience/data/bulario/drugbank/drugbank_translated.csv\",sep\u003d\u0027\\t\u0027, names\u003d[\u0027drugbank_id\u0027,\u0027name\u0027,\u0027name_pt_br\u0027])\n\ndrugbank_pt_br \u003d drugbank_df[[\u0027drugbank_id\u0027,\u0027name\u0027]]\ndrugbank_pt_br \u003d drugbank_pt_br[~drugbank_pt_br[\u0027drugbank_id\u0027].isin(df_translated[\u0027drugbank_id\u0027].values)]\n\ndf_pt_br \u003d pd.DataFrame(columns\u003d[\u0027drugbank_id\u0027,\u0027name\u0027,\u0027name_pt_br\u0027])\n\ndict1 \u003d dict() \nfor index, row in drugbank_pt_br.iterrows():\n   \n    try:\n       \n    \n        dict1[\u0027drugbank_id\u0027] \u003d row[\u0027drugbank_id\u0027]\n        dict1[\u0027name\u0027] \u003d row[\u0027name\u0027]\n        name_pt_br \u003d translate(row[\u0027name\u0027],\u0027en\u0027,\u0027pt\u0027) \n        dict1[\u0027name_pt_br\u0027] \u003d name_pt_br\n     \n        df \u003d pd.DataFrame(dict1,index \u003d [0])\n   \n        df.to_csv(\"/home/altieris/datascience/data/bulario/drugbank/drugbank_translated.csv\", mode\u003d\u0027a\u0027, header\u003dFalse,index\u003dFalse, sep\u003d\u0027\\t\u0027)\n    except Exception as err: \n        print(err)\n        print(\u0027{} - {}\u0027.format(dict1[\u0027drugbank_id\u0027],dict1[\u0027name\u0027]))\n        \n        \n    \n#drugbank_pt_br[\u0027name_pt_br\u0027] \u003d drugbank_pt_br[\u0027name\u0027].map(lambda x : translate(x,\u0027en\u0027,\u0027pt\u0027))\n",
      "user": "anonymous",
      "dateUpdated": "2019-02-05 21:30:45.027",
      "config": {
        "colWidth": 12.0,
        "fontSize": 9.0,
        "enabled": true,
        "results": {},
        "editorSetting": {
          "language": "python",
          "editOnDblClick": false,
          "completionKey": "TAB",
          "completionSupport": true
        },
        "editorMode": "ace/mode/python"
      },
      "settings": {
        "params": {},
        "forms": {}
      },
      "results": {
        "code": "SUCCESS",
        "msg": []
      },
      "apps": [],
      "jobName": "paragraph_1549195334953_-1704215603",
      "id": "20190203-100214_2104513433",
      "dateCreated": "2019-02-03 10:02:14.953",
      "dateStarted": "2019-02-05 21:30:45.101",
      "dateFinished": "2019-02-05 21:30:45.338",
      "status": "FINISHED",
      "progressUpdateIntervalMs": 500
    },
    {
      "text": "%python\nz.show(interations_df)",
      "user": "anonymous",
      "dateUpdated": "2019-02-03 09:55:16.432",
      "config": {
        "colWidth": 12.0,
        "fontSize": 9.0,
        "enabled": true,
        "results": {
          "0": {
            "graph": {
              "mode": "table",
              "height": 300.0,
              "optionOpen": false,
              "setting": {
                "table": {
                  "tableGridState": {
                    "columns": [
                      {
                        "name": "drug_interation_id",
                        "visible": true,
                        "width": 180.0,
                        "sort": {},
                        "filters": [
                          {}
                        ],
                        "pinned": ""
                      },
                      {
                        "name": "name",
                        "visible": true,
                        "width": "*",
                        "sort": {},
                        "filters": [
                          {}
                        ],
                        "pinned": ""
                      },
                      {
                        "name": "description",
                        "visible": true,
                        "width": "*",
                        "sort": {
                          "priority": 0.0,
                          "direction": "asc"
                        },
                        "filters": [
                          {}
                        ],
                        "pinned": ""
                      },
                      {
                        "name": "drugbank_id",
                        "visible": true,
                        "width": "*",
                        "sort": {},
                        "filters": [
                          {}
                        ],
                        "pinned": ""
                      }
                    ],
                    "scrollFocus": {},
                    "selection": [],
                    "grouping": {
                      "grouping": [],
                      "aggregations": [],
                      "rowExpandedStates": {}
                    },
                    "treeView": {},
                    "pagination": {
                      "paginationCurrentPage": 1.0,
                      "paginationPageSize": 250.0
                    }
                  },
                  "tableColumnTypeState": {
                    "names": {
                      "drug_interation_id": "string",
                      "name": "string",
                      "description": "string",
                      "drugbank_id": "string"
                    },
                    "updated": false
                  },
                  "tableOptionSpecHash": "[{\"name\":\"useFilter\",\"valueType\":\"boolean\",\"defaultValue\":false,\"widget\":\"checkbox\",\"description\":\"Enable filter for columns\"},{\"name\":\"showPagination\",\"valueType\":\"boolean\",\"defaultValue\":false,\"widget\":\"checkbox\",\"description\":\"Enable pagination for better navigation\"},{\"name\":\"showAggregationFooter\",\"valueType\":\"boolean\",\"defaultValue\":false,\"widget\":\"checkbox\",\"description\":\"Enable a footer for displaying aggregated values\"}]",
                  "tableOptionValue": {
                    "useFilter": false,
                    "showPagination": false,
                    "showAggregationFooter": false
                  },
                  "updated": false,
                  "initialized": false
                }
              },
              "commonSetting": {}
            }
          }
        },
        "editorSetting": {
          "language": "python",
          "editOnDblClick": false,
          "completionKey": "TAB",
          "completionSupport": true
        },
        "editorMode": "ace/mode/python"
      },
      "settings": {
        "params": {},
        "forms": {}
      },
      "results": {
        "code": "SUCCESS",
        "msg": [
          {
            "type": "TABLE",
            "data": "drug_interation_id\tname\tdescription\tdrugbank_id\nDB06605\tApixaban\tApixaban may increase the anticoagulant activities of Lepirudin.\tDB00001\nDB06695\tDabigatran etexilate\tDabigatran etexilate may increase the anticoagulant activities of Lepirudin.\tDB00001\nDB01254\tDasatinib\tThe risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Lepirudin.\tDB00001\nDB01609\tDeferasirox\tThe risk or severity of gastrointestinal bleeding can be increased when Lepirudin is combined with Deferasirox.\tDB00001\nDB03619\tDeoxycholic Acid\tThe risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Deoxycholic Acid.\tDB00001\nDB09075\tEdoxaban\tThe risk or severity of bleeding can be increased when Edoxaban is combined with Lepirudin.\tDB00001\nDB00078\tIbritumomab tiuxetan\tThe risk or severity of bleeding and hemorrhage can be increased when Lepirudin is combined with Ibritumomab tiuxetan.\tDB00001\nDB09053\tIbrutinib\tThe risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Lepirudin.\tDB00001\nDB09079\tNintedanib\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Nintedanib.\tDB00001\nDB08935\tObinutuzumab\tThe risk or severity of bleeding and hemorrhage can be increased when Lepirudin is combined with Obinutuzumab.\tDB00001\nDB06228\tRivaroxaban\tLepirudin may increase the anticoagulant activities of Rivaroxaban.\tDB00001\nDB06206\tSugammadex\tThe risk or severity of bleeding and hemorrhage can be increased when Lepirudin is combined with Sugammadex.\tDB00001\nDB09070\tTibolone\tTibolone may increase the anticoagulant activities of Lepirudin.\tDB00001\nDB00932\tTipranavir\tThe risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Lepirudin.\tDB00001\nDB00013\tUrokinase\tUrokinase may increase the anticoagulant activities of Lepirudin.\tDB00001\nDB00163\tVitamin E\tVitamin E may increase the anticoagulant activities of Lepirudin.\tDB00001\nDB09030\tVorapaxar\tThe risk or severity of bleeding and hemorrhage can be increased when Vorapaxar is combined with Lepirudin.\tDB00001\nDB01381\tGinkgo biloba\tThe therapeutic efficacy of Lepirudin can be increased when used in combination with Ginkgo biloba.\tDB00001\nDB01181\tIfosfamide\tThe risk or severity of bleeding can be increased when Ifosfamide is combined with Lepirudin.\tDB00001\nDB00468\tQuinine\tThe therapeutic efficacy of Lepirudin can be increased when used in combination with Quinine.\tDB00001\nDB00908\tQuinidine\tThe therapeutic efficacy of Lepirudin can be increased when used in combination with Quinidine.\tDB00001\nDB00675\tTamoxifen\tThe risk or severity of bleeding can be increased when Tamoxifen is combined with Lepirudin.\tDB00001\nDB00539\tToremifene\tThe risk or severity of bleeding can be increased when Toremifene is combined with Lepirudin.\tDB00001\nDB00806\tPentoxifylline\tThe therapeutic efficacy of Lepirudin can be increased when used in combination with Pentoxifylline.\tDB00001\nDB00686\tPentosan Polysulfate\tPentosan Polysulfate may increase the anticoagulant activities of Lepirudin.\tDB00001\nDB00583\tLevocarnitine\tThe therapeutic efficacy of Lepirudin can be increased when used in combination with Levocarnitine.\tDB00001\nDB00048\tCollagenase clostridium histolyticum\tThe risk or severity of bleeding and hemorrhage can be increased when Lepirudin is combined with Collagenase clostridium histolyticum.\tDB00001\nDB00255\tDiethylstilbestrol\tDiethylstilbestrol may decrease the anticoagulant activities of Lepirudin.\tDB00001\nDB00269\tChlorotrianisene\tChlorotrianisene may decrease the anticoagulant activities of Lepirudin.\tDB00001\nDB00286\tConjugated estrogens\tConjugated estrogens may decrease the anticoagulant activities of Lepirudin.\tDB00001\nDB00783\tEstradiol\tEstradiol may decrease the anticoagulant activities of Lepirudin.\tDB00001\nDB00977\tEthinylestradiol\tEthinylestradiol may decrease the anticoagulant activities of Lepirudin.\tDB00001\nDB01357\tMestranol\tMestranol may decrease the anticoagulant activities of Lepirudin.\tDB00001\nDB04573\tEstriol\tEstriol may decrease the anticoagulant activities of Lepirudin.\tDB00001\nDB04574\tEstrone sulfate\tEstrone sulfate may decrease the anticoagulant activities of Lepirudin.\tDB00001\nDB04575\tQuinestrol\tQuinestrol may decrease the anticoagulant activities of Lepirudin.\tDB00001\nDB07931\tHexestrol\tHexestrol may decrease the anticoagulant activities of Lepirudin.\tDB00001\nDB09317\tSynthetic Conjugated Estrogens, A\tSynthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Lepirudin.\tDB00001\nDB09318\tSynthetic Conjugated Estrogens, B\tSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Lepirudin.\tDB00001\nDB09369\tPolyestradiol phosphate\tPolyestradiol phosphate may decrease the anticoagulant activities of Lepirudin.\tDB00001\nDB09381\tEstrogens, esterified\tEstrogens, esterified may decrease the anticoagulant activities of Lepirudin.\tDB00001\nDB11478\tZeranol\tZeranol may decrease the anticoagulant activities of Lepirudin.\tDB00001\nDB11674\tEquol\tEquol may decrease the anticoagulant activities of Lepirudin.\tDB00001\nDB12487\tPromestriene\tPromestriene may decrease the anticoagulant activities of Lepirudin.\tDB00001\nDB13143\tMethallenestril\tMethallenestril may decrease the anticoagulant activities of Lepirudin.\tDB00001\nDB13386\tEpimestrol\tEpimestrol may decrease the anticoagulant activities of Lepirudin.\tDB00001\nDB13418\tMoxestrol\tMoxestrol may decrease the anticoagulant activities of Lepirudin.\tDB00001\nDB13952\tEstradiol acetate\tEstradiol acetate may decrease the anticoagulant activities of Lepirudin.\tDB00001\nDB13953\tEstradiol benzoate\tEstradiol benzoate may decrease the anticoagulant activities of Lepirudin.\tDB00001\nDB13954\tEstradiol cypionate\tEstradiol cypionate may decrease the anticoagulant activities of Lepirudin.\tDB00001\nDB13956\tEstradiol valerate\tEstradiol valerate may decrease the anticoagulant activities of Lepirudin.\tDB00001\nDB09211\tLimaprost\tThe risk or severity of adverse effects can be increased when Limaprost is combined with Lepirudin.\tDB00001\nDB00159\tIcosapent\tThe risk or severity of bleeding and hemorrhage can be increased when Icosapent is combined with Lepirudin.\tDB00001\nDB00328\tIndometacin\tThe risk or severity of bleeding and hemorrhage can be increased when Indometacin is combined with Lepirudin.\tDB00001\nDB00461\tNabumetone\tThe risk or severity of bleeding and hemorrhage can be increased when Nabumetone is combined with Lepirudin.\tDB00001\nDB00465\tKetorolac\tThe risk or severity of bleeding and hemorrhage can be increased when Ketorolac is combined with Lepirudin.\tDB00001\nDB00469\tTenoxicam\tThe risk or severity of bleeding and hemorrhage can be increased when Tenoxicam is combined with Lepirudin.\tDB00001\nDB00482\tCelecoxib\tThe risk or severity of bleeding and hemorrhage can be increased when Celecoxib is combined with Lepirudin.\tDB00001\nDB00500\tTolmetin\tThe risk or severity of bleeding and hemorrhage can be increased when Tolmetin is combined with Lepirudin.\tDB00001\nDB00533\tRofecoxib\tThe risk or severity of bleeding and hemorrhage can be increased when Rofecoxib is combined with Lepirudin.\tDB00001\nDB00554\tPiroxicam\tThe risk or severity of bleeding and hemorrhage can be increased when Piroxicam is combined with Lepirudin.\tDB00001\nDB00573\tFenoprofen\tThe risk or severity of bleeding and hemorrhage can be increased when Fenoprofen is combined with Lepirudin.\tDB00001\nDB00580\tValdecoxib\tThe risk or severity of bleeding and hemorrhage can be increased when Valdecoxib is combined with Lepirudin.\tDB00001\nDB00586\tDiclofenac\tThe risk or severity of bleeding and hemorrhage can be increased when Diclofenac is combined with Lepirudin.\tDB00001\nDB00605\tSulindac\tThe risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Lepirudin.\tDB00001\nDB00712\tFlurbiprofen\tThe risk or severity of bleeding and hemorrhage can be increased when Flurbiprofen is combined with Lepirudin.\tDB00001\nDB00749\tEtodolac\tThe risk or severity of bleeding and hemorrhage can be increased when Etodolac is combined with Lepirudin.\tDB00001\nDB00784\tMefenamic acid\tThe risk or severity of bleeding and hemorrhage can be increased when Mefenamic acid is combined with Lepirudin.\tDB00001\nDB00788\tNaproxen\tThe risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Lepirudin.\tDB00001\nDB00812\tPhenylbutazone\tThe risk or severity of bleeding and hemorrhage can be increased when Phenylbutazone is combined with Lepirudin.\tDB00001\nDB00814\tMeloxicam\tThe risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Lepirudin.\tDB00001\nDB00821\tCarprofen\tThe risk or severity of bleeding and hemorrhage can be increased when Carprofen is combined with Lepirudin.\tDB00001\nDB00870\tSuprofen\tThe risk or severity of bleeding and hemorrhage can be increased when Suprofen is combined with Lepirudin.\tDB00001\nDB00939\tMeclofenamic acid\tThe risk or severity of bleeding and hemorrhage can be increased when Meclofenamic acid is combined with Lepirudin.\tDB00001\nDB00991\tOxaprozin\tThe risk or severity of bleeding and hemorrhage can be increased when Oxaprozin is combined with Lepirudin.\tDB00001\nDB01009\tKetoprofen\tThe risk or severity of bleeding and hemorrhage can be increased when Ketoprofen is combined with Lepirudin.\tDB00001\nDB01283\tLumiracoxib\tThe risk or severity of bleeding and hemorrhage can be increased when Lumiracoxib is combined with Lepirudin.\tDB00001\nDB01397\tMagnesium salicylate\tThe risk or severity of bleeding and hemorrhage can be increased when Magnesium salicylate is combined with Lepirudin.\tDB00001\nDB01399\tSalsalate\tThe risk or severity of bleeding and hemorrhage can be increased when Salsalate is combined with Lepirudin.\tDB00001\nDB01401\tCholine magnesium trisalicylate\tThe risk or severity of bleeding and hemorrhage can be increased when Choline magnesium trisalicylate is combined with Lepirudin.\tDB00001\nDB01419\tAntrafenine\tThe risk or severity of bleeding and hemorrhage can be increased when Antrafenine is combined with Lepirudin.\tDB00001\nDB01424\tAminophenazone\tThe risk or severity of bleeding and hemorrhage can be increased when Aminophenazone is combined with Lepirudin.\tDB00001\nDB01435\tAntipyrine\tThe risk or severity of bleeding and hemorrhage can be increased when Antipyrine is combined with Lepirudin.\tDB00001\nDB01600\tTiaprofenic acid\tThe risk or severity of bleeding and hemorrhage can be increased when Tiaprofenic acid is combined with Lepirudin.\tDB00001\nDB01628\tEtoricoxib\tThe risk or severity of bleeding and hemorrhage can be increased when Etoricoxib is combined with Lepirudin.\tDB00001\nDB02224\tTaxifolin\tThe risk or severity of bleeding and hemorrhage can be increased when Taxifolin is combined with Lepirudin.\tDB00001\nDB03585\tOxyphenbutazone\tThe risk or severity of bleeding and hemorrhage can be increased when Oxyphenbutazone is combined with Lepirudin.\tDB00001\nDB04552\tNiflumic Acid\tThe risk or severity of bleeding and hemorrhage can be increased when Niflumic Acid is combined with Lepirudin.\tDB00001\nDB04743\tNimesulide\tThe risk or severity of bleeding and hemorrhage can be increased when Nimesulide is combined with Lepirudin.\tDB00001\nDB04812\tBenoxaprofen\tThe risk or severity of bleeding and hemorrhage can be increased when Benoxaprofen is combined with Lepirudin.\tDB00001\nDB04817\tMetamizole\tThe risk or severity of bleeding and hemorrhage can be increased when Metamizole is combined with Lepirudin.\tDB00001\nDB04828\tZomepirac\tThe risk or severity of bleeding and hemorrhage can be increased when Zomepirac is combined with Lepirudin.\tDB00001\nDB05095\tCimicoxib\tThe risk or severity of bleeding and hemorrhage can be increased when Cimicoxib is combined with Lepirudin.\tDB00001\nDB06725\tLornoxicam\tThe risk or severity of bleeding and hemorrhage can be increased when Lornoxicam is combined with Lepirudin.\tDB00001\nDB06736\tAceclofenac\tThe risk or severity of bleeding and hemorrhage can be increased when Aceclofenac is combined with Lepirudin.\tDB00001\nDB06737\tZaltoprofen\tThe risk or severity of bleeding and hemorrhage can be increased when Zaltoprofen is combined with Lepirudin.\tDB00001\nDB07402\tAzapropazone\tThe risk or severity of bleeding and hemorrhage can be increased when Azapropazone is combined with Lepirudin.\tDB00001\nDB07477\tFelbinac\tThe risk or severity of bleeding and hemorrhage can be increased when Felbinac is combined with Lepirudin.\tDB00001\nDB08439\tParecoxib\tThe risk or severity of bleeding and hemorrhage can be increased when Parecoxib is combined with Lepirudin.\tDB00001\nDB08797\tSalicylamide\tThe risk or severity of bleeding and hemorrhage can be increased when Salicylamide is combined with Lepirudin.\tDB00001\nDB08940\tKebuzone\tThe risk or severity of bleeding and hemorrhage can be increased when Kebuzone is combined with Lepirudin.\tDB00001\nDB08942\tIsoxicam\tThe risk or severity of bleeding and hemorrhage can be increased when Isoxicam is combined with Lepirudin.\tDB00001\nDB08951\tIndoprofen\tThe risk or severity of bleeding and hemorrhage can be increased when Indoprofen is combined with Lepirudin.\tDB00001\nDB08955\tIbuproxam\tThe risk or severity of bleeding and hemorrhage can be increased when Ibuproxam is combined with Lepirudin.\tDB00001\nDB08976\tFloctafenine\tThe risk or severity of bleeding and hemorrhage can be increased when Floctafenine is combined with Lepirudin.\tDB00001\nDB08981\tFenbufen\tThe risk or severity of bleeding and hemorrhage can be increased when Fenbufen is combined with Lepirudin.\tDB00001\nDB08984\tEtofenamate\tThe risk or severity of bleeding and hemorrhage can be increased when Etofenamate is combined with Lepirudin.\tDB00001\nDB08991\tEpirizole\tThe risk or severity of bleeding and hemorrhage can be increased when Epirizole is combined with Lepirudin.\tDB00001\nDB09084\tBenzydamine\tThe risk or severity of bleeding and hemorrhage can be increased when Benzydamine is combined with Lepirudin.\tDB00001\nDB09212\tLoxoprofen\tThe risk or severity of bleeding and hemorrhage can be increased when Loxoprofen is combined with Lepirudin.\tDB00001\nDB09214\tDexketoprofen\tThe risk or severity of bleeding and hemorrhage can be increased when Dexketoprofen is combined with Lepirudin.\tDB00001\nDB09215\tDroxicam\tThe risk or severity of bleeding and hemorrhage can be increased when Droxicam is combined with Lepirudin.\tDB00001\nDB09216\tTolfenamic Acid\tThe risk or severity of bleeding and hemorrhage can be increased when Tolfenamic Acid is combined with Lepirudin.\tDB00001\nDB09217\tFirocoxib\tThe risk or severity of bleeding and hemorrhage can be increased when Firocoxib is combined with Lepirudin.\tDB00001\nDB09218\tClonixin\tThe risk or severity of bleeding and hemorrhage can be increased when Clonixin is combined with Lepirudin.\tDB00001\nDB09285\tMorniflumate\tThe risk or severity of bleeding and hemorrhage can be increased when Morniflumate is combined with Lepirudin.\tDB00001\nDB09288\tPropacetamol\tThe risk or severity of bleeding and hemorrhage can be increased when Propacetamol is combined with Lepirudin.\tDB00001\nDB09295\tTalniflumate\tThe risk or severity of bleeding and hemorrhage can be increased when Talniflumate is combined with Lepirudin.\tDB00001\nDB11455\tRobenacoxib\tThe risk or severity of bleeding and hemorrhage can be increased when Robenacoxib is combined with Lepirudin.\tDB00001\nDB11466\tTepoxalin\tThe risk or severity of bleeding and hemorrhage can be increased when Tepoxalin is combined with Lepirudin.\tDB00001\nDB11518\tFlunixin\tThe risk or severity of bleeding and hemorrhage can be increased when Flunixin is combined with Lepirudin.\tDB00001\nDB12480\tBetulinic Acid\tThe risk or severity of bleeding and hemorrhage can be increased when Betulinic Acid is combined with Lepirudin.\tDB00001\nDB12545\tIndobufen\tThe risk or severity of bleeding and hemorrhage can be increased when Indobufen is combined with Lepirudin.\tDB00001\nDB12610\tEbselen\tThe risk or severity of bleeding and hemorrhage can be increased when Ebselen is combined with Lepirudin.\tDB00001\nDB13001\tTinoridine\tThe risk or severity of bleeding and hemorrhage can be increased when Tinoridine is combined with Lepirudin.\tDB00001\nDB13167\tAlclofenac\tThe risk or severity of bleeding and hemorrhage can be increased when Alclofenac is combined with Lepirudin.\tDB00001\nDB13217\tFentiazac\tThe risk or severity of bleeding and hemorrhage can be increased when Fentiazac is combined with Lepirudin.\tDB00001\nDB13232\tSuxibuzone\tThe risk or severity of bleeding and hemorrhage can be increased when Suxibuzone is combined with Lepirudin.\tDB00001\nDB13286\tBumadizone\tThe risk or severity of bleeding and hemorrhage can be increased when Bumadizone is combined with Lepirudin.\tDB00001\nDB13314\tAlminoprofen\tThe risk or severity of bleeding and hemorrhage can be increased when Alminoprofen is combined with Lepirudin.\tDB00001\nDB13317\tFlunoxaprofen\tThe risk or severity of bleeding and hemorrhage can be increased when Flunoxaprofen is combined with Lepirudin.\tDB00001\nDB13364\tFeprazone\tThe risk or severity of bleeding and hemorrhage can be increased when Feprazone is combined with Lepirudin.\tDB00001\nDB13371\tDifenpiramide\tThe risk or severity of bleeding and hemorrhage can be increased when Difenpiramide is combined with Lepirudin.\tDB00001\nDB13407\tNifenazone\tThe risk or severity of bleeding and hemorrhage can be increased when Nifenazone is combined with Lepirudin.\tDB00001\nDB13432\tLonazolac\tThe risk or severity of bleeding and hemorrhage can be increased when Lonazolac is combined with Lepirudin.\tDB00001\nDB13481\tTenidap\tThe risk or severity of bleeding and hemorrhage can be increased when Tenidap is combined with Lepirudin.\tDB00001\nDB13501\tBendazac\tThe risk or severity of bleeding and hemorrhage can be increased when Bendazac is combined with Lepirudin.\tDB00001\nDB13514\tPranoprofen\tThe risk or severity of bleeding and hemorrhage can be increased when Pranoprofen is combined with Lepirudin.\tDB00001\nDB13524\tPropyphenazone\tThe risk or severity of bleeding and hemorrhage can be increased when Propyphenazone is combined with Lepirudin.\tDB00001\nDB13527\tProglumetacin\tThe risk or severity of bleeding and hemorrhage can be increased when Proglumetacin is combined with Lepirudin.\tDB00001\nDB13544\tEthenzamide\tThe risk or severity of bleeding and hemorrhage can be increased when Ethenzamide is combined with Lepirudin.\tDB00001\nDB13629\tMofebutazone\tThe risk or severity of bleeding and hemorrhage can be increased when Mofebutazone is combined with Lepirudin.\tDB00001\nDB13649\tProquazone\tThe risk or severity of bleeding and hemorrhage can be increased when Proquazone is combined with Lepirudin.\tDB00001\nDB13657\tBenorilate\tThe risk or severity of bleeding and hemorrhage can be increased when Benorilate is combined with Lepirudin.\tDB00001\nDB13722\tPirprofen\tThe risk or severity of bleeding and hemorrhage can be increased when Pirprofen is combined with Lepirudin.\tDB00001\nDB13860\tImidazole salicylate\tThe risk or severity of bleeding and hemorrhage can be increased when Imidazole salicylate is combined with Lepirudin.\tDB00001\nDB14059\tSC-236\tThe risk or severity of bleeding and hemorrhage can be increased when SC-236 is combined with Lepirudin.\tDB00001\nDB14060\tNS-398\tThe risk or severity of bleeding and hemorrhage can be increased when NS-398 is combined with Lepirudin.\tDB00001\nDB04865\tOmacetaxine mepesuccinate\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Omacetaxine mepesuccinate.\tDB00001\nDB11133\tOmega-3 fatty acids\tOmega-3 fatty acids may increase the anticoagulant activities of Lepirudin.\tDB00001\nDB00081\tTositumomab\tThe risk or severity of bleeding and hemorrhage can be increased when Lepirudin is combined with Tositumomab.\tDB00001\nDB00834\tMifepristone\tThe therapeutic efficacy of Lepirudin can be increased when used in combination with Mifepristone.\tDB00001\nDB01115\tNifedipine\tThe therapeutic efficacy of Lepirudin can be increased when used in combination with Nifedipine.\tDB00001\nDB04066\tpara-Coumaric Acid\tThe therapeutic efficacy of Lepirudin can be increased when used in combination with para-Coumaric Acid.\tDB00001\nDB04682\tOctylphenoxy polyethoxyethanol\tThe therapeutic efficacy of Lepirudin can be increased when used in combination with Octylphenoxy polyethoxyethanol.\tDB00001\nDB05384\tCarbopol 974P\tThe therapeutic efficacy of Lepirudin can be increased when used in combination with Carbopol 974P.\tDB00001\nDB05830\tTrestolone\tThe therapeutic efficacy of Lepirudin can be increased when used in combination with Trestolone.\tDB00001\nDB06266\tLonidamine\tThe therapeutic efficacy of Lepirudin can be increased when used in combination with Lonidamine.\tDB00001\nDB08867\tUlipristal\tThe therapeutic efficacy of Lepirudin can be increased when used in combination with Ulipristal.\tDB00001\nDB09401\tIsosorbide\tThe therapeutic efficacy of Lepirudin can be increased when used in combination with Isosorbide.\tDB00001\nDB11507\tCloprostenol\tThe therapeutic efficacy of Lepirudin can be increased when used in combination with Cloprostenol.\tDB00001\nDB12025\tTriptolide\tThe therapeutic efficacy of Lepirudin can be increased when used in combination with Triptolide.\tDB00001\nDB13044\tGossypol\tThe therapeutic efficacy of Lepirudin can be increased when used in combination with Gossypol.\tDB00001\nDB13310\tOrmeloxifene\tThe therapeutic efficacy of Lepirudin can be increased when used in combination with Ormeloxifene.\tDB00001\nDB14583\tSegesterone acetate\tThe therapeutic efficacy of Lepirudin can be increased when used in combination with Segesterone acetate.\tDB00001\nDB00294\tEtonogestrel\tEtonogestrel may decrease the anticoagulant activities of Lepirudin.\tDB00001\nDB00304\tDesogestrel\tDesogestrel may decrease the anticoagulant activities of Lepirudin.\tDB00001\nDB00351\tMegestrol acetate\tMegestrol acetate may decrease the anticoagulant activities of Lepirudin.\tDB00001\nDB00367\tLevonorgestrel\tLevonorgestrel may decrease the anticoagulant activities of Lepirudin.\tDB00001\nDB00378\tDydrogesterone\tDydrogesterone may decrease the anticoagulant activities of Lepirudin.\tDB00001\nDB00396\tProgesterone\tProgesterone may decrease the anticoagulant activities of Lepirudin.\tDB00001\nDB00603\tMedroxyprogesterone acetate\tMedroxyprogesterone acetate may decrease the anticoagulant activities of Lepirudin.\tDB00001\nDB00717\tNorethisterone\tNorethisterone may decrease the anticoagulant activities of Lepirudin.\tDB00001\nDB00823\tEthynodiol diacetate\tEthynodiol diacetate may decrease the anticoagulant activities of Lepirudin.\tDB00001\nDB00957\tNorgestimate\tNorgestimate may decrease the anticoagulant activities of Lepirudin.\tDB00001\nDB01395\tDrospirenone\tDrospirenone may decrease the anticoagulant activities of Lepirudin.\tDB00001\nDB01431\tAllylestrenol\tAllylestrenol may decrease the anticoagulant activities of Lepirudin.\tDB00001\nDB04839\tCyproterone acetate\tCyproterone acetate may decrease the anticoagulant activities of Lepirudin.\tDB00001\nDB06713\tNorelgestromin\tNorelgestromin may decrease the anticoagulant activities of Lepirudin.\tDB00001\nDB06730\tGestodene\tGestodene may decrease the anticoagulant activities of Lepirudin.\tDB00001\nDB06789\tHydroxyprogesterone caproate\tHydroxyprogesterone caproate may decrease the anticoagulant activities of Lepirudin.\tDB00001\nDB09123\tDienogest\tDienogest may decrease the anticoagulant activities of Lepirudin.\tDB00001\nDB09124\tMedrogestone\tMedrogestone may decrease the anticoagulant activities of Lepirudin.\tDB00001\nDB09371\tNorethynodrel\tNorethynodrel may decrease the anticoagulant activities of Lepirudin.\tDB00001\nDB09389\tNorgestrel\tNorgestrel may decrease the anticoagulant activities of Lepirudin.\tDB00001\nDB11372\tAltrenogest\tAltrenogest may decrease the anticoagulant activities of Lepirudin.\tDB00001\nDB11619\tGestrinone\tGestrinone may decrease the anticoagulant activities of Lepirudin.\tDB00001\nDB11636\tNomegestrol\tNomegestrol may decrease the anticoagulant activities of Lepirudin.\tDB00001\nDB12474\tLynestrenol\tLynestrenol may decrease the anticoagulant activities of Lepirudin.\tDB00001\nDB13230\tGestonorone\tGestonorone may decrease the anticoagulant activities of Lepirudin.\tDB00001\nDB13528\tChlormadinone\tChlormadinone may decrease the anticoagulant activities of Lepirudin.\tDB00001\nDB13533\tMethylestrenolone\tMethylestrenolone may decrease the anticoagulant activities of Lepirudin.\tDB00001\nDB13563\tNorgestrienone\tNorgestrienone may decrease the anticoagulant activities of Lepirudin.\tDB00001\nDB13602\tPromegestone\tPromegestone may decrease the anticoagulant activities of Lepirudin.\tDB00001\nDB13685\tQuingestanol\tQuingestanol may decrease the anticoagulant activities of Lepirudin.\tDB00001\nDB13857\tDemegestone\tDemegestone may decrease the anticoagulant activities of Lepirudin.\tDB00001\nDB13866\tEtynodiol\tEtynodiol may decrease the anticoagulant activities of Lepirudin.\tDB00001\nDB13981\tNomegestrol acetate\tNomegestrol acetate may decrease the anticoagulant activities of Lepirudin.\tDB00001\nDB14570\tHydroxyprogesterone\tHydroxyprogesterone may decrease the anticoagulant activities of Lepirudin.\tDB00001\nDB14678\tNorethindrone enanthate\tNorethindrone enanthate may decrease the anticoagulant activities of Lepirudin.\tDB00001\nDB14679\tQuingestanol acetate\tQuingestanol acetate may decrease the anticoagulant activities of Lepirudin.\tDB00001\nDB00233\tAminosalicylic Acid\tThe risk or severity of bleeding can be increased when Aminosalicylic Acid is combined with Lepirudin.\tDB00001\nDB00244\tMesalazine\tThe risk or severity of bleeding can be increased when Mesalazine is combined with Lepirudin.\tDB00001\nDB00795\tSulfasalazine\tThe risk or severity of bleeding can be increased when Sulfasalazine is combined with Lepirudin.\tDB00001\nDB00861\tDiflunisal\tThe risk or severity of bleeding can be increased when Diflunisal is combined with Lepirudin.\tDB00001\nDB00936\tSalicylic acid\tThe risk or severity of bleeding can be increased when Salicylic acid is combined with Lepirudin.\tDB00001\nDB01014\tBalsalazide\tThe risk or severity of bleeding can be increased when Balsalazide is combined with Lepirudin.\tDB00001\nDB01250\tOlsalazine\tThe risk or severity of bleeding can be increased when Olsalazine is combined with Lepirudin.\tDB00001\nDB01294\tBismuth Subsalicylate\tThe risk or severity of bleeding can be increased when Bismuth Subsalicylate is combined with Lepirudin.\tDB00001\nDB06251\tDersalazine\tThe risk or severity of bleeding can be increased when Dersalazine is combined with Lepirudin.\tDB00001\nDB06807\tPhenyl aminosalicylate\tThe risk or severity of bleeding can be increased when Phenyl aminosalicylate is combined with Lepirudin.\tDB00001\nDB09543\tMethyl salicylate\tThe risk or severity of bleeding can be increased when Methyl salicylate is combined with Lepirudin.\tDB00001\nDB11079\tTrolamine salicylate\tThe risk or severity of bleeding can be increased when Trolamine salicylate is combined with Lepirudin.\tDB00001\nDB12445\tNitroaspirin\tThe risk or severity of bleeding can be increased when Nitroaspirin is combined with Lepirudin.\tDB00001\nDB13509\tAloxiprin\tThe risk or severity of bleeding can be increased when Aloxiprin is combined with Lepirudin.\tDB00001\nDB13538\tGuacetisal\tThe risk or severity of bleeding can be increased when Guacetisal is combined with Lepirudin.\tDB00001\nDB13612\tCarbaspirin calcium\tThe risk or severity of bleeding can be increased when Carbaspirin calcium is combined with Lepirudin.\tDB00001\nDB14006\tCholine salicylate\tThe risk or severity of bleeding can be increased when Choline salicylate is combined with Lepirudin.\tDB00001\nDB14026\tThiosalicylic acid\tThe risk or severity of bleeding can be increased when Thiosalicylic acid is combined with Lepirudin.\tDB00001\nDB00063\tEptifibatide\tThe risk or severity of bleeding can be increased when Eptifibatide is combined with Lepirudin.\tDB00001\nDB00208\tTiclopidine\tThe risk or severity of bleeding can be increased when Ticlopidine is combined with Lepirudin.\tDB00001\nDB00758\tClopidogrel\tThe risk or severity of bleeding can be increased when Clopidogrel is combined with Lepirudin.\tDB00001\nDB00775\tTirofiban\tThe risk or severity of bleeding can be increased when Tirofiban is combined with Lepirudin.\tDB00001\nDB01138\tSulfinpyrazone\tThe risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Lepirudin.\tDB00001\nDB01166\tCilostazol\tThe risk or severity of bleeding can be increased when Cilostazol is combined with Lepirudin.\tDB00001\nDB01207\tRidogrel\tThe risk or severity of bleeding can be increased when Ridogrel is combined with Lepirudin.\tDB00001\nDB01236\tSevoflurane\tThe risk or severity of bleeding can be increased when Sevoflurane is combined with Lepirudin.\tDB00001\nDB02709\tResveratrol\tThe risk or severity of bleeding can be increased when Resveratrol is combined with Lepirudin.\tDB00001\nDB04905\tTesmilifene\tThe risk or severity of bleeding can be increased when Tesmilifene is combined with Lepirudin.\tDB00001\nDB05266\tIbudilast\tThe risk or severity of bleeding can be increased when Ibudilast is combined with Lepirudin.\tDB00001\nDB05767\tAndrographolide\tThe risk or severity of bleeding can be increased when Andrographolide is combined with Lepirudin.\tDB00001\nDB07615\tTranilast\tThe risk or severity of bleeding can be increased when Tranilast is combined with Lepirudin.\tDB00001\nDB08887\tIcosapent ethyl\tThe risk or severity of bleeding can be increased when Icosapent ethyl is combined with Lepirudin.\tDB00001\nDB09283\tTrapidil\tThe risk or severity of bleeding can be increased when Trapidil is combined with Lepirudin.\tDB00001\nDB12092\tNaftopidil\tThe risk or severity of bleeding can be increased when Naftopidil is combined with Lepirudin.\tDB00001\nDB12163\tSarpogrelate\tThe risk or severity of bleeding can be increased when Sarpogrelate is combined with Lepirudin.\tDB00001\nDB12321\tIfetroban\tThe risk or severity of bleeding can be increased when Ifetroban is combined with Lepirudin.\tDB00001\nDB12465\tKetanserin\tThe risk or severity of bleeding can be increased when Ketanserin is combined with Lepirudin.\tDB00001\nDB12749\tButylphthalide\tThe risk or severity of bleeding can be increased when Butylphthalide is combined with Lepirudin.\tDB00001\nDB12771\tHydroxytyrosol\tThe risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Lepirudin.\tDB00001\nDB13036\tRamatroban\tThe risk or severity of bleeding can be increased when Ramatroban is combined with Lepirudin.\tDB00001\nDB13327\tPicotamide\tThe risk or severity of bleeding can be increased when Picotamide is combined with Lepirudin.\tDB00001\nDB13367\tCloricromen\tThe risk or severity of bleeding can be increased when Cloricromen is combined with Lepirudin.\tDB00001\nDB13400\tLinsidomine\tThe risk or severity of bleeding can be increased when Linsidomine is combined with Lepirudin.\tDB00001\nDB13510\tBuflomedil\tThe risk or severity of bleeding can be increased when Buflomedil is combined with Lepirudin.\tDB00001\nDB13929\tRelcovaptan\tThe risk or severity of bleeding can be increased when Relcovaptan is combined with Lepirudin.\tDB00001\nDB00374\tTreprostinil\tThe risk or severity of bleeding can be increased when Treprostinil is combined with Lepirudin.\tDB00001\nDB03404\tHemin\tHemin may increase the anticoagulant activities of Lepirudin.\tDB00001\nDB13783\tAcemetacin\tThe risk or severity of bleeding and hemorrhage can be increased when Lepirudin is combined with Acemetacin.\tDB00001\nDB00624\tTestosterone\tThe therapeutic efficacy of Lepirudin can be increased when used in combination with Testosterone.\tDB00001\nDB01420\tTestosterone propionate\tThe therapeutic efficacy of Lepirudin can be increased when used in combination with Testosterone propionate.\tDB00001\nDB01481\t1-Testosterone\tThe therapeutic efficacy of Lepirudin can be increased when used in combination with 1-Testosterone.\tDB00001\nDB01485\t4-Hydroxytestosterone\tThe therapeutic efficacy of Lepirudin can be increased when used in combination with 4-Hydroxytestosterone.\tDB00001\nDB01510\tDehydrochloromethyltestosterone\tThe therapeutic efficacy of Lepirudin can be increased when used in combination with Dehydrochloromethyltestosterone.\tDB00001\nDB01541\tBoldenone\tThe therapeutic efficacy of Lepirudin can be increased when used in combination with Boldenone.\tDB00001\nDB01543\t18-methyl-19-nortestosterone\tThe therapeutic efficacy of Lepirudin can be increased when used in combination with 18-methyl-19-nortestosterone.\tDB00001\nDB01564\tCalusterone\tThe therapeutic efficacy of Lepirudin can be increased when used in combination with Calusterone.\tDB00001\nDB01569\tFormebolone\tThe therapeutic efficacy of Lepirudin can be increased when used in combination with Formebolone.\tDB00001\nDB01572\tMethyl-1-testosterone\tThe therapeutic efficacy of Lepirudin can be increased when used in combination with Methyl-1-testosterone.\tDB00001\nDB02901\tStanolone\tThe therapeutic efficacy of Lepirudin can be increased when used in combination with Stanolone.\tDB00001\nDB07447\t5beta-dihydrotestosterone\tThe therapeutic efficacy of Lepirudin can be increased when used in combination with 5beta-dihydrotestosterone.\tDB00001\nDB08619\tTestosterone succinate\tThe therapeutic efficacy of Lepirudin can be increased when used in combination with Testosterone succinate.\tDB00001\nDB11429\tMibolerone\tThe therapeutic efficacy of Lepirudin can be increased when used in combination with Mibolerone.\tDB00001\nDB13943\tTestosterone cypionate\tThe therapeutic efficacy of Lepirudin can be increased when used in combination with Testosterone cypionate.\tDB00001\nDB13944\tTestosterone enanthate\tThe therapeutic efficacy of Lepirudin can be increased when used in combination with Testosterone enanthate.\tDB00001\nDB13946\tTestosterone undecanoate\tThe therapeutic efficacy of Lepirudin can be increased when used in combination with Testosterone undecanoate.\tDB00001\nDB13947\tTestosterone enantate benzilic acid hydrazone\tThe therapeutic efficacy of Lepirudin can be increased when used in combination with Testosterone enantate benzilic acid hydrazone.\tDB00001\nDB13951\tStanolone acetate\tThe therapeutic efficacy of Lepirudin can be increased when used in combination with Stanolone acetate.\tDB00001\nDB13958\tTrestolone acetate\tThe therapeutic efficacy of Lepirudin can be increased when used in combination with Trestolone acetate.\tDB00001\nDB14093\t(1,2,6,7-3H)Testosterone\tThe therapeutic efficacy of Lepirudin can be increased when used in combination with (1,2,6,7-3H)Testosterone.\tDB00001\nDB14655\tDrostanolone propionate\tThe therapeutic efficacy of Lepirudin can be increased when used in combination with Drostanolone propionate.\tDB00001\nDB11051\tAzficel-T\tThe risk or severity of adverse effects can be increased when Lepirudin is combined with Azficel-T.\tDB00001\nDB09568\tOmega-3-carboxylic acids\tThe therapeutic efficacy of Lepirudin can be increased when used in combination with Omega-3-carboxylic acids.\tDB00001\nDB00025\tAntihemophilic factor, human recombinant\tThe therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Lepirudin.\tDB00001\nDB00036\tCoagulation factor VIIa Recombinant Human\tThe therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Lepirudin.\tDB00001\nDB00100\tCoagulation Factor IX (Recombinant)\tThe therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Lepirudin.\tDB00001\nDB01783\tPantothenic acid\tThe therapeutic efficacy of Pantothenic acid can be decreased when used in combination with Lepirudin.\tDB00001\nDB01942\tFormic Acid\tThe therapeutic efficacy of Formic Acid can be decreased when used in combination with Lepirudin.\tDB00001\nDB02261\tPlatelet Activating Factor\tThe therapeutic efficacy of Platelet Activating Factor can be decreased when used in combination with Lepirudin.\tDB00001\nDB06724\tCalcium Carbonate\tThe therapeutic efficacy of Calcium Carbonate can be decreased when used in combination with Lepirudin.\tDB00001\nDB09109\tTuroctocog alfa\tThe therapeutic efficacy of Turoctocog alfa can be decreased when used in combination with Lepirudin.\tDB00001\nDB09222\tFibrinogen Human\tThe therapeutic efficacy of Fibrinogen Human can be decreased when used in combination with Lepirudin.\tDB00001\nDB09310\tCoagulation Factor XIII A-Subunit (Recombinant)\tThe therapeutic efficacy of Coagulation Factor XIII A-Subunit (Recombinant) can be decreased when used in combination with Lepirudin.\tDB00001\nDB09329\tAntihemophilic Factor (Recombinant), PEGylated\tThe therapeutic efficacy of Antihemophilic Factor (Recombinant), PEGylated can be decreased when used in combination with Lepirudin.\tDB00001\nDB11093\tCalcium Citrate\tThe therapeutic efficacy of Calcium Citrate can be decreased when used in combination with Lepirudin.\tDB00001\nDB11168\tCalcium threonate\tThe therapeutic efficacy of Calcium threonate can be decreased when used in combination with Lepirudin.\tDB00001\nDB11311\tProthrombin\tThe therapeutic efficacy of Prothrombin can be decreased when used in combination with Lepirudin.\tDB00001\nDB11330\tFactor IX Complex (Human)\tThe therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Lepirudin.\tDB00001\nDB11348\tCalcium Phosphate\tThe therapeutic efficacy of Calcium Phosphate can be decreased when used in combination with Lepirudin.\tDB00001\nDB11606\tSusoctocog alfa\tThe therapeutic efficacy of Susoctocog alfa can be decreased when used in combination with Lepirudin.\tDB00001\nDB11668\tRusalatide acetate\tThe therapeutic efficacy of Rusalatide acetate can be decreased when used in combination with Lepirudin.\tDB00001\nDB12409\tVatreptacog alfa\tThe therapeutic efficacy of Vatreptacog alfa can be decreased when used in combination with Lepirudin.\tDB00001\nDB12909\tFactor XIII (human)\tThe therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Lepirudin.\tDB00001\nDB13133\tVon Willebrand Factor Human\tThe therapeutic efficacy of Von Willebrand Factor Human can be decreased when used in combination with Lepirudin.\tDB00001\nDB13148\tCoagulation factor X human\tThe therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Lepirudin.\tDB00001\nDB13150\tCoagulation factor VII human\tThe therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Lepirudin.\tDB00001\nDB13151\tAnti-inhibitor coagulant complex\tThe therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Lepirudin.\tDB00001\nDB13152\tCoagulation Factor IX Human\tThe therapeutic efficacy of Coagulation Factor IX Human can be decreased when used in combination with Lepirudin.\tDB00001\nDB13192\tAntihemophilic factor human\tThe therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Lepirudin.\tDB00001\nDB13197\tKallidinogenase\tThe therapeutic efficacy of Kallidinogenase can be decreased when used in combination with Lepirudin.\tDB00001\nDB13201\tTrenonacog alfa\tThe therapeutic efficacy of Trenonacog alfa can be decreased when used in combination with Lepirudin.\tDB00001\nDB13923\tEmicizumab\tThe therapeutic efficacy of Emicizumab can be decreased when used in combination with Lepirudin.\tDB00001\nDB13933\tNonacog beta pegol\tThe therapeutic efficacy of Nonacog beta pegol can be decreased when used in combination with Lepirudin.\tDB00001\nDB13999\tMoroctocog alfa\tThe therapeutic efficacy of Moroctocog alfa can be decreased when used in combination with Lepirudin.\tDB00001\nDB14473\tBeroctocog alfa\tThe therapeutic efficacy of Beroctocog alfa can be decreased when used in combination with Lepirudin.\tDB00001\nDB14562\tAndexanet alfa\tThe therapeutic efficacy of Andexanet alfa can be decreased when used in combination with Lepirudin.\tDB00001\nDB14577\tCalcium cation\tThe therapeutic efficacy of Calcium cation can be decreased when used in combination with Lepirudin.\tDB00001\nDB14700\tDamoctocog alfa pegol\tThe therapeutic efficacy of Damoctocog alfa pegol can be decreased when used in combination with Lepirudin.\tDB00001\nDB00176\tFluvoxamine\tThe risk or severity of hemorrhage can be increased when Fluvoxamine is combined with Lepirudin.\tDB00001\nDB00215\tCitalopram\tThe risk or severity of hemorrhage can be increased when Citalopram is combined with Lepirudin.\tDB00001\nDB00472\tFluoxetine\tThe risk or severity of hemorrhage can be increased when Fluoxetine is combined with Lepirudin.\tDB00001\nDB00656\tTrazodone\tThe risk or severity of hemorrhage can be increased when Trazodone is combined with Lepirudin.\tDB00001\nDB00715\tParoxetine\tThe risk or severity of hemorrhage can be increased when Paroxetine is combined with Lepirudin.\tDB00001\nDB01104\tSertraline\tThe risk or severity of hemorrhage can be increased when Sertraline is combined with Lepirudin.\tDB00001\nDB01149\tNefazodone\tThe risk or severity of hemorrhage can be increased when Nefazodone is combined with Lepirudin.\tDB00001\nDB01175\tEscitalopram\tThe risk or severity of hemorrhage can be increased when Escitalopram is combined with Lepirudin.\tDB00001\nDB04832\tZimelidine\tThe risk or severity of hemorrhage can be increased when Zimelidine is combined with Lepirudin.\tDB00001\nDB04884\tDapoxetine\tThe risk or severity of hemorrhage can be increased when Dapoxetine is combined with Lepirudin.\tDB00001\nDB06731\tSeproxetine\tThe risk or severity of hemorrhage can be increased when Seproxetine is combined with Lepirudin.\tDB00001\nDB08953\tIndalpine\tThe risk or severity of hemorrhage can be increased when Indalpine is combined with Lepirudin.\tDB00001\nDB12693\tRitanserin\tThe risk or severity of hemorrhage can be increased when Ritanserin is combined with Lepirudin.\tDB00001\nDB13233\tAlaproclate\tThe risk or severity of hemorrhage can be increased when Alaproclate is combined with Lepirudin.\tDB00001\nDB00285\tVenlafaxine\tVenlafaxine may increase the antiplatelet activities of Lepirudin.\tDB00001\nDB00476\tDuloxetine\tDuloxetine may increase the antiplatelet activities of Lepirudin.\tDB00001\nDB01105\tSibutramine\tSibutramine may increase the antiplatelet activities of Lepirudin.\tDB00001\nDB04896\tMilnacipran\tMilnacipran may increase the antiplatelet activities of Lepirudin.\tDB00001\nDB06700\tDesvenlafaxine\tDesvenlafaxine may increase the antiplatelet activities of Lepirudin.\tDB00001\nDB08918\tLevomilnacipran\tLevomilnacipran may increase the antiplatelet activities of Lepirudin.\tDB00001\nDB00601\tLinezolid\tThe risk or severity of bleeding and hemorrhage can be increased when Linezolid is combined with Lepirudin.\tDB00001\nDB00614\tFurazolidone\tThe risk or severity of bleeding and hemorrhage can be increased when Furazolidone is combined with Lepirudin.\tDB00001\nDB00752\tTranylcypromine\tThe risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Lepirudin.\tDB00001\nDB00780\tPhenelzine\tThe risk or severity of bleeding and hemorrhage can be increased when Phenelzine is combined with Lepirudin.\tDB00001\nDB00805\tMinaprine\tThe risk or severity of bleeding and hemorrhage can be increased when Minaprine is combined with Lepirudin.\tDB00001\nDB01037\tSelegiline\tThe risk or severity of bleeding and hemorrhage can be increased when Selegiline is combined with Lepirudin.\tDB00001\nDB01171\tMoclobemide\tThe risk or severity of bleeding and hemorrhage can be increased when Moclobemide is combined with Lepirudin.\tDB00001\nDB01247\tIsocarboxazid\tThe risk or severity of bleeding and hemorrhage can be increased when Isocarboxazid is combined with Lepirudin.\tDB00001\nDB01367\tRasagiline\tThe risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Lepirudin.\tDB00001\nDB01626\tPargyline\tThe risk or severity of bleeding and hemorrhage can be increased when Pargyline is combined with Lepirudin.\tDB00001\nDB04017\tClorgiline\tThe risk or severity of bleeding and hemorrhage can be increased when Clorgiline is combined with Lepirudin.\tDB00001\nDB04818\tIproniazid\tThe risk or severity of bleeding and hemorrhage can be increased when Iproniazid is combined with Lepirudin.\tDB00001\nDB04820\tNialamide\tThe risk or severity of bleeding and hemorrhage can be increased when Nialamide is combined with Lepirudin.\tDB00001\nDB06654\tSafinamide\tThe risk or severity of bleeding and hemorrhage can be increased when Safinamide is combined with Lepirudin.\tDB00001\nDB09241\tMethylene blue\tThe risk or severity of bleeding and hemorrhage can be increased when Methylene blue is combined with Lepirudin.\tDB00001\nDB09243\tHydracarbazine\tThe risk or severity of bleeding and hemorrhage can be increased when Hydracarbazine is combined with Lepirudin.\tDB00001\nDB09244\tPirlindole\tThe risk or severity of bleeding and hemorrhage can be increased when Pirlindole is combined with Lepirudin.\tDB00001\nDB09245\tToloxatone\tThe risk or severity of bleeding and hemorrhage can be increased when Toloxatone is combined with Lepirudin.\tDB00001\nDB09246\tBenmoxin\tThe risk or severity of bleeding and hemorrhage can be increased when Benmoxin is combined with Lepirudin.\tDB00001\nDB09248\tMebanazine\tThe risk or severity of bleeding and hemorrhage can be increased when Mebanazine is combined with Lepirudin.\tDB00001\nDB09249\tOctamoxin\tThe risk or severity of bleeding and hemorrhage can be increased when Octamoxin is combined with Lepirudin.\tDB00001\nDB09250\tPheniprazine\tThe risk or severity of bleeding and hemorrhage can be increased when Pheniprazine is combined with Lepirudin.\tDB00001\nDB09251\tPhenoxypropazine\tThe risk or severity of bleeding and hemorrhage can be increased when Phenoxypropazine is combined with Lepirudin.\tDB00001\nDB09252\tPivhydrazine\tThe risk or severity of bleeding and hemorrhage can be increased when Pivhydrazine is combined with Lepirudin.\tDB00001\nDB09253\tSafrazine\tThe risk or severity of bleeding and hemorrhage can be increased when Safrazine is combined with Lepirudin.\tDB00001\nDB09254\tCaroxazone\tThe risk or severity of bleeding and hemorrhage can be increased when Caroxazone is combined with Lepirudin.\tDB00001\nDB13875\tHarmaline\tThe risk or severity of bleeding and hemorrhage can be increased when Harmaline is combined with Lepirudin.\tDB00001\nDB00006\tBivalirudin\tThe risk or severity of bleeding can be increased when Bivalirudin is combined with Lepirudin.\tDB00001\nDB00054\tAbciximab\tThe risk or severity of bleeding can be increased when Abciximab is combined with Lepirudin.\tDB00001\nDB00266\tDicoumarol\tThe risk or severity of bleeding can be increased when Dicoumarol is combined with Lepirudin.\tDB00001\nDB00278\tArgatroban\tThe risk or severity of bleeding can be increased when Argatroban is combined with Lepirudin.\tDB00001\nDB00407\tArdeparin\tThe risk or severity of bleeding can be increased when Ardeparin is combined with Lepirudin.\tDB00001\nDB00498\tPhenindione\tThe risk or severity of bleeding can be increased when Phenindione is combined with Lepirudin.\tDB00001\nDB00569\tFondaparinux\tThe risk or severity of bleeding can be increased when Fondaparinux is combined with Lepirudin.\tDB00001\nDB00682\tWarfarin\tThe risk or severity of bleeding can be increased when Warfarin is combined with Lepirudin.\tDB00001\nDB00946\tPhenprocoumon\tThe risk or severity of bleeding can be increased when Phenprocoumon is combined with Lepirudin.\tDB00001\nDB00974\tEdetic Acid\tThe risk or severity of bleeding can be increased when Edetic Acid is combined with Lepirudin.\tDB00001\nDB01109\tHeparin\tThe risk or severity of bleeding can be increased when Heparin is combined with Lepirudin.\tDB00001\nDB01225\tEnoxaparin\tThe risk or severity of bleeding can be increased when Enoxaparin is combined with Lepirudin.\tDB00001\nDB01418\tAcenocoumarol\tThe risk or severity of bleeding can be increased when Acenocoumarol is combined with Lepirudin.\tDB00001\nDB04898\tXimelagatran\tThe risk or severity of bleeding can be increased when Ximelagatran is combined with Lepirudin.\tDB00001\nDB05099\tAncrod\tThe risk or severity of bleeding can be increased when Ancrod is combined with Lepirudin.\tDB00001\nDB06271\tSulodexide\tThe risk or severity of bleeding can be increased when Sulodexide is combined with Lepirudin.\tDB00001\nDB06406\tIdraparinux\tThe risk or severity of bleeding can be increased when Idraparinux is combined with Lepirudin.\tDB00001\nDB06635\tOtamixaban\tThe risk or severity of bleeding can be increased when Otamixaban is combined with Lepirudin.\tDB00001\nDB06754\tDanaparoid\tThe risk or severity of bleeding can be increased when Danaparoid is combined with Lepirudin.\tDB00001\nDB06779\tDalteparin\tThe risk or severity of bleeding can be increased when Dalteparin is combined with Lepirudin.\tDB00001\nDB07767\tFerulic acid\tThe risk or severity of bleeding can be increased when Ferulic acid is combined with Lepirudin.\tDB00001\nDB08794\tEthyl biscoumacetate\tThe risk or severity of bleeding can be increased when Ethyl biscoumacetate is combined with Lepirudin.\tDB00001\nDB08813\tNadroparin\tThe risk or severity of bleeding can be increased when Nadroparin is combined with Lepirudin.\tDB00001\nDB09255\tDextran\tThe risk or severity of bleeding can be increased when Dextran is combined with Lepirudin.\tDB00001\nDB09259\tReviparin\tThe risk or severity of bleeding can be increased when Reviparin is combined with Lepirudin.\tDB00001\nDB09261\tCertoparin\tThe risk or severity of bleeding can be increased when Certoparin is combined with Lepirudin.\tDB00001\nDB11095\tDesirudin\tThe risk or severity of bleeding can be increased when Desirudin is combined with Lepirudin.\tDB00001\nDB11268\tProtocatechualdehyde\tThe risk or severity of bleeding can be increased when Protocatechualdehyde is combined with Lepirudin.\tDB00001\nDB11312\tProtein C\tThe risk or severity of bleeding can be increased when Protein C is combined with Lepirudin.\tDB00001\nDB11598\tAntithrombin III human\tThe risk or severity of bleeding can be increased when Antithrombin III human is combined with Lepirudin.\tDB00001\nDB11984\tLetaxaban\tThe risk or severity of bleeding can be increased when Letaxaban is combined with Lepirudin.\tDB00001\nDB12289\tDarexaban\tThe risk or severity of bleeding can be increased when Darexaban is combined with Lepirudin.\tDB00001\nDB12598\tNafamostat\tThe risk or severity of bleeding can be increased when Nafamostat is combined with Lepirudin.\tDB00001\nDB12831\tGabexate\tThe risk or severity of bleeding can be increased when Gabexate is combined with Lepirudin.\tDB00001\nDB13124\tTroxerutin\tThe risk or severity of bleeding can be increased when Troxerutin is combined with Lepirudin.\tDB00001\nDB13136\tFluindione\tThe risk or severity of bleeding can be increased when Fluindione is combined with Lepirudin.\tDB00001\nDB13149\tProtein S human\tThe risk or severity of bleeding can be increased when Protein S human is combined with Lepirudin.\tDB00001\nDB13616\tMelagatran\tThe risk or severity of bleeding can be increased when Melagatran is combined with Lepirudin.\tDB00001\nDB09125\tPotassium Citrate\tThe risk or severity of bleeding can be increased when Potassium Citrate is combined with Lepirudin.\tDB00001\nDB09154\tSodium Citrate\tThe risk or severity of bleeding can be increased when Sodium Citrate is combined with Lepirudin.\tDB00001\nDB00031\tTenecteplase\tThe risk or severity of bleeding can be increased when Tenecteplase is combined with Lepirudin.\tDB00001\nDB00055\tDrotrecogin alfa\tThe risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Lepirudin.\tDB00001\nDB04932\tDefibrotide\tThe risk or severity of bleeding can be increased when Defibrotide is combined with Lepirudin.\tDB00001\nDB06822\tTinzaparin\tThe risk or severity of bleeding can be increased when Tinzaparin is combined with Lepirudin.\tDB00001\nDB13199\tBrinase\tThe risk or severity of bleeding can be increased when Brinase is combined with Lepirudin.\tDB00001\nDB13646\tSaruplase\tThe risk or severity of bleeding can be increased when Saruplase is combined with Lepirudin.\tDB00001\nDB00086\tStreptokinase\tThe risk or severity of bleeding can be increased when Streptokinase is combined with Lepirudin.\tDB00001\nDB00261\tAnagrelide\tThe risk or severity of bleeding can be increased when Anagrelide is combined with Lepirudin.\tDB00001\nDB00945\tAcetylsalicylic acid\tThe risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Lepirudin.\tDB00001\nDB04925\tDesmoteplase\tThe risk or severity of bleeding can be increased when Desmoteplase is combined with Lepirudin.\tDB00001\nDB05254\tFibrinolysin\tThe risk or severity of bleeding can be increased when Fibrinolysin is combined with Lepirudin.\tDB00001\nDB06543\tAstaxanthin\tThe risk or severity of bleeding can be increased when Astaxanthin is combined with Lepirudin.\tDB00001\nDB00975\tDipyridamole\tThe risk or severity of bleeding can be increased when Dipyridamole is combined with Lepirudin.\tDB00001\nDB01088\tIloprost\tThe risk or severity of bleeding can be increased when Iloprost is combined with Lepirudin.\tDB00001\nDB01240\tEpoprostenol\tThe risk or severity of bleeding can be increased when Epoprostenol is combined with Lepirudin.\tDB00001\nDB05229\tBeraprost\tThe risk or severity of bleeding can be increased when Beraprost is combined with Lepirudin.\tDB00001\nDB06209\tPrasugrel\tThe risk or severity of bleeding can be increased when Prasugrel is combined with Lepirudin.\tDB00001\nDB06441\tCangrelor\tThe risk or severity of bleeding can be increased when Cangrelor is combined with Lepirudin.\tDB00001\nDB08814\tTriflusal\tThe risk or severity of bleeding can be increased when Triflusal is combined with Lepirudin.\tDB00001\nDB08816\tTicagrelor\tThe risk or severity of bleeding can be increased when Ticagrelor is combined with Lepirudin.\tDB00001\nDB08994\tDitazole\tThe risk or severity of bleeding can be increased when Ditazole is combined with Lepirudin.\tDB00001\nDB09258\tBemiparin\tThe risk or severity of bleeding can be increased when Bemiparin is combined with Lepirudin.\tDB00001\nDB09260\tParnaparin\tThe risk or severity of bleeding can be increased when Parnaparin is combined with Lepirudin.\tDB00001\nDB13275\tClorindione\tThe risk or severity of bleeding can be increased when Clorindione is combined with Lepirudin.\tDB00001\nDB13347\tDiphenadione\tThe risk or severity of bleeding can be increased when Diphenadione is combined with Lepirudin.\tDB00001\nDB13451\tTioclomarol\tThe risk or severity of bleeding can be increased when Tioclomarol is combined with Lepirudin.\tDB00001\nDB00009\tAlteplase\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Alteplase.\tDB00001\nDB00015\tReteplase\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Reteplase.\tDB00001\nDB00029\tAnistreplase\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Anistreplase.\tDB00001\nDB14094\tTocopherylquinone\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Tocopherylquinone.\tDB00001\nDB06679\tAmediplase\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Amediplase.\tDB00001\nDB03410\t4-hydroxycoumarin\tThe risk or severity of bleeding can be increased when Lepirudin is combined with 4-hydroxycoumarin.\tDB00001\nDB08496\t(R)-warfarin\tThe risk or severity of bleeding can be increased when Lepirudin is combined with (R)-warfarin.\tDB00001\nDB14055\t(S)-Warfarin\tThe risk or severity of bleeding can be increased when Lepirudin is combined with (S)-Warfarin.\tDB00001\nDB12364\tBetrixaban\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Betrixaban.\tDB00001\nDB14598\tEdetate calcium disodium anhydrous\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Edetate calcium disodium anhydrous.\tDB00001\nDB11154\tZinc citrate\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Zinc citrate.\tDB00001\nDB14600\tEdetate disodium anhydrous\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Edetate disodium anhydrous.\tDB00001\nDB11166\tAntithrombin Alfa\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Antithrombin Alfa.\tDB00001\nDB04665\tCoumarin\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Coumarin.\tDB00001\nDB14726\tDabigatran\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Dabigatran.\tDB00001\nDB00203\tSildenafil\tThe risk or severity of hemorrhage can be increased when Lepirudin is combined with Sildenafil.\tDB00001\nDB00008\tPeginterferon alfa-2a\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Peginterferon alfa-2a.\tDB00001\nDB00011\tInterferon alfa-n1\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Interferon alfa-n1.\tDB00001\nDB00018\tInterferon alfa-n3\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Interferon alfa-n3.\tDB00001\nDB00022\tPeginterferon alfa-2b\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Peginterferon alfa-2b.\tDB00001\nDB00033\tInterferon gamma-1b\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Interferon gamma-1b.\tDB00001\nDB00034\tInterferon Alfa-2a, Recombinant\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Interferon Alfa-2a, Recombinant.\tDB00001\nDB00041\tAldesleukin\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Aldesleukin.\tDB00001\nDB00056\tGemtuzumab ozogamicin\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Gemtuzumab ozogamicin.\tDB00001\nDB00068\tInterferon beta-1b\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Interferon beta-1b.\tDB00001\nDB00069\tInterferon alfacon-1\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Interferon alfacon-1.\tDB00001\nDB00073\tRituximab\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Rituximab.\tDB00001\nDB00078\tIbritumomab tiuxetan\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Ibritumomab tiuxetan.\tDB00001\nDB00081\tTositumomab\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Tositumomab.\tDB00001\nDB00087\tAlemtuzumab\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Alemtuzumab.\tDB00001\nDB00105\tInterferon Alfa-2b, Recombinant\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Interferon Alfa-2b, Recombinant.\tDB00001\nDB00112\tBevacizumab\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Bevacizumab.\tDB00001\nDB00120\tL-Phenylalanine\tThe risk or severity of bleeding can be increased when Lepirudin is combined with L-Phenylalanine.\tDB00001\nDB00188\tBortezomib\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Bortezomib.\tDB00001\nDB00242\tCladribine\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Cladribine.\tDB00001\nDB00262\tCarmustine\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Carmustine.\tDB00001\nDB00276\tAmsacrine\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Amsacrine.\tDB00001\nDB00291\tChlorambucil\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Chlorambucil.\tDB00001\nDB00293\tRaltitrexed\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Raltitrexed.\tDB00001\nDB00305\tMitomycin\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Mitomycin.\tDB00001\nDB00307\tBexarotene\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Bexarotene.\tDB00001\nDB00309\tVindesine\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Vindesine.\tDB00001\nDB00322\tFloxuridine\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Floxuridine.\tDB00001\nDB00352\tTioguanine\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Tioguanine.\tDB00001\nDB00361\tVinorelbine\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Vinorelbine.\tDB00001\nDB00380\tDexrazoxane\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Dexrazoxane.\tDB00001\nDB00398\tSorafenib\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Sorafenib.\tDB00001\nDB00428\tStreptozocin\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Streptozocin.\tDB00001\nDB00441\tGemcitabine\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Gemcitabine.\tDB00001\nDB00444\tTeniposide\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Teniposide.\tDB00001\nDB00445\tEpirubicin\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Epirubicin.\tDB00001\nDB00446\tChloramphenicol\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Chloramphenicol.\tDB00001\nDB00480\tLenalidomide\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Lenalidomide.\tDB00001\nDB00488\tAltretamine\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Altretamine.\tDB00001\nDB00495\tZidovudine\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Zidovudine.\tDB00001\nDB00501\tCimetidine\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Cimetidine.\tDB00001\nDB00515\tCisplatin\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Cisplatin.\tDB00001\nDB00526\tOxaliplatin\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Oxaliplatin.\tDB00001\nDB00531\tCyclophosphamide\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Cyclophosphamide.\tDB00001\nDB00544\tFluorouracil\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Fluorouracil.\tDB00001\nDB00550\tPropylthiouracil\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Propylthiouracil.\tDB00001\nDB00552\tPentostatin\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Pentostatin.\tDB00001\nDB00563\tMethotrexate\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Methotrexate.\tDB00001\nDB00564\tCarbamazepine\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Carbamazepine.\tDB00001\nDB00570\tVinblastine\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Vinblastine.\tDB00001\nDB00619\tImatinib\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Imatinib.\tDB00001\nDB00631\tClofarabine\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Clofarabine.\tDB00001\nDB00642\tPemetrexed\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Pemetrexed.\tDB00001\nDB00694\tDaunorubicin\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Daunorubicin.\tDB00001\nDB00762\tIrinotecan\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Irinotecan.\tDB00001\nDB00763\tMethimazole\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Methimazole.\tDB00001\nDB00773\tEtoposide\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Etoposide.\tDB00001\nDB00851\tDacarbazine\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Dacarbazine.\tDB00001\nDB00853\tTemozolomide\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Temozolomide.\tDB00001\nDB00859\tPenicillamine\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Penicillamine.\tDB00001\nDB00864\tTacrolimus\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Tacrolimus.\tDB00001\nDB00877\tSirolimus\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Sirolimus.\tDB00001\nDB00888\tMechlorethamine\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Mechlorethamine.\tDB00001\nDB00928\tAzacitidine\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Azacitidine.\tDB00001\nDB00958\tCarboplatin\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Carboplatin.\tDB00001\nDB00970\tDactinomycin\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Dactinomycin.\tDB00001\nDB00987\tCytarabine\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Cytarabine.\tDB00001\nDB00997\tDoxorubicin\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Doxorubicin.\tDB00001\nDB01005\tHydroxyurea\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Hydroxyurea.\tDB00001\nDB01008\tBusulfan\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Busulfan.\tDB00001\nDB01030\tTopotecan\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Topotecan.\tDB00001\nDB01033\tMercaptopurine\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Mercaptopurine.\tDB00001\nDB01041\tThalidomide\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Thalidomide.\tDB00001\nDB01042\tMelphalan\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Melphalan.\tDB00001\nDB01073\tFludarabine\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Fludarabine.\tDB00001\nDB01099\tFlucytosine\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Flucytosine.\tDB00001\nDB01101\tCapecitabine\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Capecitabine.\tDB00001\nDB01168\tProcarbazine\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Procarbazine.\tDB00001\nDB01169\tArsenic trioxide\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Arsenic trioxide.\tDB00001\nDB01177\tIdarubicin\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Idarubicin.\tDB00001\nDB01204\tMitoxantrone\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Mitoxantrone.\tDB00001\nDB01206\tLomustine\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Lomustine.\tDB00001\nDB01229\tPaclitaxel\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Paclitaxel.\tDB00001\nDB01248\tDocetaxel\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Docetaxel.\tDB00001\nDB01262\tDecitabine\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Decitabine.\tDB00001\nDB01280\tNelarabine\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Nelarabine.\tDB00001\nDB01394\tColchicine\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Colchicine.\tDB00001\nDB01590\tEverolimus\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Everolimus.\tDB00001\nDB02546\tVorinostat\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Vorinostat.\tDB00001\nDB04572\tThiotepa\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Thiotepa.\tDB00001\nDB04845\tIxabepilone\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Ixabepilone.\tDB00001\nDB04868\tNilotinib\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Nilotinib.\tDB00001\nDB05015\tBelinostat\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Belinostat.\tDB00001\nDB05109\tTrabectedin\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Trabectedin.\tDB00001\nDB05258\tNatural alpha interferon\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Natural alpha interferon.\tDB00001\nDB05472\tomega interferon\tThe risk or severity of bleeding can be increased when Lepirudin is combined with omega interferon.\tDB00001\nDB05773\tTrastuzumab emtansine\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Trastuzumab emtansine.\tDB00001\nDB06287\tTemsirolimus\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Temsirolimus.\tDB00001\nDB06616\tBosutinib\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Bosutinib.\tDB00001\nDB06769\tBendamustine\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Bendamustine.\tDB00001\nDB06772\tCabazitaxel\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Cabazitaxel.\tDB00001\nDB08871\tEribulin\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Eribulin.\tDB00001\nDB08877\tRuxolitinib\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Ruxolitinib.\tDB00001\nDB08889\tCarfilzomib\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Carfilzomib.\tDB00001\nDB08895\tTofacitinib\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Tofacitinib.\tDB00001\nDB08901\tPonatinib\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Ponatinib.\tDB00001\nDB08910\tPomalidomide\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Pomalidomide.\tDB00001\nDB09042\tTedizolid phosphate\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Tedizolid phosphate.\tDB00001\nDB09052\tBlinatumomab\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Blinatumomab.\tDB00001\nDB09073\tPalbociclib\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Palbociclib.\tDB00001\nDB09074\tOlaparib\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Olaparib.\tDB00001\nDB09077\tDinutuximab\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Dinutuximab.\tDB00001\nDB09122\tPeginterferon beta-1a\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Peginterferon beta-1a.\tDB00001\nDB12814\tCepeginterferon alfa-2B\tThe risk or severity of bleeding can be increased when Lepirudin is combined with Cepeginterferon alfa-2B.\tDB00001\nDB08860\tPitavastatin\tThe serum concentration of Pitavastatin can be decreased when it is combined with Lepirudin.\tDB00001\nDB00229\tCefotiam\tThe therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefotiam.\tDB00001\nDB00267\tCefmenoxime\tThe therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefmenoxime.\tDB00001\nDB00274\tCefmetazole\tThe therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefmetazole.\tDB00001\nDB00430\tCefpiramide\tThe therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefpiramide.\tDB00001\nDB00438\tCeftazidime\tThe therapeutic efficacy of Lepirudin can be decreased when used in combination with Ceftazidime.\tDB00001\nDB00447\tLoracarbef\tThe therapeutic efficacy of Lepirudin can be decreased when used in combination with Loracarbef.\tDB00001\nDB00456\tCefalotin\tThe therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefalotin.\tDB00001\nDB00493\tCefotaxime\tThe therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefotaxime.\tDB00001\nDB00535\tCefdinir\tThe therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefdinir.\tDB00001\nDB00567\tCephalexin\tThe therapeutic efficacy of Lepirudin can be decreased when used in combination with Cephalexin.\tDB00001\nDB00671\tCefixime\tThe therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefixime.\tDB00001\nDB00689\tCephaloglycin\tThe therapeutic efficacy of Lepirudin can be decreased when used in combination with Cephaloglycin.\tDB00001\nDB00833\tCefaclor\tThe therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefaclor.\tDB00001\nDB00923\tCeforanide\tThe therapeutic efficacy of Lepirudin can be decreased when used in combination with Ceforanide.\tDB00001\nDB01066\tCefditoren\tThe therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefditoren.\tDB00001\nDB01112\tCefuroxime\tThe therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefuroxime.\tDB00001\nDB01139\tCefapirin\tThe therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefapirin.\tDB00001\nDB01140\tCefadroxil\tThe therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefadroxil.\tDB00001\nDB01150\tCefprozil\tThe therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefprozil.\tDB00001\nDB01212\tCeftriaxone\tThe therapeutic efficacy of Lepirudin can be decreased when used in combination with Ceftriaxone.\tDB00001\nDB01326\tCefamandole\tThe therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefamandole.\tDB00001\nDB01327\tCefazolin\tThe therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefazolin.\tDB00001\nDB01328\tCefonicid\tThe therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefonicid.\tDB00001\nDB01329\tCefoperazone\tThe therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefoperazone.\tDB00001\nDB01330\tCefotetan\tThe therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefotetan.\tDB00001\nDB01331\tCefoxitin\tThe therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefoxitin.\tDB00001\nDB01332\tCeftizoxime\tThe therapeutic efficacy of Lepirudin can be decreased when used in combination with Ceftizoxime.\tDB00001\nDB01333\tCefradine\tThe therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefradine.\tDB00001\nDB01413\tCefepime\tThe therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefepime.\tDB00001\nDB01414\tCefacetrile\tThe therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefacetrile.\tDB00001\nDB01415\tCeftibuten\tThe therapeutic efficacy of Lepirudin can be decreased when used in combination with Ceftibuten.\tDB00001\nDB01416\tCefpodoxime\tThe therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefpodoxime.\tDB00001\nDB04570\tLatamoxef\tThe therapeutic efficacy of Lepirudin can be decreased when used in combination with Latamoxef.\tDB00001\nDB04918\tCeftobiprole\tThe therapeutic efficacy of Lepirudin can be decreased when used in combination with Ceftobiprole.\tDB00001\nDB06590\tCeftaroline fosamil\tThe therapeutic efficacy of Lepirudin can be decreased when used in combination with Ceftaroline fosamil.\tDB00001\nDB09008\tCefaloridine\tThe therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefaloridine.\tDB00001\nDB09050\tCeftolozane\tThe therapeutic efficacy of Lepirudin can be decreased when used in combination with Ceftolozane.\tDB00001\nDB09062\tCefminox\tThe therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefminox.\tDB00001\nDB11367\tCefroxadine\tThe therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefroxadine.\tDB00001\nDB11935\tFlomoxef\tThe therapeutic efficacy of Lepirudin can be decreased when used in combination with Flomoxef.\tDB00001\nDB13266\tCefatrizine\tThe therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefatrizine.\tDB00001\nDB13461\tCefcapene\tThe therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefcapene.\tDB00001\nDB13470\tCefodizime\tThe therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefodizime.\tDB00001\nDB13499\tCefsulodin\tThe therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefsulodin.\tDB00001\nDB13504\tCefetamet\tThe therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefetamet.\tDB00001\nDB13638\tCefbuperazone\tThe therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefbuperazone.\tDB00001\nDB13667\tCefozopran\tThe therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefozopran.\tDB00001\nDB13682\tCefpirome\tThe therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefpirome.\tDB00001\nDB13778\tCefazedone\tThe therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefazedone.\tDB00001\nDB13821\tCeftezole\tThe therapeutic efficacy of Lepirudin can be decreased when used in combination with Ceftezole.\tDB00001\nDB14725\tCefamandole nafate\tThe therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefamandole nafate.\tDB00001\nDB00255\tDiethylstilbestrol\tDiethylstilbestrol may increase the thrombogenic activities of Cetuximab.\tDB00002\nDB00269\tChlorotrianisene\tChlorotrianisene may increase the thrombogenic activities of Cetuximab.\tDB00002\nDB00286\tConjugated estrogens\tConjugated estrogens may increase the thrombogenic activities of Cetuximab.\tDB00002\nDB00655\tEstrone\tEstrone may increase the thrombogenic activities of Cetuximab.\tDB00002\nDB00783\tEstradiol\tEstradiol may increase the thrombogenic activities of Cetuximab.\tDB00002\nDB00890\tDienestrol\tDienestrol may increase the thrombogenic activities of Cetuximab.\tDB00002\nDB00977\tEthinylestradiol\tEthinylestradiol may increase the thrombogenic activities of Cetuximab.\tDB00002\nDB01357\tMestranol\tMestranol may increase the thrombogenic activities of Cetuximab.\tDB00002\nDB04573\tEstriol\tEstriol may increase the thrombogenic activities of Cetuximab.\tDB00002\nDB04574\tEstrone sulfate\tEstrone sulfate may increase the thrombogenic activities of Cetuximab.\tDB00002\nDB04575\tQuinestrol\tQuinestrol may increase the thrombogenic activities of Cetuximab.\tDB00002\nDB07931\tHexestrol\tHexestrol may increase the thrombogenic activities of Cetuximab.\tDB00002\nDB09070\tTibolone\tTibolone may increase the thrombogenic activities of Cetuximab.\tDB00002\nDB09317\tSynthetic Conjugated Estrogens, A\tSynthetic Conjugated Estrogens, A may increase the thrombogenic activities of Cetuximab.\tDB00002\nDB09318\tSynthetic Conjugated Estrogens, B\tSynthetic Conjugated Estrogens, B may increase the thrombogenic activities of Cetuximab.\tDB00002\nDB09369\tPolyestradiol phosphate\tPolyestradiol phosphate may increase the thrombogenic activities of Cetuximab.\tDB00002\nDB09381\tEstrogens, esterified\tEstrogens, esterified may increase the thrombogenic activities of Cetuximab.\tDB00002\nDB11478\tZeranol\tZeranol may increase the thrombogenic activities of Cetuximab.\tDB00002\nDB11674\tEquol\tEquol may increase the thrombogenic activities of Cetuximab.\tDB00002\nDB12487\tPromestriene\tPromestriene may increase the thrombogenic activities of Cetuximab.\tDB00002\nDB13143\tMethallenestril\tMethallenestril may increase the thrombogenic activities of Cetuximab.\tDB00002\nDB13386\tEpimestrol\tEpimestrol may increase the thrombogenic activities of Cetuximab.\tDB00002\nDB13418\tMoxestrol\tMoxestrol may increase the thrombogenic activities of Cetuximab.\tDB00002\nDB13952\tEstradiol acetate\tEstradiol acetate may increase the thrombogenic activities of Cetuximab.\tDB00002\nDB13953\tEstradiol benzoate\tEstradiol benzoate may increase the thrombogenic activities of Cetuximab.\tDB00002\nDB13954\tEstradiol cypionate\tEstradiol cypionate may increase the thrombogenic activities of Cetuximab.\tDB00002\nDB13956\tEstradiol valerate\tEstradiol valerate may increase the thrombogenic activities of Cetuximab.\tDB00002\nDB00028\tImmune Globulin Human\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Immune Globulin Human.\tDB00002\nDB00043\tOmalizumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Omalizumab.\tDB00002\nDB00051\tAdalimumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Adalimumab.\tDB00002\nDB00054\tAbciximab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Abciximab.\tDB00002\nDB00056\tGemtuzumab ozogamicin\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Gemtuzumab ozogamicin.\tDB00002\nDB00057\tIndium In-111 satumomab pendetide\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Indium In-111 satumomab pendetide.\tDB00002\nDB00065\tInfliximab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Infliximab.\tDB00002\nDB00072\tTrastuzumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Trastuzumab.\tDB00002\nDB00073\tRituximab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Rituximab.\tDB00002\nDB00074\tBasiliximab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Basiliximab.\tDB00002\nDB00075\tMuromonab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Muromonab.\tDB00002\nDB00076\tDigoxin Immune Fab (Ovine)\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Digoxin Immune Fab (Ovine).\tDB00002\nDB00078\tIbritumomab tiuxetan\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Ibritumomab tiuxetan.\tDB00002\nDB00081\tTositumomab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Tositumomab.\tDB00002\nDB00087\tAlemtuzumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Alemtuzumab.\tDB00002\nDB00089\tCapromab pendetide\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Capromab pendetide.\tDB00002\nDB00095\tEfalizumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Efalizumab.\tDB00002\nDB00098\tAntithymocyte immunoglobulin (rabbit)\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Antithymocyte immunoglobulin (rabbit).\tDB00002\nDB00108\tNatalizumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Natalizumab.\tDB00002\nDB00110\tPalivizumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Palivizumab.\tDB00002\nDB00111\tDaclizumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Daclizumab.\tDB00002\nDB00112\tBevacizumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Bevacizumab.\tDB00002\nDB00113\tTechnetium Tc-99m arcitumomab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Technetium Tc-99m arcitumomab.\tDB00002\nDB01257\tEculizumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Eculizumab.\tDB00002\nDB01269\tPanitumumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Panitumumab.\tDB00002\nDB01270\tRanibizumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Ranibizumab.\tDB00002\nDB04901\tGaliximab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Galiximab.\tDB00002\nDB04949\tPexelizumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Pexelizumab.\tDB00002\nDB04956\tAfelimomab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Afelimomab.\tDB00002\nDB04958\tEpratuzumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Epratuzumab.\tDB00002\nDB04962\tBectumomab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Bectumomab.\tDB00002\nDB04964\tOregovomab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Oregovomab.\tDB00002\nDB04988\tIGN311\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with IGN311.\tDB00002\nDB05006\tAdecatumumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Adecatumumab.\tDB00002\nDB05097\tLabetuzumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Labetuzumab.\tDB00002\nDB05101\tMatuzumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Matuzumab.\tDB00002\nDB05111\tFontolizumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Fontolizumab.\tDB00002\nDB05136\tBavituximab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Bavituximab.\tDB00002\nDB05139\tCR002\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with CR002.\tDB00002\nDB05209\tSYM001\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with SYM001.\tDB00002\nDB05276\tHepatitis B Immune Globulin\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Hepatitis B Immune Globulin.\tDB00002\nDB05336\tObiltoxaximab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Obiltoxaximab.\tDB00002\nDB05405\tXTL-001\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with XTL-001.\tDB00002\nDB05437\tRIGScan CR49\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with RIGScan CR49.\tDB00002\nDB05459\tBriakinumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Briakinumab.\tDB00002\nDB05496\tOtelixizumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Otelixizumab.\tDB00002\nDB05545\tAMG 108\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with AMG 108.\tDB00002\nDB05550\tIratumumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Iratumumab.\tDB00002\nDB05555\tEnokizumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Enokizumab.\tDB00002\nDB05578\tRamucirumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Ramucirumab.\tDB00002\nDB05595\tFarletuzumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Farletuzumab.\tDB00002\nDB05656\tVeltuzumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Veltuzumab.\tDB00002\nDB05679\tUstekinumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Ustekinumab.\tDB00002\nDB05773\tTrastuzumab emtansine\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Trastuzumab emtansine.\tDB00002\nDB05793\tPRO-542\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with PRO-542.\tDB00002\nDB05797\tTNX-901\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with TNX-901.\tDB00002\nDB05889\tInotuzumab ozogamicin\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Inotuzumab ozogamicin.\tDB00002\nDB05892\tRI 624\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with RI 624.\tDB00002\nDB05915\tMYO-029\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with MYO-029.\tDB00002\nDB05941\tLeronlimab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Leronlimab.\tDB00002\nDB05996\tGlembatumumab vedotin\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Glembatumumab vedotin.\tDB00002\nDB06043\tOlaratumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Olaratumab.\tDB00002\nDB06049\tIPH 2101\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with IPH 2101.\tDB00002\nDB06050\tTB-402\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with TB-402.\tDB00002\nDB06081\tCaplacizumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Caplacizumab.\tDB00002\nDB06101\tIMC-1C11\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with IMC-1C11.\tDB00002\nDB06116\tEldelumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Eldelumab.\tDB00002\nDB06162\tLumiliximab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Lumiliximab.\tDB00002\nDB06168\tCanakinumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Canakinumab.\tDB00002\nDB06186\tIpilimumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Ipilimumab.\tDB00002\nDB06192\tNimotuzumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Nimotuzumab.\tDB00002\nDB06241\tClenoliximab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Clenoliximab.\tDB00002\nDB06273\tTocilizumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Tocilizumab.\tDB00002\nDB06304\tBIIB015\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with BIIB015.\tDB00002\nDB06310\tMotavizumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Motavizumab.\tDB00002\nDB06317\tElotuzumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Elotuzumab.\tDB00002\nDB06318\tAVE9633\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with AVE9633.\tDB00002\nDB06322\tTRC105\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with TRC105.\tDB00002\nDB06324\tXmAb 2513\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with XmAb 2513.\tDB00002\nDB06342\tColtuximab ravtansine\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Coltuximab ravtansine.\tDB00002\nDB06343\tTeprotumumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Teprotumumab.\tDB00002\nDB06360\tLucatumumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Lucatumumab.\tDB00002\nDB06366\tPertuzumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Pertuzumab.\tDB00002\nDB06371\tSiplizumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Siplizumab.\tDB00002\nDB06467\tApolizumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Apolizumab.\tDB00002\nDB06474\tSibrotuzumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Sibrotuzumab.\tDB00002\nDB06550\tBivatuzumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Bivatuzumab.\tDB00002\nDB06557\tLerdelimumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Lerdelimumab.\tDB00002\nDB06599\tLexatumumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Lexatumumab.\tDB00002\nDB06602\tReslizumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Reslizumab.\tDB00002\nDB06606\tTeplizumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Teplizumab.\tDB00002\nDB06607\tCatumaxomab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Catumaxomab.\tDB00002\nDB06612\tMepolizumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Mepolizumab.\tDB00002\nDB06643\tDenosumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Denosumab.\tDB00002\nDB06647\tVolociximab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Volociximab.\tDB00002\nDB06650\tOfatumumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Ofatumumab.\tDB00002\nDB06674\tGolimumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Golimumab.\tDB00002\nDB08870\tBrentuximab vedotin\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Brentuximab vedotin.\tDB00002\nDB08879\tBelimumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Belimumab.\tDB00002\nDB08902\tRaxibacumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Raxibacumab.\tDB00002\nDB08904\tCertolizumab pegol\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Certolizumab pegol.\tDB00002\nDB08935\tObinutuzumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Obinutuzumab.\tDB00002\nDB09029\tSecukinumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Secukinumab.\tDB00002\nDB09033\tVedolizumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Vedolizumab.\tDB00002\nDB09035\tNivolumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Nivolumab.\tDB00002\nDB09036\tSiltuximab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Siltuximab.\tDB00002\nDB09037\tPembrolizumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Pembrolizumab.\tDB00002\nDB09045\tDulaglutide\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Dulaglutide.\tDB00002\nDB09052\tBlinatumomab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Blinatumomab.\tDB00002\nDB09057\tAnthrax immune globulin human\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Anthrax immune globulin human.\tDB00002\nDB09077\tDinutuximab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Dinutuximab.\tDB00002\nDB09105\tAsfotase Alfa\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Asfotase Alfa.\tDB00002\nDB09264\tIdarucizumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Idarucizumab.\tDB00002\nDB09302\tAlirocumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Alirocumab.\tDB00002\nDB09303\tEvolocumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Evolocumab.\tDB00002\nDB09312\tAntilymphocyte immunoglobulin (horse)\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Antilymphocyte immunoglobulin (horse).\tDB00002\nDB09331\tDaratumumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Daratumumab.\tDB00002\nDB09559\tNecitumumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Necitumumab.\tDB00002\nDB11569\tIxekizumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Ixekizumab.\tDB00002\nDB11595\tAtezolizumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Atezolizumab.\tDB00002\nDB11604\tTetanus Immune Globulin\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Tetanus Immune Globulin.\tDB00002\nDB11621\tHuman Varicella-Zoster Immune Globulin\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Human Varicella-Zoster Immune Globulin.\tDB00002\nDB11646\tConatumumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Conatumumab.\tDB00002\nDB11657\tTabalumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Tabalumab.\tDB00002\nDB11680\tFiclatuzumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Ficlatuzumab.\tDB00002\nDB11685\tFigitumumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Figitumumab.\tDB00002\nDB11714\tDurvalumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Durvalumab.\tDB00002\nDB11715\tBapineuzumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Bapineuzumab.\tDB00002\nDB11731\tDepatuxizumab mafodotin\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Depatuxizumab mafodotin.\tDB00002\nDB11746\tOnartuzumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Onartuzumab.\tDB00002\nDB11756\tSolanezumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Solanezumab.\tDB00002\nDB11767\tSarilumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Sarilumab.\tDB00002\nDB11771\tTremelimumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Tremelimumab.\tDB00002\nDB11776\tBrodalumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Brodalumab.\tDB00002\nDB11803\tSirukumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Sirukumab.\tDB00002\nDB11826\tLampalizumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Lampalizumab.\tDB00002\nDB11834\tGuselkumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Guselkumab.\tDB00002\nDB11840\tDalotuzumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Dalotuzumab.\tDB00002\nDB11849\tEmibetuzumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Emibetuzumab.\tDB00002\nDB11856\tLigelizumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Ligelizumab.\tDB00002\nDB11857\tSeribantumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Seribantumab.\tDB00002\nDB11862\tLandogrozumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Landogrozumab.\tDB00002\nDB11866\tRomosozumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Romosozumab.\tDB00002\nDB11914\tLebrikizumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Lebrikizumab.\tDB00002\nDB11945\tAvelumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Avelumab.\tDB00002\nDB11959\tCrenezumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Crenezumab.\tDB00002\nDB11972\tRilotumumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Rilotumumab.\tDB00002\nDB11976\tAnifrolumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Anifrolumab.\tDB00002\nDB11988\tOcrelizumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Ocrelizumab.\tDB00002\nDB12023\tBenralizumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Benralizumab.\tDB00002\nDB12034\tGantenerumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Gantenerumab.\tDB00002\nDB12053\tVisilizumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Visilizumab.\tDB00002\nDB12089\tLorvotuzumab mertansine\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Lorvotuzumab mertansine.\tDB00002\nDB12090\tPatritumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Patritumab.\tDB00002\nDB12102\tFulranumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Fulranumab.\tDB00002\nDB12104\tTarextumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Tarextumab.\tDB00002\nDB12118\tSotatercept\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Sotatercept.\tDB00002\nDB12119\tGevokizumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Gevokizumab.\tDB00002\nDB12142\tDuligotuzumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Duligotuzumab.\tDB00002\nDB12159\tDupilumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Dupilumab.\tDB00002\nDB12169\tTralokinumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Tralokinumab.\tDB00002\nDB12189\tEtrolizumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Etrolizumab.\tDB00002\nDB12202\tZalutumumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Zalutumumab.\tDB00002\nDB12205\tGanitumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Ganitumab.\tDB00002\nDB12213\tEtaracizumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Etaracizumab.\tDB00002\nDB12240\tPolatuzumab Vedotin\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Polatuzumab Vedotin.\tDB00002\nDB12246\tInclacumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Inclacumab.\tDB00002\nDB12250\tCixutumumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Cixutumumab.\tDB00002\nDB12261\tAscrinvacumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Ascrinvacumab.\tDB00002\nDB12274\tAducanumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Aducanumab.\tDB00002\nDB12335\tTanezumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Tanezumab.\tDB00002\nDB12363\tDusigitumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Dusigitumab.\tDB00002\nDB12396\tFresolimumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Fresolimumab.\tDB00002\nDB12456\tBococizumab\tThe risk or severity of adverse effects can be increased when Cetuximab is combined with Bococizumab.\tDB00002"
          },
          {
            "type": "HTML",
            "data": "\u003cdiv class\u003d\"result-alert alert-warning\" role\u003d\"alert\"\u003e\u003cbutton type\u003d\"button\" class\u003d\"close\" data-dismiss\u003d\"alert\" aria-label\u003d\"Close\"\u003e\u003cspan aria-hidden\u003d\"true\"\u003e\u0026times;\u003c/span\u003e\u003c/button\u003e\u003cstrong\u003eOutput is truncated\u003c/strong\u003e to 102400 bytes. Learn more about \u003cstrong\u003eZEPPELIN_INTERPRETER_OUTPUT_LIMIT\u003c/strong\u003e\u003c/div\u003e"
          }
        ]
      },
      "apps": [],
      "jobName": "paragraph_1549135423351_483212827",
      "id": "20190202-172343_1909811078",
      "dateCreated": "2019-02-02 17:23:43.352",
      "dateStarted": "2019-02-02 17:23:48.533",
      "dateFinished": "2019-02-02 17:23:53.655",
      "status": "FINISHED",
      "progressUpdateIntervalMs": 500
    },
    {
      "text": "%python\n\nclass Neo4JConnection(object):\n\n    def __init__(self, uri, user, password):\n        self._driver \u003d GraphDatabase.driver(uri, auth\u003d(user, password))\n\n    def close(self):\n        self._driver.close()\n\n\n    def create_patology(self,nome):\n        with self._driver.session() as session:\n            return session.run(\"CREATE (p:Patologia) \" \n                            \" SET p.nome \u003d $nome  RETURN id(p)\", nome\u003dnome).single().value()\n                           \n    def create_principio_ativo(self,term,english_term,drugbank_id,drugbank_description,drugbank_descricao):\n        with self._driver.session() as session:\n            \n            return session.run(\"MERGE (p:ItemPrincipioAtivo {term: $term, english_term: $english_term,drugbank_id:$drugbank_id,drugbank_description:$drugbank_description,drugbank_descricao:$drugbank_descricao}) RETURN id(p)\", \\\n            term\u003dterm,english_term\u003denglish_term,drugbank_id\u003ddrugbank_id,drugbank_description\u003ddrugbank_description,drugbank_descricao\u003ddrugbank_descricao).single().value()\n            #return session.run(\"CREATE (p:ItemPrincipioAtivo {nome:$nome}) RETURN id(p)\", nome\u003dnome).single().value()\n    \n    def create_contra_indicacao_term(self,nome):\n        with self._driver.session() as session:\n            return session.run(\"CREATE (c:ContraIndicacaoTerm {nome:$nome}) RETURN id(c)\", nome\u003dnome).single().value()\n            \n    def create_relationship_principio_ativo_patologia(self,nome_patologia,nome_principio_ativo,term_frequency):\n        with self._driver.session() as session:\n            return session.run(\"MATCH (p:Patologia),(i:ItemPrincipioAtivo) \"\n                            \"WHERE p.nome \u003d $patologia and  i.term \u003d $principio_ativo \"\n                            \"CREATE (i)-[r:active_principle_indication { nome: p.nome + \u0027 \u003c-\u003e \u0027 + i.term , freq: $frequency }]-\u003e(p) RETURN type(r), r.nome\", patologia\u003dnome_patologia, principio_ativo\u003d nome_principio_ativo,frequency \u003d term_frequency)\n    \n    \n    def create_relationship_contra_indicacao_patologia(self,nome_patologia,nome_contra_indicacao,term_frequency):\n        with self._driver.session() as session:\n            return session.run(\"MATCH (p:Patologia),(c:ItemPrincipioAtivo) \"\n                            \"WHERE p.nome \u003d $patologia and  c.term \u003d $nome_contra_indicacao \"\n                            \"CREATE (c)-[r:counter_indication_term_associated { nome: p.nome + \u0027 \u003c-\u003e \u0027 + c.term , freq: $frequency }]-\u003e(p) RETURN type(r), r.nome\", patologia\u003dnome_patologia, nome_contra_indicacao\u003d nome_contra_indicacao,frequency \u003d term_frequency)\n    \n    \n    def create_relationship_principio_ativo(self,term1,term2,term_frequency):\n        with self._driver.session() as session:\n            return session.run(\"MATCH (i1:ItemPrincipioAtivo),(i2:ItemPrincipioAtivo) \"\n                    \"WHERE i1.term \u003d $term1 and  i2.term \u003d $term2 \"\n                    \"CREATE (i1)-[r:active_principle_linked_term { nome: i1.term + \u0027 \u003c-\u003e \u0027 + i2.term , freq: $frequency }]-\u003e(i2) RETURN type(r), r.nome\", term1\u003dterm1, term2\u003d term2,frequency \u003dterm_frequency)\n    \n                            \n    def delete_all(self):\n        with self._driver.session() as session:\n            return session.run(\"MATCH (n) DETACH DELETE n\").single()\n",
      "user": "anonymous",
      "dateUpdated": "2019-02-02 10:49:07.121",
      "config": {
        "colWidth": 12.0,
        "fontSize": 9.0,
        "enabled": true,
        "results": {},
        "editorSetting": {
          "language": "python",
          "editOnDblClick": false,
          "completionKey": "TAB",
          "completionSupport": true
        },
        "editorMode": "ace/mode/python"
      },
      "settings": {
        "params": {},
        "forms": {}
      },
      "results": {
        "code": "SUCCESS",
        "msg": []
      },
      "apps": [],
      "jobName": "paragraph_1548595379128_1483697430",
      "id": "20190127-112259_894328358",
      "dateCreated": "2019-01-27 11:22:59.128",
      "dateStarted": "2019-02-02 10:49:07.159",
      "dateFinished": "2019-02-02 10:49:07.248",
      "status": "FINISHED",
      "progressUpdateIntervalMs": 500
    },
    {
      "text": "%python\n\nneo \u003d Neo4JConnection(uri,user,password)\n\ndef create_patology(name):\n    neo.create_patology(name)\n\ndef create_termos_principio_ativo(terms):\n    for index, row in terms.iterrows():\n        neo.create_principio_ativo(row[\u0027term\u0027],row[\u0027english_term\u0027],row[\u0027drugbank_id\u0027],row[\u0027drugbank_description\u0027],row[\u0027drugbank_descricao\u0027])\n\n\ndef create_termos_contra_indicacao(terms):\n    for index, row in terms.iterrows():\n        neo.create_contra_indicacao_term(row[\u0027term\u0027])\n        \n        \ndef create_relatioship_between_patology_term(patology_name,terms):\n    for index, row in terms.iterrows():\n        neo.create_relationship_principio_ativo_patologia(patology_name,row[\u0027term\u0027],row[\u0027term_freq\u0027]) \n         \n         \ndef create_relatioship_between_principio_ativo(dataframe):\n     for key, value in dataframe.value_counts().to_dict().items():\n        try:\n            itens \u003d np.array(key.split(\u0027,\u0027))\n            c \u003d set(itertools.combinations(itens, 2))\n            for i in c:\n                neo.create_relationship_principio_ativo(i[0],i[1],value)\n        except Exception as err:\n            print(err)\n            print(\u0027error on {}\u0027.format(key)) \n        \n \ndef create_relatioship_between_patology_counter_indication(patology_name,terms):\n    for index, row in terms.iterrows():\n        neo.create_relationship_contra_indicacao_patologia(patology_name,row[\u0027term\u0027],row[\u0027term_freq\u0027]) \n \n\ndef create_relationship_between_ci_terms(dataframe):\n    for key, value in dataframe.value_counts().to_dict().items():\n        try:\n            itens \u003d np.array(key.split(\u0027,\u0027))\n            c \u003d set(itertools.combinations(itens, 2))\n            for i in c:\n                neo.create_relationship_contra_indicacao(i[0],i[1],value)\n        except Exception as err:\n            print(err)\n            print(\u0027error on {}\u0027.format(key))   \n\n            \ndef create_dataframe_word_occurrences(dataframe):\n    df_frequencies \u003d pd.DataFrame(columns\u003d[\u0027term\u0027,\u0027term_freq\u0027])\n\n    itemset \u003d set()\n    for key, value in dataframe.value_counts().to_dict().items():\n        try:\n            itens \u003d np.array(key.split(\u0027,\u0027))\n            for item in itens:\n                if item !\u003d \u0027\u0027:\n                    df_frequencies \u003d df_frequencies.append ({\u0027term\u0027: item,\u0027term_freq\u0027:value}, ignore_index\u003dTrue)\n        except Exception as err:\n            print(\u0027error on {}\u0027.format(key))\n    df_frequencies.drop_duplicates(inplace\u003dTrue)\n    return df_frequencies\n\n\ndef create_counter_indications_diseases(diseases):\n\n    try:\n        c \u003d set(itertools.combinations(diseases, 2))\n        for i in c:\n             \n             disease_df \u003d bulas_df[(bulas_df[\u0027indicacao_keywords\u0027].str.contains(i[0])\u003d\u003dTrue) \u0026 (bulas_df[\u0027contraindicacao_keywords\u0027].str.contains(i[0])\u003d\u003dFalse)]\n             counter_indications \u003d disease_df[disease_df[\u0027contraindicacao_keywords\u0027].str.contains(i[1])\u003d\u003dTrue]\n             df_principio_ativo_terms_all \u003d create_dataframe_word_occurrences(counter_indications[\u0027principio_ativo_keywords\u0027])\n             #print(df_principio_ativo_terms_all)\n             create_relatioship_between_patology_counter_indication(i[1],df_principio_ativo_terms_all)\n             \n             \n             disease_df \u003d bulas_df[(bulas_df[\u0027indicacao_keywords\u0027].str.contains(i[1])\u003d\u003dTrue) \u0026 (bulas_df[\u0027contraindicacao_keywords\u0027].str.contains(i[1])\u003d\u003dFalse)]\n             counter_indications \u003d disease_df[disease_df[\u0027contraindicacao_keywords\u0027].str.contains(i[0])\u003d\u003dTrue]\n             df_principio_ativo_terms_all \u003d create_dataframe_word_occurrences(counter_indications[\u0027principio_ativo_keywords\u0027])\n             #print(df_principio_ativo_terms_all)\n             create_relatioship_between_patology_counter_indication(i[0],df_principio_ativo_terms_all)\n             \n             \n    except Exception as err:\n        print(err)\n        print(\u0027error on {}\u0027.format(key))   \n\n",
      "user": "anonymous",
      "dateUpdated": "2019-02-03 10:03:28.001",
      "config": {
        "colWidth": 12.0,
        "fontSize": 9.0,
        "enabled": true,
        "results": {},
        "editorSetting": {
          "language": "python",
          "editOnDblClick": false,
          "completionKey": "TAB",
          "completionSupport": true
        },
        "editorMode": "ace/mode/python"
      },
      "settings": {
        "params": {},
        "forms": {}
      },
      "results": {
        "code": "SUCCESS",
        "msg": []
      },
      "apps": [],
      "jobName": "paragraph_1548507237651_717243025",
      "id": "20190126-105357_35423309",
      "dateCreated": "2019-01-26 10:53:57.651",
      "dateStarted": "2019-02-02 10:49:11.051",
      "dateFinished": "2019-02-02 10:49:11.229",
      "status": "FINISHED",
      "progressUpdateIntervalMs": 500
    },
    {
      "text": "%python\n\ndef lookup_drugbank(term):\n    if term !\u003d \u0027\u0027:\n        drugbank_id \u003d drugbank_df[(drugbank_df[\u0027lower_name\u0027] \u003d\u003d term)][\u0027drugbank_id\u0027].values\n        if drugbank_id.size \u003e 0:\n            return drugbank_id[0]\n    return \u0027\u0027\n    \ndef lookup_drugbank_description(id):\n    if id !\u003d \u0027\u0027:\n        drugbank_description \u003d drugbank_df[(drugbank_df[\u0027drugbank_id\u0027] \u003d\u003d id)][\u0027description\u0027].values\n        if drugbank_description.size \u003e 0:\n            return str(drugbank_description[0]).strip()\n        else:\n            return \u0027\u0027\n    return \u0027\u0027\n\n\n            \nneo.delete_all()\n\ndiseases \u003d [\u0027diabetes\u0027,\u0027hipertensao\u0027,\u0027osteoporose\u0027,\u0027parkinson\u0027,\u0027alzheimer\u0027]\ndiseases_df \u003d []\n\nfor disease in diseases:\n    disease_df \u003d bulas_df[(bulas_df[\u0027indicacao_keywords\u0027].str.contains(disease)\u003d\u003dTrue) \u0026 (bulas_df[\u0027contraindicacao_keywords\u0027].str.contains(disease)\u003d\u003dFalse)]\n    df_principio_ativo_terms_all \u003d create_dataframe_word_occurrences(disease_df[\u0027principio_ativo_keywords\u0027])\n    principio_ativo_terms_dictionary \u003d df_principio_ativo_terms_all[[\u0027term\u0027]]\n    \n    principio_ativo_terms_dictionary \u003d principio_ativo_terms_dictionary.drop_duplicates()\n    principio_ativo_terms_dictionary[\u0027english_term\u0027] \u003d principio_ativo_terms_dictionary[\u0027term\u0027].apply(lambda x : translate(x,\u0027pt\u0027,\u0027en\u0027))\n    principio_ativo_terms_dictionary[\u0027drugbank_id\u0027] \u003d principio_ativo_terms_dictionary[\u0027english_term\u0027].apply(lambda x : lookup_drugbank(x))\n    principio_ativo_terms_dictionary \u003d principio_ativo_terms_dictionary.replace(np.nan, \u0027\u0027, regex\u003dTrue)\n    principio_ativo_terms_dictionary[\u0027drugbank_description\u0027] \u003d principio_ativo_terms_dictionary[\u0027drugbank_id\u0027].apply(lambda x : lookup_drugbank_description(x))\n    principio_ativo_terms_dictionary[\u0027drugbank_descricao\u0027] \u003d principio_ativo_terms_dictionary[\u0027drugbank_description\u0027].apply(lambda x : translate(x.replace(\u0027(\u0027,\u0027\u0027).replace(\u0027)\u0027,\u0027\u0027),\u0027en\u0027,\u0027pt\u0027))\n\n    create_patology(disease)\n    create_termos_principio_ativo(principio_ativo_terms_dictionary)\n    create_relatioship_between_patology_term(disease,df_principio_ativo_terms_all)\n    create_relatioship_between_principio_ativo(disease_df[\u0027principio_ativo_keywords\u0027])\n\n\n\ncreate_counter_indications_diseases(diseases)\n",
      "user": "anonymous",
      "dateUpdated": "2019-02-02 10:49:13.992",
      "config": {
        "colWidth": 12.0,
        "fontSize": 9.0,
        "enabled": true,
        "results": {},
        "editorSetting": {
          "language": "python",
          "editOnDblClick": false,
          "completionKey": "TAB",
          "completionSupport": true
        },
        "editorMode": "ace/mode/python",
        "tableHide": false
      },
      "settings": {
        "params": {},
        "forms": {}
      },
      "results": {
        "code": "SUCCESS",
        "msg": []
      },
      "apps": [],
      "jobName": "paragraph_1548713872383_1901330681",
      "id": "20190128-201752_984582256",
      "dateCreated": "2019-01-28 20:17:52.383",
      "dateStarted": "2019-02-02 10:49:14.036",
      "dateFinished": "2019-02-02 10:59:24.300",
      "status": "FINISHED",
      "progressUpdateIntervalMs": 500
    },
    {
      "text": "%neo4j\nmatch(p:Patologia {nome:\u0027hipertensao\u0027})-[r:active_principle_indication]-(i:ItemPrincipioAtivo)-[r1:counter_indication_term_associated]-(p1:Patologia {nome:\u0027diabetes\u0027}) return distinct i.term as indicado_para,p.nome as tratamento_patologia,p1.nome as contra_indicado\n",
      "user": "anonymous",
      "dateUpdated": "2019-02-02 11:03:55.896",
      "config": {
        "colWidth": 12.0,
        "fontSize": 9.0,
        "enabled": true,
        "results": {
          "0": {
            "graph": {
              "mode": "table",
              "height": 300.0,
              "optionOpen": false,
              "setting": {
                "table": {
                  "tableGridState": {},
                  "tableColumnTypeState": {
                    "names": {
                      "indicado_para": "string",
                      "tratamento_patologia": "string",
                      "contra_indicado": "string"
                    },
                    "updated": false
                  },
                  "tableOptionSpecHash": "[{\"name\":\"useFilter\",\"valueType\":\"boolean\",\"defaultValue\":false,\"widget\":\"checkbox\",\"description\":\"Enable filter for columns\"},{\"name\":\"showPagination\",\"valueType\":\"boolean\",\"defaultValue\":false,\"widget\":\"checkbox\",\"description\":\"Enable pagination for better navigation\"},{\"name\":\"showAggregationFooter\",\"valueType\":\"boolean\",\"defaultValue\":false,\"widget\":\"checkbox\",\"description\":\"Enable a footer for displaying aggregated values\"}]",
                  "tableOptionValue": {
                    "useFilter": false,
                    "showPagination": false,
                    "showAggregationFooter": false
                  },
                  "updated": false,
                  "initialized": false
                }
              },
              "commonSetting": {}
            },
            "helium": {}
          }
        },
        "editorSetting": {
          "language": "python",
          "editOnDblClick": false,
          "completionKey": "TAB",
          "completionSupport": true
        },
        "editorMode": "ace/mode/undefined"
      },
      "settings": {
        "params": {},
        "forms": {}
      },
      "results": {
        "code": "SUCCESS",
        "msg": [
          {
            "type": "TABLE",
            "data": "indicado_para\ttratamento_patologia\tcontra_indicado\n\"arginina\"\t\"hipertensao\"\t\"diabetes\"\n\"hidroclorotiazida\"\t\"hipertensao\"\t\"diabetes\"\n\"lisinopril\"\t\"hipertensao\"\t\"diabetes\"\n\"indapamida\"\t\"hipertensao\"\t\"diabetes\"\n\"perindopril\"\t\"hipertensao\"\t\"diabetes\"\n\"micardis\"\t\"hipertensao\"\t\"diabetes\"\n\"telmisartana\"\t\"hipertensao\"\t\"diabetes\"\n\"irbesartana\"\t\"hipertensao\"\t\"diabetes\"\n\"aprozide\"\t\"hipertensao\"\t\"diabetes\"\n\"potassica\"\t\"hipertensao\"\t\"diabetes\"\n\"besilato\"\t\"hipertensao\"\t\"diabetes\"\n\"losartana\"\t\"hipertensao\"\t\"diabetes\"\n\"anlodipino\"\t\"hipertensao\"\t\"diabetes\"\n\"cilexetila\"\t\"hipertensao\"\t\"diabetes\"\n\"candesartana\"\t\"hipertensao\"\t\"diabetes\"\n\"maleato\"\t\"hipertensao\"\t\"diabetes\"\n\"enalapril\"\t\"hipertensao\"\t\"diabetes\"\n"
          }
        ]
      },
      "apps": [],
      "jobName": "paragraph_1548813999884_421316340",
      "id": "20190130-000639_1654007420",
      "dateCreated": "2019-01-30 00:06:39.884",
      "dateStarted": "2019-02-02 11:03:55.937",
      "dateFinished": "2019-02-02 11:03:55.956",
      "status": "FINISHED",
      "progressUpdateIntervalMs": 500
    },
    {
      "text": "%python\ndisease_df \u003d bulas_df[(bulas_df[\u0027indicacao_keywords\u0027].str.contains(\u0027hipertensao\u0027)\u003d\u003dTrue) \u0026 (bulas_df[\u0027contraindicacao_keywords\u0027].str.contains(\u0027hipertensao\u0027)\u003d\u003dFalse)]\nz.show(disease_df)",
      "user": "anonymous",
      "dateUpdated": "2019-02-02 17:26:29.364",
      "config": {
        "colWidth": 12.0,
        "fontSize": 9.0,
        "enabled": true,
        "results": {
          "0": {
            "graph": {
              "mode": "table",
              "height": 300.0,
              "optionOpen": false,
              "setting": {
                "table": {
                  "tableGridState": {},
                  "tableColumnTypeState": {
                    "names": {
                      "filename": "string",
                      "composicao": "string",
                      "indicacao": "string",
                      "contraindicacao": "string",
                      "composicao_keywords": "string",
                      "indicacao_keywords": "string",
                      "contraindicacao_keywords": "string",
                      "principio_ativo": "string",
                      "principio_ativo_keywords": "string"
                    },
                    "updated": false
                  },
                  "tableOptionSpecHash": "[{\"name\":\"useFilter\",\"valueType\":\"boolean\",\"defaultValue\":false,\"widget\":\"checkbox\",\"description\":\"Enable filter for columns\"},{\"name\":\"showPagination\",\"valueType\":\"boolean\",\"defaultValue\":false,\"widget\":\"checkbox\",\"description\":\"Enable pagination for better navigation\"},{\"name\":\"showAggregationFooter\",\"valueType\":\"boolean\",\"defaultValue\":false,\"widget\":\"checkbox\",\"description\":\"Enable a footer for displaying aggregated values\"}]",
                  "tableOptionValue": {
                    "useFilter": false,
                    "showPagination": false,
                    "showAggregationFooter": false
                  },
                  "updated": false,
                  "initialized": false
                }
              },
              "commonSetting": {}
            }
          }
        },
        "editorSetting": {
          "language": "python",
          "editOnDblClick": false,
          "completionKey": "TAB",
          "completionSupport": true
        },
        "editorMode": "ace/mode/python"
      },
      "settings": {
        "params": {},
        "forms": {}
      },
      "results": {
        "code": "SUCCESS",
        "msg": [
          {
            "type": "TABLE",
            "data": "filename\tcomposicao\tindicacao\tcontraindicacao\tcomposicao_keywords\tindicacao_keywords\tcontraindicacao_keywords\tprincipio_ativo\tprincipio_ativo_keywords\n/home/altieris/datascience/data/bulario/bulas-txt/482/482-8135782017-6392253.txt\t  identificacao do medicamento  hyperium 1mg rilmenidina 1mg  apresentacoes: embalagem contendo 15 ou 30 comprimidos de 1mg.  uso oral  uso adulto   composicao: cada comprimido de hyperium (rilmenidina) contem: dihidrogenofosfato de rilmenidina (dcb 07726)..........................1,544 mg  correspondente a 1mg de rilmenidina base (dcb 07725) excipientes q.s.p ........................................................................... 1 comprimido   excipientes: lactose monoidratada, celulose microcristalina, parafina, amidoglicolato de sodio, dioxido de silicio, estearato de magnesio, talco, cera branca de abelha, cloreto de metileno.    informacoes ao paciente  \thyperium e indicado para o tratamento da hipertensao arterial.  \t hyperium nao deve ser utilizado nos seguintes casos: - se voce e alergico a rilmenidina ou a qualquer um dos componentes da formula (listados no item composicao); - se voce sofre de depressao grave; - se voce tem insuficiencia renal grave (clearance de creatinina \u003c 15 ml/min); - se voce esta tomando sultoprida.  este medicamento e  contraindicado para menores de 18 anos.  este medicamento nao deve ser utilizado por mulheres gravidas sem orientacao medica ou do cirurgiao-dentista.  \tmonoidratada,cera,silicio,dioxido,magnesio,cloreto,hyperium,rilmenidina,talco,dihidrogenofosfato,sodio,metileno,amidoglicolato,estearato,lactose\thipertensao,hyperium,arterial\tdepressao,creatinina,hyperium,rilmenidina,sultoprida,renal,clearance,insuficiencia\t: dihidrogenofosfato de rilmenidina (dcb 07726)..........................1,544 mg  correspondente a 1mg de rilmenidina base (dcb 07725) \tdihidrogenofosfato,rilmenidina\n/home/altieris/datascience/data/bulario/bulas-txt/108/108-12297112018-10925630.txt\t     biconcor hemifumarato de bisoprolol hidroclorotiazida  merck s/a  comprimidos revestidos 2,5/6,25 mg; 5/6,25 mg; 10/6,25 mg   biconcor hemifumarato de bisoprolol, hidroclorotiazida  apresentacoes  biconcor 2,5/6,25 mg; biconcor 5/6,25 mg; biconcor 10/6,25 mg embalagens contendo 30 comprimidos revestidos.  uso oral uso adulto   composicao cada comprimido revestido contem:  biconcor 2,5/6,25 mg hemifumarato de bisoprolol .................................. 2,5 mg hidroclorotiazida ................................................... 6,25 mg excipientes: amido, crospovidona, fosfato de calcio dibasico anidro, celulose microcristalina, estearato de magnesio, hipromelose, polissorbato 80, macrogol, dioxido de titanio e oxido de ferro amarelo.  biconcor 5/6,25 mg hemifumarato de bisoprolol .................................. 5 mg hidroclorotiazida ................................................... 6,25 mg excipientes: amido, fosfato de calcio dibasico anidro, celulose microcristalina, estearato de magnesio, dioxido de silicio, hipromelose, polissorbato 80, macrogol, dioxido de titanio, oxido de ferro amarelo e oxido de ferro vermelho.  biconcor 10/6,25 mg hemifumarato de bisoprolol .................................. 10 mg hidroclorotiazida .................................................... 6,25 mg excipientes: amido, fosfato de calcio dibasico anidro, celulose microcristalina, estearato de magnesio, dioxido de silicio, hipromelose, polissorbato 80, macrogol e dioxido de titanio.  informacoes ao paciente \tbiconcor e usado para baixar a pressao sanguinea de pessoas com hipertensao (pressao alta).  \tvoce nao deve tomar biconcor nas seguintes situacoes:   hipersensibilidade (alergia) ao bisoprolol, a hidroclorotiazida, a outras tiazidas, a sulfonamidas ou a qualquer outro componente da formula;  insuficiencia cardiaca aguda ou durante episodios de insuficiencia cardiaca descompensada que requeiram tratamento intravenoso com medicamentos que aumentem a forca de contracao do coracao;  choque cardiogenico (condicao cardiaca aguda grave que provoca queda da pressao e insuficiencia circulatoria);  determinadas doencas cardiacas que provocam ritmo cardiaco muito lento ou batimentos cardiacos irregulares: bloqueio atrioventricular de segundo e terceiro graus (sem-marca passo), sindrome do no sinusal, bloqueio sinoatrial;  bradicardia sintomatica (ritmo cardiaco lento, causando desconforto);  asma bronquica grave;  problemas graves da circulacao sanguinea nos membros (tal como sindrome de raynaud), que pode fazer com que os dedos das maos e dos pes fiquem dormentes, palidos ou azuis;  feomocromitoma nao tratado (tumor raro da glandula suprarrenal);  acidose metabolica, que e uma condicao na qual o sangue esta muito acido, resultante de doencas graves;  problemas graves do figado ou rins;  hipopotassemia refrataria (concentracao baixa de potassio no sangue, nao respondendo a tratamento); este medicamento e contraindicado para uso em criancas de qualquer idade.  \tsilicio,polissorbato,macrogol,titanio,fosfato,anidro,calcio,dioxido,hidroclorotiazida,bisoprolol,magnesio,dibasico,ferro,merck,hipromelose,biconcor,amido,oxido,crospovidona,hemifumarato,estearato\thipertensao,biconcor,alta,pressao\tsinusal,provocam,atrioventricular,coracao,requeiram,tal,cardiaco,fiquem,insuficiencia,bronquica,desconforto,cardiaca,pes,potassio,hidroclorotiazida,aumentem,refrataria,bisoprolol,suprarrenal,acido,cardiacas,bradicardia,raynaud,queda,hipersensibilidade,determinadas,episodios,rins,respondendo,biconcor,tiazidas,asma,tumor,descompensada,alergia,sulfonamidas,sinoatrial,dedos,baixa,cardiogenico,pressao,palidos,feomocromitoma,hipopotassemia,doencas,circulacao,causando,figado,intravenoso,dormentes\t:  biconcor 2,5/6,25 mg hemifumarato de bisoprolol .................................. 2,5 mg hidroclorotiazida ................................................... 6,25 mg \thidroclorotiazida,bisoprolol,biconcor,hemifumarato\n/home/altieris/datascience/data/bulario/bulas-txt/100/100-5231342013-1676362.txt\t  i) identificacao do medicamento    besilato de anlodipino medicamento generico, lei no 9.787, de 1999  apresentacoes  besilato de anlodipino 5 mg. embalagem contendo 10, 20 e 30 comprimidos. besilato de anlodipino 10 mg. embalagem contendo 10, 20 e 30 comprimidos.    uso oral uso adulto   composicao cada comprimido de 5 mg contem: besilato de anlodipino  ............................................................................................................................ 6,936 mg (equivalente a 5 mg de anlodipino) excipientes q.s.p. ............................................................................................................................. 1 comprimido (celulose microcristalina, hidrogeno fosfato de calcio anidro, estearato de magnesio, amidoglicolato de sodio)  cada comprimido de 10 mg contem: besilato de anlodipino  ........................................................................................................................... 13,872  mg (equivalente a 10 mg de anlodipino) excipientes q.s.p. ................................................................................................................................ 1 comprimido (celulose microcristalina, hidrogeno fosfato de calcio anidro, estearato de magnesio, amidoglicolato de sodio)   ii) informacoes ao paciente  \t o medicamento besilato de anlodipino e  indicado  como  medicamento   de  primeira  escolha  no  tratamento  da hipertensao (pressao alta) e angina de peito (dor no peito, por doenca do coracao) devido a isquemia miocardica (falta de sangue no coracao). o medicamento besilato de anlodipino pode  ser usado  isoladamente  ou em combinacao  com outros medicamentos  para tratar  as mesmas indicacoes acima.  \t nao use besilato  de  anlodipino se voce tem hipersensibilidade  as diidropiridinas*  (classe de medicamentos  a que pertence o anlodipino, principio ativo do medicamento), ao anlodipino ou a qualquer componente da formula.  este medicamento nao deve ser utilizado por mulheres gravidas sem orientacao medica ou do cirurgiao--dentista.  nao utilize besilato de  anlodipino durante a amamentacao sem orientacao medica. avise ao seu medico ou cirurgiao-dentista se voce estiver amamentando ou vai iniciar amamentacao durante o uso deste medicamento.  *o anlodipino e um bloqueador do canal de calcio diidropiridino.  \tcalcio,magnesio,amidoglicolato,anlodipino,estearato,besilato,sodio,anidro,fosfato\tmiocardica,hipertensao,pressao,anlodipino,coracao,angina,besilato,peito,alta\tcanal,calcio,anlodipino,cirurgiao,hipersensibilidade,besilato,diidropiridino,dentista\t: besilato de anlodipino  ............................................................................................................................ 6,936 mg (equivalente a 5 mg de anlodipino) \tanlodipino,besilato\n/home/altieris/datascience/data/bulario/bulas-txt/100/100-10994712017-7190057.txt\tbula paciente                           besilato de anlodipino  cimed industria de medicamentos ltda.  comprimidos  5 e 10 mg                       bula paciente    i- identificacao do medicamento   besilato de anlodipino medicamento generico lei n 9.787, de 1999  apresentacoes comprimidos de 5 e 10 mg em embalagens com 30 comprimidos.  uso oral uso adulto  composicao cada comprimido de 5 mg contem: besilato de anlodipino...................... 6,935 mg excipientesq.s.p.:......................... 1 comprimido equivalente a 5 mg de anlodipino  fosfato de calcio dibasico, celulose microcristalina, croscarmelose sodica e estearato de magnesio.  cada comprimido de 10 mg contem: besilato de anlodipino..................... 13,870 mg excipientesq.s.p.;........................ 1 comprimido equivalente a 10 mg de anlodipino  fosfato de calcio dibasico, celulose microcristalina, croscarmelose sodica e estearato de magnesio.   ii. informacoes ao paciente  \to besilato de anlodipino comprimidos e indicado como medicamento de primeira escolha no tratamento da hipertensao (pressao alta) e angina de peito (dor no peito, por doenca do coracao) devido a isquemia miocardica (falta de sangue no coracao). o besilato de anlodipino comprimidos pode ser usado isoladamente ou em combinacao com outros medicamentos para tratar as mesmas indicacoes acima.  \tnao use este medicamento se voce tem hipersensibilidade as di-hidropiridinas* (classe de medicamentos a que pertence o anlodipino, principio ativo do medicamento) ou a qualquer componente da formula. *este medicamento e um bloqueador do canal de calcio di-hidropiridino.  \tcimed,calcio,magnesio,dibasico,anlodipino,estearato,besilato,croscarmelose,sodica,fosfato\tmiocardica,hipertensao,pressao,anlodipino,coracao,angina,besilato,peito,alta\tanlodipino,canal,hipersensibilidade,calcio\t: besilato de anlodipino...................... 6,935 mg \tanlodipino,besilato\n/home/altieris/datascience/data/bulario/bulas-txt/100/100-9791702018-10804393.txt\tbesilato de anlodipino _bula_paciente          besilato de anlodipino prati-donaduzzi comprimido 5 mg e 10 mg            besilato de anlodipino_bula_paciente  1  identificacao do medicamento besilato de anlodipino medicamento generico lei no 9.787, de 1999  apresentacoes comprimido de 5 mg ou 10 mg em embalagem com 20, 30, 60, 80, 120, 240 ou 320 comprimidos.  uso oral uso adulto  composicao cada comprimido de 5 mg contem: besilato de anlodipino.................................................................6,9 mg equivalente a 5 mg de anlodipino  excipiente q.s.p............................................................................1 comprimido excipientes: celulose microcristalina, fosfato de calcio dibasico, amidoglicolato de sodio e estearato de magnesio.  cada comprimido de 10 mg contem: besilato de anlodipino...................................................................13,8 mg equivalente a 10 mg de anlodipino  excipiente q.s.p.............................................................................1 comprimido excipientes: celulose microcristalina, fosfato de calcio dibasico, amidoglicolato de sodio e estearato de magnesio.  informacoes ao paciente \teste medicamento e indicado como medicamento de primeira escolha no tratamento da hipertensao (pressao alta) e angina de peito (dor no peito, por doenca do coracao) devido a isquemia miocardica (falta de sangue no coracao). este medicamento pode ser usado isoladamente ou em combinacao com outros medicamentos para tratar as mesmas indicacoes acima.  \tnao use este medicamento se voce tem hipersensibilidade as diidropiridinas* (classe de medicamentos a que pertence o anlodipino, principio ativo do medicamento), ou a qualquer componente da formula.  *o anlodipino e um bloqueador do canal de calcio diidropiridino.  \tcalcio,magnesio,dibasico,anlodipino,estearato,besilato,sodio,amidoglicolato,fosfato\tmiocardica,hipertensao,pressao,coracao,angina,peito,alta\tcanal,calcio,anlodipino,hipersensibilidade,diidropiridino\t: besilato de anlodipino.................................................................6,9 mg equivalente a 5 mg de anlodipino  excipiente q.s.p............................................................................1 comprimido \tanlodipino,besilato\n/home/altieris/datascience/data/bulario/bulas-txt/100/100-14077802017-8036545.txt\t nova quimica farmaceutica s/a.  comprimidos 5 mg e 10 mg  besilato de anlodipino  medicamento generico lei n 9.787 de 1999   i) identificacao do medicamento nome generico: besilato de anlodipino  apresentacoes comprimidos 5 mg embalagens com 20 ou 30 comprimidos e embalagem fracionavel com 60 ou 90 comprimidos.   comprimidos 10 mg embalagens com 20 ou 30 comprimidos e embalagem fracionavel com 60 ou 90 comprimidos.   via de administracao: uso oral  uso adulto  composicao cada comprimido de 5 mg contem: besilato de anlodipino.......................................................................6,935 mg excipiente  q.s.p..............................................................................1 com.  equivalente a 5 mg de anlodipino.  croscarmelose sodica, fosfato de calcio dibasico di-hidratado, estearato de magnesio e celulose microcristalina.  cada comprimido de 10 mg contem: besilato de anlodipino.......................................................................13,870 mg excipiente  q.s.p..............................................................................1 com.  equivalente a 10 mg de anlodipino.  croscarmelose sodica, fosfato de calcio dibasico di-hidratado, estearato de magnesio, celulose microcristalina, corante aluminio laca amarelo tartrazina n 5.  ii) informacoes ao paciente  \to besilato de anlodipino e indicado como medicamento de primeira escolha no tratamento da hipertensao (pressao alta) e angina de peito (dor no peito, por doenca do coracao) devido a isquemia miocardica (falta de sangue no coracao). o besilato de anlodipino pode ser usado isoladamente ou em combinacao com outros medicamentos para tratar as mesmas indicacoes acima.  \tnao use o besilato de anlodipino se voce tem hipersensibilidade as diidropiridinas* (classe de medicamentos a que pertence o anlodipino, principio ativo do medicamento) ou a qualquer componente da formula. *o anlodipino e um bloqueador do canal de calcio diidropiridino.  este medicamento nao deve ser utilizado por mulheres gravidas sem orientacao medica ou do cirurgiao-dentista.   atencao: este produto, na concentracao de 10 mg, contem o corante amarelo de tartrazina que pode causar reacoes de natureza alergica, entre as quais asma bronquica, especialmente em pessoas alergicas ao acido acetilsalicilico. \tcalcio,tartrazina,magnesio,dibasico,aluminio,anlodipino,estearato,besilato,croscarmelose,sodica,fosfato\tmiocardica,hipertensao,pressao,anlodipino,coracao,angina,besilato,peito,alta\tbronquica,asma,canal,acido,calcio,tartrazina,anlodipino,hipersensibilidade,besilato,acetilsalicilico,diidropiridino\t: besilato de anlodipino.......................................................................6,935 mg \tanlodipino,besilato\n/home/altieris/datascience/data/bulario/bulas-txt/100/100-16821092017-8775158.txt\tmedicamento generico, lei no 9.787, de 1999  cristalia prod. quim. farm. ltda.  comprimido 5 mg e 10 mg  modelo de bula para o paciente     i- identificacao do medicamento besilato de anlodipino medicamento generico, lei no. 9.787, de 1999 apresentacoes embalagens contendo 30 comprimidos de 5 mg ou 10 mg   uso oral  uso adulto  composicao cada comprimido de 5 mg contem: besilato de anlodipino ..................................................................... 6,9 mg equivalente a 5 mg de anlodipino excipiente qsp .................................................................................. 1 comprimido excipientes: fosfato de calcio dibasico, celulose microcristalina, croscarmelose sodica, dioxido de silicio e estearato de magnesio.  cada comprimido de 10 mg contem: besilato de anlodipino ....................................................................... 13,9 mg equivalente a 10 mg de anlodipino excipiente qsp .................................................................................... 1 comprimido excipientes: fosfato de calcio dibasico, celulose microcristalina, croscarmelose sodica, dioxido de silicio e estearato de magnesio.  ii - informacoes ao paciente  \to besilato de anlodipino e indicado como medicamento de primeira escolha no tratamento da hipertensao (pressao alta) e angina de peito (dor no peito, por doenca do coracao) devido a isquemia miocardica (falta de sangue no coracao).  o besilato de anlodipino pode ser usado isoladamente ou em combinacao com outros medicamentos para tratar as mesmas indicacoes acima.  \tnao use este medicamento se voce tem hipersensibilidade as diidropiridinas* (classe de medicamentos a que pertence o besilato de anlodipino, principio ativo do medicamento) ou a qualquer componente da formula. * o besilato de anlodipino e um bloqueador do canal de calcio diidropiridino. este medicamento nao deve ser utilizado por mulheres gravidas sem orientacao medica ou do cirurgiao-dentista.  \tcalcio,silicio,dioxido,magnesio,cristalia,dibasico,anlodipino,estearato,besilato,croscarmelose,sodica,fosfato\tmiocardica,hipertensao,pressao,anlodipino,coracao,angina,besilato,peito,alta\tcanal,calcio,anlodipino,hipersensibilidade,besilato,diidropiridino\t: besilato de anlodipino ..................................................................... 6,9 mg equivalente a 5 mg de anlodipino excipiente qsp .................................................................................. 1 comprimido \tanlodipino,besilato\n/home/altieris/datascience/data/bulario/bulas-txt/100/100-4767052018-10578885.txt\t            besilapin  geolab industria farmaceutica s/a comprimido 5mg e 10mg                v.04_04/2018  modelo de bula para o paciente esta bula e continuamente atualizada. favor proceder a sua leitura antes de utilizar o medicamento.   besilapin besilato de anlodipino  medicamento similar equivalente ao medicamento referencia  forma farmaceutica e apresentacao: comprimido de 5mg ou 10mg: embalagem contendo 30 comprimidos.  uso oral uso adulto  composicao cada comprimido contem: besilato de anlodipino....................................................................................................................6,95mgou 13,90mg equivalente a 5mg de anlodipino. equivalente a 10mg de anlodipino. excipientes: celulose microcristalina, lactose monoidratada, amidoglicolato de sodio, dioxido de silicio e estearato de magnesio.  \tbesilapin e indicado como medicamento de primeira escolha no tratamento da hipertensao (pressao alta) e angina de peito (dor no peito, por doenca do coracao) devido a isquemia miocardica (falta de sangue no coracao). besilapin pode ser usado isoladamente ou em combinacao com outros medicamentos para tratar as mesmas indicacoes acima.  \tv.04_04/2018 nao use besilapin se voce tem hipersensibilidade as diidropiridinas* (classe de medicamentos a que pertence o anlodipino, principio ativo do medicamento) ou a qualquer componente da formula. * o anlodipino e um bloqueador do canal de calcio diidropiridino.  \tmonoidratada,silicio,dioxido,magnesio,anlodipino,besilapin,besilato,sodio,amidoglicolato,estearato,lactose\tmiocardica,hipertensao,pressao,coracao,besilapin,angina,peito,alta\tcanal,calcio,anlodipino,besilapin,hipersensibilidade,diidropiridino\t: besilato de anlodipino....................................................................................................................6,95mgou 13,90mg equivalente a 5mg de anlodipino. equivalente a 10mg de anlodipino. \tanlodipino,besilato\n/home/altieris/datascience/data/bulario/bulas-txt/100/100-3517512014-2043499.txt\t   pagina 1 de 7 modelo de texto de bula: besilato de anlodipino- paciente / versao: 03  04/2014       besilato de anlodipino zydus nikkho farmaceutica ltda. comprimido revestido 5,0 mg bula do paciente                  pagina 2 de 7 modelo de texto de bula: besilato de anlodipino- paciente / versao: 03  04/2014  besilato de anlodipino medicamento generico lei 9.787, de 1999.  i - identificacao do medicamento  besilato de anlodipino  comprimidos revestidos 5mg.  cartucho contendo 30 comprimidos revestidos.  via de administracao: oral  uso adulto  composicao: cada comprimido revestido contem: besilato de anlodipino.....................................................................................................................................6,930mg (equivalente a 5,0mg de anlodipino)  excipientes.................................................................................................................q.s.p.1comprimido revestido fosfato de calcio dibasico, celulose microcristalina, oxido de ferro vermelho, amido de milho, estearato de magnesio, talco purificado, amidoglicolato de sodio, dioxido de silicio coloidal, hipromelose, macrogol.  ii - informacoes ao paciente  \tbesilato de anlodipino e indicado como medicamento de primeira escolha no tratamento da hipertensao (pressao alta) e angina de peito (dor no peito, por doenca do coracao) devido a isquemia miocardica (falta de sangue no coracao). besilato de anlodipino pode ser usado isoladamente ou em combinacao com outros medicamentos para tratar as mesmas indicacoes acima.  \tnao use besilato de anlodipino se voce tem hipersensibilidade as diidropiridinas (classe de medicamentos a que pertence o anlodipino, principio ativo do medicamento), ao anlodipino ou a qualquer componente da formula.  este medicamento nao deve ser utilizado por mulheres gravidas sem orientacao medica ou do cirurgiao-dentista.  nao utilize besilato de anlodipino durante a amamentacao sem orientacao medica. avise ao seu medico ou cirurgiao-dentista se voce estiver amamentando ou vai iniciar amamentacao durante o uso deste medicamento. o anlodipino e um bloqueador do canal de calcio diidropiridino.  \tamido,zydus,calcio,silicio,oxido,magnesio,dioxido,dibasico,ferro,coloidal,talco,macrogol,anlodipino,estearato,besilato,hipromelose,milho,sodio,amidoglicolato,fosfato\tmiocardica,hipertensao,pressao,anlodipino,coracao,angina,besilato,peito,alta\tcanal,calcio,diidropiridinas,anlodipino,hipersensibilidade,besilato,diidropiridino\t: besilato de anlodipino.....................................................................................................................................6,930mg (equivalente a 5,0mg de anlodipino)  \tanlodipino,besilato\n/home/altieris/datascience/data/bulario/bulas-txt/429/429-9713642014-2286303.txt\t  bulfj0005rev01                                                                                                                                    1  modelo de texto de bula funed captopril captopril  forma farmaceutica e apresentacao funed captopril de 25 mg  blister com 10 comprimidos.  uso oral uso adulto  composicao cada comprimido de funed captopril contem: captopril .................................................................................................................... 25 mg excipientes...................................................................................................... q.s.p. 1 comprimido (amido, lactose monoidratada, celulose microcristalina, acido estearico).  informacoes ao paciente  \tfuned captopril e indicado para tratar pacientes com: - hipertensao; - insuficiencia cardiaca congestiva (usado com outros medicamentos - diureticos e digitalicos); - infarto do miocardio; - nefropatia diabetica (doenca renal causada por diabetes).  \tcontraindicacoes voce nao deve utilizar funed captopril se ja teve reacoes alergicas anteriores com o uso deste medicamento ou qualquer outro medicamento que aja da mesma maneira que o captopril.  este medicamento nao deve ser utilizado por mulheres gravidas sem orientacao medica. informe imediatamente seu medico em caso de suspeita de gravidez.  \tamido,monoidratada,acido,blister,estearico,captopril,lactose\thipertensao,diabetica,infarto,cardiaca,renal,nefropatia,captopril,diabetes,insuficiencia\tcaptopril\t: captopril .................................................................................................................... 25 mg \tcaptopril\n/home/altieris/datascience/data/bulario/bulas-txt/623/623-9541042017-6780655.txt\t           nepresol  cloridrato de hidralazina  solucao injetavel  20 mg/ml  cristalia prod. quim. farm. ltda.  modelo de bula para o paciente                           i - identificacao do medicamento nepresol cloridrato de hidralazina  apresentacao solucao injetavel 20 mg/ml embalagem com 25 e 50 ampolas de 1 ml.  uso im / iv / infusao iv  uso adulto e pediatrico  composicao nepresol 20 mg/ml cada ml contem: cloridrato de hidralazina ......................................................... 20 mg veiculo esteril q.s.p. .................................................................... 1 ml (veiculo: propilenoglicol, agua para injetaveis).  ii - informacoes ao paciente  \teste medicamento e indicado para o tratamento de hipertensao essencial, isolada ou acompanhada. e utilizado concomitante, com outros anti-hipertensivos, como betabloqueadores e diureticos.  \tnepresol e contraindicado em casos de hipersensibilidade ao cloridrato e derivados de hidralazina, dihidralazina ou aos componentes da formula, doenca cardiaca reumatica da valvula mitral, taquicardia severa ou com caso recente de infarto do miocardio, aneurisma dissecante da aorta e lupus eritematoso sistemico idiopatico e doencas correlatas. seu uso deve ser cauteloso em pacientes com historico de disturbios coronarianos ou sob tratamento com medicamentos antidepressivos.   categoria de risco na gravidez: c - nao ha estudos controlados em mulheres gravidas.  este medicamento nao deve ser utilizado por mulheres gravidas sem orientacao medica ou do cirurgiao-dentista.  \tnepresol,cristalia,hidralazina,esteril,cloridrato,propilenoglicol\tisolada,hipertensao,betabloqueadores\tcorrelatas,controlados,mitral,lupus,estudos,severa,taquicardia,coronarianos,dihidralazina,aneurisma,infarto,cardiaca,reumatica,nepresol,idiopatico,hipersensibilidade,cloridrato,aorta,eritematoso,recente,valvula,hidralazina,dissecante,doencas\t: cloridrato de hidralazina ......................................................... 20 mg \tcloridrato,hidralazina\n/home/altieris/datascience/data/bulario/bulas-txt/68/68-20269152017-9703893.txt\t  medicamento similar equivalente ao medicamento de referencia apresentacoes solucao oftalmica esteril 50 mcg/ml (0,005%) em embalagem contendo frasco gotejador de 2,5 ml.  via de administracao: uso oftalmico  uso adulto e pediatrico acima de 1 ano (vide item 1 - para que este medicamento e indicado?) composicao cada ml da solucao oftalmica esteril de arulatan contem 50 mcg de latanoprosta.  excipientes: cloreto de sodio, fosfato de sodio monobasico monoidratado, fosfato de sodio dibasico (anidro), cloreto de benzalconio e agua.  uma gota da solucao contem aproximadamente 1,5 mcg de latanoprosta.  cada 1 ml da solucao oftalmica de arulatan corresponde a aproximadamente 33 gotas.  informacoes ao paciente \tarulatan (latanoprosta) solucao oftalmica e indicado a pacientes com glaucoma de angulo aberto (doenca cronica do olho em que a pressao dentro deste aumenta, o que pode levar a morte das fibras do nervo optico e reducao do campo de visao progressiva ate a perda total da visao) e hipertensao ocular (condicao em que a pressao dentro dos olhos esta aumentada, sem lesao do nervo optico). arulatan tambem esta indicado para a reducao da pressao intraocular elevada (aumento da pressao interna dos olhos que pode levar a perda irreversivel da visao) e glaucoma, em pacientes pediatricos. \tarulatan e contraindicado a pacientes que apresentam hipersensibilidade (reacao alergica) a latanoprosta ou a qualquer componente da formula. se arulatan for acidentalmente ingerido (engolido), procure seu medico.  este medicamento e contraindicado para pacientes menores de 1 ano. \tbenzalconio,latanoprosta,monobasico,cloreto,dibasico,esteril,sodio,anidro,monoidratado,fosfato,arulatan\thipertensao,olhos,latanoprosta,glaucoma,optico,irreversivel,pressao,pediatricos,interna,nervo,intraocular,aumentada,elevada,arulatan\tacidentalmente,latanoprosta,ingerido,engolido,hipersensibilidade,arulatan\t 50 mcg de latanoprosta.  \tlatanoprosta\n/home/altieris/datascience/data/bulario/bulas-txt/137/137-1343352017-4758083.txt\t      cadenza  ache laboratorios farmaceuticos s.a. comprimido 8 mg e 16 mg  cadenza_bu 02_vp  1 bula para paciente bula de acordo com a resolucao-rdc no 47/2009  identificacao do medicamento  cadenza candesartana cilexetila medicamento similar equivalente ao medicamento de referencia  apresentacoes comprimidos de 8 mg: embalagens com 30 comprimidos comprimidos de 16 mg: embalagens com 30 comprimidos  uso oral uso adulto  composicao cada comprimido contem: candesartana cilexetila .............................................................................................8 mg excipientes: lactose monoidratada, amido, corante oxido de ferro vermelho, macrogol, hiprolose, croscarmelose sodica e estearato de magnesio. candesartana cilexetila ...........................................................................................16 mg excipientes: lactose monoidratada, amido, corante oxido de ferro vermelho, macrogol, hiprolose, croscarmelose sodica e estearato de magnesio.  ii- informacoes ao paciente  \tcadenza e indicada para o tratamento de insuficiencia cardiaca (coracao fraco) e hipertensao arterial (pressao alta) leve, moderada e grave. o tratamento com candesartana cilexetila reduz a mortalidade, reduz a hospitalizacao devido a insuficiencia cardiaca e melhora os sintomas.  \tvoce nao deve utilizar cadenza se tiver alergia a candesartana cilexetila ou a qualquer um dos componentes da formula; se estiver gravida ou amamentando; se tiver alteracoes graves no figado e/ou colestase (reducao do fluxo biliar, no qual surge uma cor amarelada na pele); se tiver diabetes mellitus (tipo i ou ii) ou insuficiencia renal moderada a grave (tgf \u003c 60ml/min/1,73m2) e fizer uso de medicamento contendo alisquireno.  \tamido,monoidratada,cilexetila,cadenza,oxido,magnesio,ferro,macrogol,hiprolose,croscarmelose,candesartana,sodica,estearato,lactose\thipertensao,cadenza,arterial,cilexetila,pressao,mortalidade,coracao,cardiaca,alta,candesartana,insuficiencia\tbiliar,diabetes,alergia,cilexetila,cadenza,alisquireno,mellitus,tgf,renal,candesartana,figado,colestase,insuficiencia\t: candesartana cilexetila .............................................................................................8 mg \tcandesartana,cilexetila\n/home/altieris/datascience/data/bulario/bulas-txt/141/141-6384472015-2749699.txt\t     candecor hct candesartana cilexetila + hidroclorotiazida  nova quimica farmaceutica ltda  comprimido  8mg/12,5mg 16mg/12,5mg                    i -  identificacao do medicamento medicamento similar equivalente ao medicamento referencia.  candecor hct candesartana cilexetila + hidroclorotiazida   apresentacoes candecor hct e apresentado na forma de comprimido revestido para uso oral nas seguintes embalagens: candecor hct comprimido 8 mg + 12,5 mg - embalagens com 20, 30, 60, 100 ou 200. comprimidos. candecor hct comprimido 16 mg + 12,5 mg embalagens com 20, 30, 60, 100 ou 200. comprimidos. embalagem hospitalar  uso adulto  uso oral  composicao  cada comprimido contem:  candesartana cilexetila.................................. 8 mg  hidroclorotiazida........................................... 12,5 mg  excipientes q.s.p. ......................................... 1 comprimido  excipientes: lactose monoidratada, celulose microcristalina, macrogol, hiprolose, croscarmelose sodica, estearato de magnesio, dioxido de silicio.  candesartana cilexetila.................................. 16 mg  hidroclorotiazida........................................... 12,5 mg  excipientes q.s.p. ......................................... 1 comprimido  excipientes: lactose monoidratada, celulose microcristalina, macrogol, hiprolose, croscarmelose sodica, estearato de magnesio, dioxido de silicio, oxido de ferro amarelo, oxido de ferro vermelho.   ii -  informacoes ao paciente  \t candecor hct e indicado para o tratamento da hipertensao (pressao alta) essencial, quando a monoterapia (uso de apenas um medicamento) nao e suficientemente eficaz.  \t voce nao deve usar o medicamento se tiver alergia a candesartana cilexetila, a hidroclorotiazida, aos derivados da sulfonamida (a hidroclorotiazida e derivada das sulfonamidas) ou a qualquer um dos componentes da formula; durante a gravidez ou amamentacao; doenca grave nos rins, figado e/ou colestase (reducao do fluxo biliar, no qual surge uma cor amarelada na pele); gota; diabetes mellitus (tipo i ou ii) ou insuficiencia renal moderada a grave (tgf \u003c 60ml/min/1,73m2) se fizer uso de medicamentos contendo alisquireno. este medicamento nao deve ser utilizado por mulheres gravidas sem orientacao medica. informe imediatamente seu medico em caso de suspeita de gravidez.  \tcandecor,monoidratada,cilexetila,dioxido,magnesio,silicio,macrogol,hiprolose,oxido,ferro,croscarmelose,hidroclorotiazida,candesartana,sodica,estearato,lactose\tcandecor,hipertensao,monoterapia,pressao,alta\tbiliar,diabetes,alergia,cilexetila,sulfonamidas,alisquireno,mellitus,tgf,figado,renal,hidroclorotiazida,candesartana,rins,sulfonamida,colestase,insuficiencia\t:  candesartana cilexetila.................................. 8 mg  hidroclorotiazida........................................... 12,5 mg  \thidroclorotiazida,candesartana,cilexetila\n/home/altieris/datascience/data/bulario/bulas-txt/141/141-6381662015-2749561.txt\t     candemed hct  candesartana cilexetila + hidroclorotiazida  germed farmaceutica ltda  comprimido 8mg/12,5mg 16mg/12,5mg               i -  identificacao do medicamento medicamento similar equivalente ao medicamento referencia.  candemed hct candesartana cilexetila + hidroclorotiazida   apresentacoes candemed hct e apresentado na forma de comprimido revestido para uso oral nas seguintes embalagens: candemed hct comprimido 8 mg + 12,5 mg - embalagens com 20, 30, 60, 100 ou 200. comprimidos. candemed hct comprimido 16 mg + 12,5 mg embalagens com 20, 30, 60, 100 ou 200. comprimidos. embalagem hospitalar  uso adulto  uso oral  composicao  cada comprimido contem:  candesartana cilexetila.................................. 8 mg  hidroclorotiazida........................................... 12,5 mg  excipientes q.s.p. ......................................... 1 comprimido  excipientes: lactose monoidratada, celulose microcristalina, macrogol, hiprolose, croscarmelose sodica, estearato de magnesio, dioxido de silicio.  candesartana cilexetila.................................. 16 mg  hidroclorotiazida........................................... 12,5 mg  excipientes q.s.p. ......................................... 1 comprimido  excipientes: lactose monoidratada, celulose microcristalina, macrogol, hiprolose, croscarmelose sodica, estearato de magnesio, dioxido de silicio, oxido de ferro amarelo, oxido de ferro vermelho.   ii -  informacoes ao paciente  \t candemed hct e indicado para o tratamento da hipertensao (pressao alta) essencial, quando a monoterapia (uso de apenas um medicamento) nao e suficientemente eficaz.  \t voce nao deve usar o medicamento se tiver alergia a candemed hct, aos derivados da sulfonamida (a hidroclorotiazida e derivada das sulfonamidas) ou a qualquer um dos componentes da formula; durante a gravidez ou amamentacao; doenca grave nos rins, figado e/ou colestase (reducao do fluxo biliar, no qual surge uma cor amarelada na pele); gota; diabetes mellitus (tipo i ou ii) ou insuficiencia renal moderada a grave (tgf \u003c 60ml/min/1,73m2) se fizer uso de medicamentos contendo alisquireno. este medicamento nao deve ser utilizado por mulheres gravidas sem orientacao medica. informe imediatamente seu medico em caso de suspeita de gravidez.  \tmonoidratada,cilexetila,dioxido,magnesio,candemed,macrogol,hiprolose,silicio,oxido,ferro,croscarmelose,hidroclorotiazida,candesartana,sodica,estearato,lactose\thipertensao,monoterapia,candemed,pressao,alta\tbiliar,diabetes,alergia,sulfonamidas,alisquireno,candemed,mellitus,tgf,figado,renal,hidroclorotiazida,rins,sulfonamida,colestase,insuficiencia\t:  candesartana cilexetila.................................. 8 mg  hidroclorotiazida........................................... 12,5 mg  \thidroclorotiazida,candesartana,cilexetila\n/home/altieris/datascience/data/bulario/bulas-txt/141/141-4808982018-10579716.txt\t         candesartana cilexetila   sandoz do brasil ind. farm. ltda.  comprimido    8 mg e 16mg    candesartana cilexetila 8 mg e 16 mg - vp 04 i) identificacao do medicamento    candesartana cilexetila medicamento generico, lei no 9.787, de 1999.   apresentacoes candesartana cilexetila comprimidos de 8mg. embalagem contendo 30 ou 60 comprimidos. candesartana cilexetila comprimidos de 16mg. embalagem contendo 30 ou 60 comprimidos.  uso oral uso adulto  composicao  cada comprimido de candesartana cilexetila 8 mg contem: candesartana cilexetila  ................................................................................................................................ 8 mg excipientes ........................................................................................................................... q.s.p. 1 comprimido (lactose monoidratada, oxido de ferro vermelho, dioxido de titanio, amido, povidona, carragenina, croscarmelose sodica, estearato de magnesio).  cada comprimido de candesartana cilexetila 16 mg contem: candesartana cilexetila  .............................................................................................................................. 16 mg excipientes ........................................................................................................................... q.s.p. 1 comprimido (lactose monoidratada, oxido de ferro vermelho, dioxido de titanio, amido, povidona, carragenina, croscarmelose sodica, estearato de magnesio).  ii) informacoes ao paciente  \t a candesartana cilexetila e indicada para o tratamento de insuficiencia cardiaca (coracao fraco) e hipertensao arterial (pressao alta) leve, moderada e grave. o tratamento com candesartana cilexetila reduz a mortalidade, reduz a hospitalizacao devido a insuficiencia cardiaca e melhora os sintomas.  \t voce nao deve utilizar este medicamento se tiver alergia a candesartana cilexetila ou a qualquer um dos componentes da formula; se estiver gravida ou amamentando; se tiver alteracoes graves no figado e/ou colestase (reducao do fluxo biliar, no qual surge uma cor amarelada na pele); se tiver diabetes mellitus (tipo i ou ii) ou insuficiencia renal moderada a grave (tgf \u003c 60ml/min/1,73m2) e fizer uso de medicamento contendo alisquireno.  \tamido,monoidratada,sodica,cilexetila,oxido,dioxido,magnesio,ferro,carragenina,titanio,croscarmelose,candesartana,povidona,estearato,lactose\thipertensao,cilexetila,arterial,pressao,mortalidade,coracao,cardiaca,alta,candesartana,insuficiencia\tbiliar,diabetes,alergia,cilexetila,alisquireno,mellitus,tgf,renal,candesartana,figado,colestase,insuficiencia\t: candesartana cilexetila  ................................................................................................................................ 8 mg \tcandesartana,cilexetila\n/home/altieris/datascience/data/bulario/bulas-txt/141/141-13579532016-3155583.txt\t      candesartana cilexetila  biosintetica farmaceutica ltda. comprimidos simples 8 mg e 16 mg  candesartana cilexetila _bu 02_vp  1 bula para paciente bula de acordo com a resolucao-rdc no 47/2009  i- identificacao do medicamento  candesartana cilexetila medicamento generico lei no 9.787, de 1999  apresentacoes comprimidos de 8 mg: embalagens com 20 e 30 comprimidos comprimidos de 16 mg: embalagens com 20 e 30 comprimidos  uso oral  uso adulto  composicao cada comprimido contem: candesartana cilexetila ............................................................................................8 mg excipientes: lactose monoidratada, amido, corante oxido de ferro vermelho, macrogol, hiprolose, croscarmelose sodica e estearato de magnesio.   candesartana cilexetila ...........................................................................................16 mg excipientes: lactose monoidratada, amido, corante oxido de ferro vermelho, macrogol, hiprolose, croscarmelose sodica e estearato de magnesio.   ii- informacoes ao paciente  \tcandesartana cilexetila e indicada para o tratamento de insuficiencia cardiaca (coracao fraco) e hipertensao arterial (pressao alta) leve, moderada e grave. o tratamento com candesartana cilexetila reduz a mortalidade, reduz a hospitalizacao devido a insuficiencia cardiaca e melhora os sintomas.  \tvoce nao deve utilizar candesartana cilexetila se tiver alergia a candesartana cilexetila ou a qualquer um dos componentes da formula; se estiver gravida ou amamentando; se tiver alteracoes graves no figado e/ou colestase (reducao do fluxo biliar, no qual surge uma cor amarelada na pele); se tiver diabetes mellitus (tipo i ou ii) ou insuficiencia renal moderada a grave (tgf \u003c 60ml/min/1,73m2) e fizer uso de medicamento contendo alisquireno.  \tamido,monoidratada,cilexetila,oxido,magnesio,biosintetica,ferro,macrogol,hiprolose,croscarmelose,candesartana,sodica,estearato,lactose\thipertensao,cilexetila,arterial,pressao,mortalidade,coracao,cardiaca,alta,candesartana,insuficiencia\tbiliar,diabetes,alergia,cilexetila,alisquireno,mellitus,tgf,renal,candesartana,figado,colestase,insuficiencia\t: candesartana cilexetila ............................................................................................8 mg \tcandesartana,cilexetila\n/home/altieris/datascience/data/bulario/bulas-txt/141/141-6379192015-2749460.txt\t               candecor  candesartana cilexetila nova quimica farmaceutica ltda  comprimido  8, 16 e 32 mg                                    i  identificacao do medicamento  medicamento similar equivalente ao medicamento referencia.  candecor candesartana cilexetila  apresentacoes candecor e apresentado na forma de comprimido revestido para uso oral nas seguintes embalagens: candecor comprimido 8 mg - embalagens com 20, 30, 60 comprimidos. candecor comprimido 16 mg - embalagens com 20, 30, 60 comprimidos. candecor comprimido 32 mg - embalagens com 20, 30, 60 comprimidos.   uso oral uso adulto  composicao  cada comprimido 8 mg contem: candesartana cilexetila  ................................................................................................................ ....8,000 mg excipiente q.s.p.  ............................................................................................................................. 1 com.   lactose monoidratada, celulose microcristalina, macrogol, hiprolose, croscarmelose sodica, oxido de ferro vermelho, estearato de magnesio, dioxido de silicio.  cada comprimido 16 mg contem: candesartana cilexetila  .............................................................................................................. ....16,000 mg excipiente q.s.p.  ............................................................................................................................. 1 com.   lactose monoidratada, celulose microcristalina, macrogol, hiprolose, croscarmelose sodica, oxido de ferro vermelho, estearato de magnesio, dioxido de silicio.  cada comprimido 32 mg contem: candesartana cilexetila  .............................................................................................................. ....32,000 mg excipiente q.s.p.  ............................................................................................................................. 1 com.   lactose monoidratada, celulose microcristalina, macrogol, hiprolose, croscarmelose sodica, oxido de ferro vermelho, estearato de magnesio, dioxido de silicio.  ii -  informacoes ao paciente  \t candecor e indicado para o tratamento de insuficiencia cardiaca (coracao fraco) e hipertensao arterial (pressao alta) leve, moderada e grave. o tratamento com candecor reduz a mortalidade, reduz a hospitalizacao devido a insuficiencia cardiaca e melhora os sintomas.  \t voce nao deve utilizar este medicamento se tiver alergia a candecor ou a qualquer um dos componentes da formula e se estiver gravida ou amamentando; se tiver alteracoes graves do figado e/ ou colestase (reducao do fluxo biliar, no qual surge uma cor amarelada na pele); se tiver diabetes mellitus (tipo i ou ii) ou insuficiencia renal moderada a grave (tgf \u003c 60 ml/min/1,76 m2) e fizer uso de medicamento alisquireno.  \tcandecor,monoidratada,cilexetila,oxido,magnesio,dioxido,macrogol,hiprolose,ferro,silicio,croscarmelose,candesartana,sodica,estearato,lactose\tcandecor,hipertensao,arterial,pressao,mortalidade,coracao,cardiaca,alta,insuficiencia\tbiliar,candecor,diabetes,alergia,alisquireno,mellitus,tgf,renal,figado,colestase,insuficiencia\t: candesartana cilexetila  ................................................................................................................ ....8,000 mg \tcandesartana,cilexetila\n/home/altieris/datascience/data/bulario/bulas-txt/141/141-6377392015-2749333.txt\t               candesartana cilexetila  legrand pharma industria farmaceutica ltda  comprimido  8, 16 e 32 mg                                     i  identificacao do medicamento  candesartana cilexetila medicamento generico lei n 9.787, de 1999.  apresentacoes candesartana cilexetila e apresentado na forma de comprimido revestido para uso oral nas seguintes embalagens: candesartana cilexetila comprimido 8 mg - embalagens com 20, 30, 60, 90 ou 100. comprimidos. candesartana cilexetila comprimido 16 mg - embalagens com 20, 30, 60, 90 ou 100. comprimidos. candesartana cilexetila comprimido 32 mg - embalagens com 20, 30, 60, 90 ou 100. comprimidos.  embalagem fracionavel embalagem hospitalar.  uso oral uso adulto  composicao  cada comprimido 8 mg contem: candesartana cilexetila  ................................................................................................................ ....8,000 mg excipiente q.s.p.  ............................................................................................................................. 1 com.   lactose monoidratada, celulose microcristalina, macrogol, hiprolose, croscarmelose sodica, oxido de ferro vermelho, estearato de magnesio, dioxido de silicio.  cada comprimido 16 mg contem: candesartana cilexetila  .............................................................................................................. ....16,000 mg excipiente q.s.p.  ............................................................................................................................. 1 com.   lactose monoidratada, celulose microcristalina, macrogol, hiprolose, croscarmelose sodica, oxido de ferro vermelho, estearato de magnesio, dioxido de silicio.  cada comprimido 32 mg contem: candesartana cilexetila  .............................................................................................................. ....32,000 mg excipiente q.s.p.  ............................................................................................................................. 1 com.   lactose monoidratada, celulose microcristalina, macrogol, hiprolose, croscarmelose sodica, oxido de ferro vermelho, estearato de magnesio, dioxido de silicio.  ii -  informacoes ao paciente  \t candesartana cilexetila e indicado para o tratamento de insuficiencia cardiaca (coracao fraco) e hipertensao arterial (pressao alta) leve, moderada e grave. o tratamento com candesartana cilexetila reduz a mortalidade, reduz a hospitalizacao devido a insuficiencia cardiaca e melhora os sintomas.  \t voce nao deve utilizar este medicamento se tiver alergia a candesartana cilexetila ou a qualquer um dos componentes da formula e se estiver gravida ou amamentando; se tiver alteracoes graves do figado e/ ou colestase (reducao do fluxo biliar, no qual surge uma cor amarelada na pele); se tiver diabetes mellitus (tipo i ou ii) ou insuficiencia renal moderada a grave (tgf \u003c 60 ml/min/1,76 m2) e fizer uso de medicamento alisquireno.  \tmonoidratada,cilexetila,oxido,magnesio,dioxido,macrogol,hiprolose,ferro,silicio,croscarmelose,candesartana,sodica,estearato,lactose\thipertensao,cilexetila,arterial,pressao,mortalidade,coracao,cardiaca,alta,candesartana,insuficiencia\tbiliar,diabetes,alergia,cilexetila,alisquireno,mellitus,tgf,renal,candesartana,figado,colestase,insuficiencia\t: candesartana cilexetila  ................................................................................................................ ....8,000 mg \tcandesartana,cilexetila\n/home/altieris/datascience/data/bulario/bulas-txt/141/141-6378792015-2749436.txt\t               candesartana cilexetila  nova quimica farmaceutica ltda  comprimido  8, 16 e 32 mg                                     i  identificacao do medicamento  candesartana cilexetila medicamento generico lei n 9.787, de 1999.  apresentacoes candesartana cilexetila e apresentado na forma de comprimido revestido para uso oral nas seguintes embalagens: candesartana cilexetila comprimido 8 mg - embalagens com 20, 30, 60 comprimidos. candesartana cilexetila comprimido 16 mg - embalagens com 20, 30, 60 comprimidos. candesartana cilexetila comprimido 32 mg - embalagens com 20, 30, 60 comprimidos.   uso oral uso adulto  composicao  cada comprimido 8 mg contem: candesartana cilexetila  ................................................................................................................ ....8,000 mg excipiente q.s.p.  ............................................................................................................................. 1 com.   lactose monoidratada, celulose microcristalina, macrogol, hiprolose, croscarmelose sodica, oxido de ferro vermelho, estearato de magnesio, dioxido de silicio.  cada comprimido 16 mg contem: candesartana cilexetila  .............................................................................................................. ....16,000 mg excipiente q.s.p.  ............................................................................................................................. 1 com.   lactose monoidratada, celulose microcristalina, macrogol, hiprolose, croscarmelose sodica, oxido de ferro vermelho, estearato de magnesio, dioxido de silicio.  cada comprimido 32 mg contem: candesartana cilexetila  .............................................................................................................. ....32,000 mg excipiente q.s.p.  ............................................................................................................................. 1 com.   lactose monoidratada, celulose microcristalina, macrogol, hiprolose, croscarmelose sodica, oxido de ferro vermelho, estearato de magnesio, dioxido de silicio.  ii -  informacoes ao paciente  \t candesartana cilexetila e indicado para o tratamento de insuficiencia cardiaca (coracao fraco) e hipertensao arterial (pressao alta) leve, moderada e grave. o tratamento com candesartana cilexetila reduz a mortalidade, reduz a hospitalizacao devido a insuficiencia cardiaca e melhora os sintomas.  \t voce nao deve utilizar este medicamento se tiver alergia a candesartana cilexetila ou a qualquer um dos componentes da formula e se estiver gravida ou amamentando; se tiver alteracoes graves do figado e/ ou colestase (reducao do fluxo biliar, no qual surge uma cor amarelada na pele); se tiver diabetes mellitus (tipo i ou ii) ou insuficiencia renal moderada a grave (tgf \u003c 60 ml/min/1,76 m2) e fizer uso de medicamento alisquireno.  \tmonoidratada,cilexetila,oxido,magnesio,dioxido,macrogol,hiprolose,ferro,silicio,croscarmelose,candesartana,sodica,estearato,lactose\thipertensao,cilexetila,arterial,pressao,mortalidade,coracao,cardiaca,alta,candesartana,insuficiencia\tbiliar,diabetes,alergia,cilexetila,alisquireno,mellitus,tgf,renal,candesartana,figado,colestase,insuficiencia\t: candesartana cilexetila  ................................................................................................................ ....8,000 mg \tcandesartana,cilexetila\n/home/altieris/datascience/data/bulario/bulas-txt/522/522-400832018-10420670.txt\t          latanoprosta + maleato de timolol nova quimica farmaceutica s/a. solucao oftalmica  0,05mg/ml + 5mg/ml                          latanoprosta + maleato de timolol medicamento generico lei n 9.787, de 1999 i - identificacao do produto latanoprosta + maleato de timolol  apresentacao solucao oftalmica esteril em embalagem contendo 1 frasco gotejador de 2,5 ml.  via de administracao: uso oftalmico uso adulto  composicao cada ml da solucao oftalmica de latanoprosta e maleato de timolol contem: latanoprosta ................................................................................................................ ........................ 0,05mg maleato de timolol ....................................................................... .................................................... 6,83mg  veiculo qsp .............................................................................................................. ........................... 1 ml equivalente a 5,0mg de timolol. cloreto de sodio, fosfato de sodio monobasico, fosfato de sodio dibasico, cloreto de benzalconio, agua para injetaveis. uma gota da solucao contem aproximadamente 1,56 mcg de latanoprosta e 156 mcg de timolol. cada mililitro da solucao oftalmica de latanoprosta e maleato de timolol equivale aproximadamente a 32 gotas.   ii - informacoes ao paciente  \ta solucao oftalmica de latanoprosta e maleato de timolol e indicada no tratamento de glaucoma de angulo aberto (doenca cronica do olho em que a pressao dentro deste aumenta, o que pode levar a morte das fibras do nervo optico e reducao progressiva do campo de visao ate a perda total da visao) ou hipertensao ocular (condicoes em que a pressao dentro dos olhos esta aumentada, mas sem lesao do nervo optico) em pacientes que apresentam resposta insuficiente ao uso de colirio contendo uma unica medicacao redutora da pressao dentro dos olhos.  \ta solucao oftalmica de latanoprosta e maleato de timolol nao deve ser utilizada em pacientes que apresentam hipersensibilidade (alergia) a latanoprosta, maleato de timolol ou a qualquer componente do produto. a solucao oftalmica de latanoprosta e maleato de timolol nao deve ser utilizada em pacientes: (1) com historia de quadros de broncoespasmo (reacao onde os bronquios se fecham), incluindo asma (doenca respiratoria, onde a respiracao e dificil, curta, ofegante e com chiado) e doenca pulmonar obstrutiva cronica (dpoc) grave, (2) portadores de alteracoes do ritmo cardiaco, tais como bradicardia sinusal, sindrome do no sinusal, bloqueio sino-atrial (disfuncao eletrica do coracao), bloqueio atrioventricular de segundo ou terceiro grau nao controlado com marca-passo; (3) historia de alteracoes da funcao do musculo do coracao, tais como insuficiencia cardiaca congestiva e choque cardiogenico.  \tbenzalconio,latanoprosta,monobasico,timolol,cloreto,dibasico,maleato,esteril,sodio,fosfato\thipertensao,olhos,latanoprosta,glaucoma,optico,timolol,pressao,maleato,nervo,redutora,aumentada\tsinusal,atrioventricular,coracao,cardiaco,insuficiencia,broncoespasmo,latanoprosta,disfuncao,cardiaca,ofegante,musculo,pulmonar,timolol,bradicardia,chiado,hipersensibilidade,asma,dificil,eletrica,alergia,fecham,cardiogenico,maleato\t: latanoprosta ................................................................................................................ ........................ 0,05mg maleato de timolol ....................................................................... .................................................... 6,83mg  \ttimolol,latanoprosta,maleato\n/home/altieris/datascience/data/bulario/bulas-txt/522/522-406812018-10420850.txt\t          latanoprosta + maleato de timolol germed farmaceutica ltda. solucao oftalmica  0,05mg/ml + 5mg/ml                          latanoprosta + maleato de timolol medicamento generico lei n 9.787, de 1999 i - identificacao do produto latanoprosta + maleato de timolol  apresentacao solucao oftalmica esteril em embalagem contendo 1 frasco gotejador de 2,5 ml.  via de administracao: uso oftalmico uso adulto  composicao cada ml da solucao oftalmica de latanoprosta e maleato de timolol contem: latanoprosta ................................................................................................................ ........................ 0,05mg maleato de timolol ............................................................................... ............................................ 6,83mg  veiculo qsp .............................................................................................................. ........................... 1 ml equivalente a 5,0mg de timolol. cloreto de sodio, fosfato de sodio monobasico, fosfato de sodio dibasico, cloreto de benzalconio, agua para injetaveis. uma gota da solucao contem aproximadamente 1,56 mcg de latanoprosta e 156 mcg de timolol. cada mililitro da solucao oftalmica de latanoprosta e maleato de timolol equivale aproximadamente a 32 gotas.   ii - informacoes ao paciente  \ta solucao oftalmica de latanoprosta e maleato de timolol e indicada no tratamento de glaucoma de angulo aberto (doenca cronica do olho em que a pressao dentro deste aumenta, o que pode levar a morte das fibras do nervo optico e reducao progressiva do campo de visao ate a perda total da visao) ou hipertensao ocular (condicoes em que a pressao dentro dos olhos esta aumentada, mas sem lesao do nervo optico) em pacientes que apresentam resposta insuficiente ao uso de colirio contendo uma unica medicacao redutora da pressao dentro dos olhos.  \ta solucao oftalmica de latanoprosta e maleato de timolol nao deve ser utilizada em pacientes que apresentam hipersensibilidade (alergia) a latanoprosta, maleato de timolol ou a qualquer componente do produto. a solucao oftalmica de latanoprosta e maleato de timolol nao deve ser utilizada em pacientes: (1) com historia de quadros de broncoespasmo (reacao onde os bronquios se fecham), incluindo asma (doenca respiratoria, onde a respiracao e dificil, curta, ofegante e com chiado) e doenca pulmonar obstrutiva cronica (dpoc) grave, (2) portadores de alteracoes do ritmo cardiaco, tais como bradicardia sinusal, sindrome do no sinusal, bloqueio sino-atrial (disfuncao eletrica do coracao), bloqueio atrioventricular de segundo ou terceiro grau nao controlado com marca-passo; (3) historia de alteracoes da funcao do musculo do coracao, tais como insuficiencia cardiaca congestiva e choque cardiogenico.  \tbenzalconio,latanoprosta,monobasico,timolol,cloreto,dibasico,maleato,esteril,sodio,fosfato\thipertensao,olhos,latanoprosta,glaucoma,optico,timolol,pressao,maleato,nervo,redutora,aumentada\tsinusal,atrioventricular,coracao,cardiaco,insuficiencia,broncoespasmo,latanoprosta,disfuncao,cardiaca,ofegante,musculo,pulmonar,timolol,bradicardia,chiado,hipersensibilidade,asma,dificil,eletrica,alergia,fecham,cardiogenico,maleato\t: latanoprosta ................................................................................................................ ........................ 0,05mg maleato de timolol ............................................................................... ............................................ 6,83mg  \ttimolol,latanoprosta,maleato\n/home/altieris/datascience/data/bulario/bulas-txt/522/522-7440622018-10704502.txt\tv.06_06/2018              latanoprosta + maleato de timolol geolab industria farmaceutica s/a solucao oftalmica esteril 50mcg/ml + 5mg/ml                                                  v.06_06/2018   modelo de bula para o paciente esta bula e continuamente atualizada. favor proceder a sua leitura antes de utilizar o medicamento.   latanoprosta + maleato de timolol  medicamento generico, lei n 9.787 de 1999   forma farmaceutica e apresentacao: solucao oftalmica esteril de 50mcg/ml + 5mg/ml: embalagem contendo 1 frasco gotejador com 2,5ml.  uso oftalmico uso adulto  composicao cada ml (34 gotas) da solucao oftalmica contem: latanoprosta..................................................................................................................................................................50mcg maleato de timolol......................................................................................................................................................6,8mg equivalente a 5mg de timolol. excipientes: polissorbato 80, fosfato de sodio monobasico monoidratado, fosfato de sodio dibasico, cloreto de sodio, cloreto de benzalconio e agua purificada.  \ta latanoprosta + maleato de timolol e indicada no tratamento de glaucoma de angulo aberto (doenca cronica do olho em que a pressao dentro deste aumenta, o que pode levar a morte das fibras do nervo optico e reducao progressiva do campo de visao ate a perda total da visao) ou hipertensao ocular (condicoes em que a pressao dentro dos olhos esta aumentada, mas sem lesao do nervo optico) em pacientes que apresentam resposta insuficiente ao uso de colirio contendo uma unica medicacao redutora da pressao dentro dos olhos.   \ta latanoprosta + maleato de timolol nao deve ser utilizada em pacientes que apresentam hipersensibilidade (alergia) a latanoprosta, maleato de timolol ou a qualquer componente do produto.   a latanoprosta + maleato de timolol nao deve ser utilizada em pacientes: (1) com historia de quadros de broncoespasmo (reacao onde os bronquios se fecham), incluindo asma (doenca respiratoria, onde a respiracao e dificil, curta, ofegante e com chiado) e doenca pulmonar obstrutiva cronica (dpoc) grave, (2) portadores de alteracoes do ritmo cardiaco, tais como bradicardia sinusal, sindrome do no sinusal, bloqueio sinoatrial (disfuncao eletrica do                             v.06_06/2018 coracao), bloqueio atrioventricular de segundo ou terceiro grau nao controlado com marcapasso; (3) historia de alteracoes da funcao do musculo do coracao, tais como insuficiencia cardiaca congestiva e choque cardiogenico.  \tbenzalconio,latanoprosta,monobasico,timolol,cloreto,polissorbato,dibasico,maleato,esteril,sodio,monoidratado,fosfato\thipertensao,olhos,latanoprosta,glaucoma,optico,timolol,pressao,maleato,nervo,redutora,aumentada\tsinusal,atrioventricular,coracao,cardiaco,insuficiencia,broncoespasmo,latanoprosta,disfuncao,cardiaca,ofegante,musculo,marcapasso,pulmonar,timolol,bradicardia,chiado,hipersensibilidade,asma,dificil,eletrica,alergia,fecham,sinoatrial,cardiogenico,maleato\t: latanoprosta..................................................................................................................................................................50mcg maleato de timolol......................................................................................................................................................6,8mg equivalente a 5mg de timolol. \ttimolol,latanoprosta,maleato\n/home/altieris/datascience/data/bulario/bulas-txt/522/522-399312018-10420822.txt\t         latonan latanoprosta + maleato de timolol ems s/a solucao oftalmica 50 mcg/ml + 5 mg/ml                            i - identificacao do produto latonan latanoprosta + maleato de timolol  medicamento similar equivalente ao medicamento de referencia  apresentacao solucao oftalmica esteril em embalagem contendo 1 frasco gotejador de 2,5 ml.  via de administracao: uso oftalmico uso adulto  composicao cada ml da solucao oftalmica de latonan contem 50 mcg de latanoprosta e maleato de timolol equivalente a 5,0 mg de timolol (cada 6,830 mg de maleato de timolol equivale a 5,00 mg de timolol base). excipientes: cloreto de benzalconio, cloreto de sodio, fosfato de sodio monobasico, fosfato de sodio dibasico, agua para injetaveis. uma gota da solucao contem aproximadamente 1,56 mcg de latanoprosta e 156 mcg de timolol. cada mililitro de latonan equivale aproximadamente a 32 gotas.  ii - informacoes ao paciente  \tlatonan (latanoprosta e maleato de timolol) e indicada no tratamento de glaucoma de angulo aberto (doenca cronica do olho em que a pressao dentro deste aumenta, o que pode levar a morte das fibras do nervo optico e reducao progressiva do campo de visao ate a perda total da visao) ou hipertensao ocular (condicoes em que a pressao dentro dos olhos esta aumentada, mas sem lesao do nervo optico) em pacientes que apresentam resposta insuficiente ao uso de colirio contendo uma unica medicacao redutora da pressao dentro dos olhos.  \tlatonan nao deve ser utilizada em pacientes que apresentam hipersensibilidade (alergia) a latanoprosta, maleato de timolol ou a qualquer componente do produto. latonan nao deve ser utilizada em pacientes: (1) com historia de quadros de broncoespasmo (reacao onde os bronquios se fecham), incluindo asma (doenca respiratoria, onde a respiracao e dificil, curta, ofegante e com chiado) e doenca pulmonar obstrutiva cronica (dpoc) grave, (2) portadores de alteracoes do ritmo cardiaco, tais como bradicardia sinusal, sindrome do no sinusal, bloqueio sino-atrial (disfuncao eletrica do coracao), bloqueio atrioventricular de segundo ou terceiro grau nao controlado com marca-passo; (3) historia de alteracoes da funcao do musculo do coracao, tais como insuficiencia cardiaca congestiva e choque cardiogenico.  \tbenzalconio,latanoprosta,monobasico,timolol,cloreto,dibasico,latonan,maleato,esteril,sodio,fosfato\thipertensao,olhos,latanoprosta,glaucoma,optico,timolol,latonan,maleato,pressao,nervo,redutora,aumentada\tsinusal,atrioventricular,coracao,cardiaco,insuficiencia,broncoespasmo,latanoprosta,disfuncao,cardiaca,ofegante,musculo,pulmonar,timolol,bradicardia,chiado,hipersensibilidade,asma,dificil,eletrica,alergia,fecham,latonan,cardiogenico,maleato\t 50 mcg de latanoprosta e maleato de timolol equivalente a 5,0 mg de timolol (cada 6,830 mg de maleato de timolol equivale a 5,00 mg de timolol base). \ttimolol,latanoprosta,maleato\n/home/altieris/datascience/data/bulario/bulas-txt/522/522-397492018-10420693.txt\t          latanoprosta + maleato de timolol legrand pharma industria farmaceutica ltda. solucao oftalmica  0,05mg/ml + 5mg/ml                          latanoprosta + maleato de timolol medicamento generico lei n 9.787, de 1999 i - identificacao do produto latanoprosta + maleato de timolol  apresentacao solucao oftalmica esteril em embalagem contendo 1 frasco gotejador de 2,5 ml.  via de administracao: uso oftalmico uso adulto  composicao cada ml da solucao oftalmica de latanoprosta e maleato de timolol contem: latanoprosta ................................................................................................................ ........................ 0,05mg maleato de timolol ........................................................................................................................... 6,83mg  veiculo qsp .............................................................................................................. ........................... 1 ml equivalente a 5,0mg de timolol. cloreto de sodio, fosfato de sodio monobasico, fosfato de sodio dibasico, cloreto de benzalconio, agua para injetaveis. uma gota da solucao contem aproximadamente 1,56 mcg de latanoprosta e 156 mcg de timolol. cada mililitro da solucao oftalmica de latanoprosta e maleato de timolol equivale aproximadamente a 32 gotas.   ii - informacoes ao paciente  \ta solucao oftalmica de latanoprosta e maleato de timolol e indicada no tratamento de glaucoma de angulo aberto (doenca cronica do olho em que a pressao dentro deste aumenta, o que pode levar a morte das fibras do nervo optico e reducao progressiva do campo de visao ate a perda total da visao) ou hipertensao ocular (condicoes em que a pressao dentro dos olhos esta aumentada, mas sem lesao do nervo optico) em pacientes que apresentam resposta insuficiente ao uso de colirio contendo uma unica medicacao redutora da pressao dentro dos olhos.  \ta solucao oftalmica de latanoprosta e maleato de timolol nao deve ser utilizada em pacientes que apresentam hipersensibilidade (alergia) a latanoprosta, maleato de timolol ou a qualquer componente do produto. a solucao oftalmica de latanoprosta e maleato de timolol nao deve ser utilizada em pacientes: (1) com historia de quadros de broncoespasmo (reacao onde os bronquios se fecham), incluindo asma (doenca respiratoria, onde a respiracao e dificil, curta, ofegante e com chiado) e doenca pulmonar obstrutiva cronica (dpoc) grave, (2) portadores de alteracoes do ritmo cardiaco, tais como bradicardia sinusal, sindrome do no sinusal, bloqueio sino-atrial (disfuncao eletrica do coracao), bloqueio atrioventricular de segundo ou terceiro grau nao controlado com marca-passo; (3) historia de alteracoes da funcao do musculo do coracao, tais como insuficiencia cardiaca congestiva e choque cardiogenico.  \tbenzalconio,latanoprosta,monobasico,timolol,cloreto,dibasico,maleato,esteril,sodio,fosfato\thipertensao,olhos,latanoprosta,glaucoma,optico,timolol,pressao,maleato,nervo,redutora,aumentada\tsinusal,atrioventricular,coracao,cardiaco,insuficiencia,broncoespasmo,latanoprosta,disfuncao,cardiaca,ofegante,musculo,pulmonar,timolol,bradicardia,chiado,hipersensibilidade,asma,dificil,eletrica,alergia,fecham,cardiogenico,maleato\t: latanoprosta ................................................................................................................ ........................ 0,05mg maleato de timolol ........................................................................................................................... 6,83mg  \ttimolol,latanoprosta,maleato\n/home/altieris/datascience/data/bulario/bulas-txt/551/551-23318282016-3917883.txt\tbula_losacoron_50mg                                                                           vitamedic 2016 -  xxxxxx  03/16a  anexo a  folha de rosto para a bula           losacoron  losartana potassica  vitamedic industria farmaceutica ltda.  comprimido revestido  50mg                          2 bula do paciente bula_losacoron_50mg                                                                           vitamedic 2016 -  xxxxxx  03/16a  i. identificacao do medicamento losacoron  losartana potassica  medicamento similar equivalente ao medicamento de referencia  apresentacoes comprimidos revestidos 50mg: embalagens contendo 30 e 495 comprimidos revestidos.  uso oral uso adulto   composicao cada comprimido revestido de 50mg contem: losartana potassica.........................................................................................................50mg excipiente q.s.p.........................................................................................................1 comprimido revestido (celulose microcristalina, amido, lactose, croscarmelose sodica, dioxido de silicio, estearato de magnesio, dioxido de titanio, hipromelose + macrogol e alcool etilico). evapora durante o processo.  ii. informacoes ao paciente   \to seu medico receitou losacoron para tratar a sua hipertensao (pressao alta) ou por voce ter uma doenca conhecida como insuficiencia cardiaca (enfraquecimento do coracao). em pacientes com pressao alta e hipertrofia ventricular esquerda, losacoron  reduziu o risco de derrame (acidente vascular cerebral) e de ataque cardiaco (infarto do miocardio) e ajudou esses pacientes a viverem mais (veja o item 4. o que devo saber antes de usar este medicamento?  uso em pacientes de raca negra com pressao alta e hipertrofia do ventriculo esquerdo).  o seu medico tambem pode ter receitado losacoron por voce ter diabetes tipo 2 e proteinuria; nesse caso, losacoron pode retardar a piora da doenca renal.  \tvoce nao deve tomar losacoron se: - for alergico a losartana ou a qualquer outro componente deste medicamento (veja o item composicao); - sua funcao hepatica estiver seriamente prejudicada; - voce estiver com mais de 3 meses de gestacao. o uso de losacoron tambem deve ser evitado no inicio da \tamido,losartana,etilico,potassica,silicio,dioxido,magnesio,macrogol,hipromelose,croscarmelose,losacoron,titanio,sodica,estearato,lactose\thipertensao,vascular,coracao,renal,cardiaco,insuficiencia,infarto,cardiaca,acidente,ventriculo,cerebral,ventricular,derrame,hipertrofia,ataque,alta,diabetes,pressao,proteinuria,losacoron,receitou\tlosartana,gestacao,seriamente,hepatica,losacoron\t: losartana potassica.........................................................................................................50mg \tlosartana,potassica\n/home/altieris/datascience/data/bulario/bulas-txt/551/551-10652932018-10844500.txt\tlosartana potassica_bula_paciente             losartana potassica prati-donaduzzi comprimido revestido 50 mg e 100 mg            losartana potassica_bula_paciente  1  identificacao do medicamento losartana potassica medicamento generico lei no 9.787, de 1999  apresentacoes comprimido revestido de 50 mg em embalagem com 15, 30, 60, 90, 120, 200, 280, 400 ou 500 comprimidos revestidos. comprimido revestido de 100 mg em embalagem com 15, 30, 100, 150, 200 ou 280 comprimidos revestidos.  uso oral uso adulto  composicao cada comprimido revestido de 50 mg contem: losartana potassica.........................................................................................50 mg excipiente q.s.p..............................................................................................1 comprimido revestido excipientes: amido, celulose microcristalina, lactose monoidratada, estearato de magnesio, copolimero de alcool polivinilico e macrogol, dioxido de titanio e macrogol.   cada comprimido revestido de 100 mg contem: losartana potassica......................................................................................100 mg excipiente q.s.p............................................................................................1 comprimido revestido excipientes: amido, celulose microcristalina, lactose monoidratada, estearato de magnesio, copolimero de alcool polivinilico e macrogol, dioxido de titanio e macrogol.  informacoes ao paciente \to seu medico receitou este medicamento para tratar a sua hipertensao (pressao alta) ou por voce ter uma doenca conhecida como insuficiencia cardiaca (enfraquecimento do coracao). em pacientes com pressao alta e hipertrofia ventricular esquerda, este medicamento reduziu o risco de derrame (acidente vascular cerebral) e de ataque cardiaco (infarto do miocardio) e ajudou esses pacientes a viverem mais (vide o que devo saber antes de usar este medicamento? - uso em pacientes de raca negra com pressao alta e hipertrofia do ventriculo esquerdo). o seu medico tambem pode ter receitado este medicamento por voce ter diabetes tipo 2 e proteinuria; nesse caso, este medicamento pode retardar a piora da doenca renal.  \tvoce nao deve tomar este medicamento se: - for alergico a losartana ou a qualquer outro componente deste medicamento (vide composicao ); - sua funcao hepatica estiver seriamente prejudicada; - voce estiver com mais de 3 meses de gestacao. o uso deste medicamento tambem deve ser evitado no inicio da gestacao (vide o que devo saber antes de usar este medicamento?  gravidez e amamentacao); - voce tiver diabetes ou insuficiencia renal e estiver tomando algum medicamento para reduzir a pressao arterial que contenha alisquireno.    losartana potassica_bula_paciente  3   \tamido,monoidratada,losartana,potassica,polivinilico,dioxido,magnesio,macrogol,copolimero,titanio,estearato,lactose\tdiabetes,hipertensao,derrame,vascular,infarto,pressao,proteinuria,coracao,cardiaca,hipertrofia,acidente,ventriculo,ataque,alta,renal,cardiaco,cerebral,receitou,ventricular,insuficiencia\tlosartana,gestacao,arterial,alisquireno,seriamente,pressao,renal,hepatica,diabetes,insuficiencia\t: losartana potassica.........................................................................................50 mg excipiente q.s.p..............................................................................................1 comprimido revestido \tlosartana,potassica\n/home/altieris/datascience/data/bulario/bulas-txt/551/551-24866352016-4018928.txt\t anexo a  folha de rosto para os rotulos           losartana potassica   vitamedic industria farmaceutica ltda.  comprimido revestido  50mg                               bula do paciente bula losartana potassica 50mg                                                          vitamedic 2016 -  xxxxxx  03/16a  i. identificacao do medicamento losartana potassica medicamento generico, lei no 9.787, de 1999  apresentacoes comprimidos revestidos 50mg: embalagens contendo 30 comprimidos revestidos.  uso oral uso adulto   composicao cada comprimido revestido de 50mg contem: losartana potassica.........................................................................................................50mg excipiente q.s.p.........................................................................................................1 comprimido revestido (celulose microcristalina, amido, lactose, croscarmelose sodica, dioxido de silicio, estearato de magnesio, dioxido de titanio, hipromelose + macrogol e alcool etilico). evapora durante o processo.  ii. informacoes ao paciente   \to seu medico receitou losartana potassica para tratar a sua hipertensao (pressao alta) ou por voce ter uma doenca conhecida como insuficiencia cardiaca (enfraquecimento do coracao). em pacientes com pressao alta e hipertrofia ventricular esquerda, losartana potassica reduziu o risco de derrame (acidente vascular cerebral) e de ataque cardiaco (infarto do miocardio) e ajudou esses pacientes a viverem mais (veja o item 4. o que devo saber antes de usar este medicamento?  uso em pacientes de raca negra com pressao alta e hipertrofia do ventriculo esquerdo).  o seu medico tambem pode ter receitado losartana potassica por voce ter diabetes tipo 2 e proteinuria; nesse caso, losartana potassica pode retardar a piora da doenca renal.  \tvoce nao deve tomar losartana potassica se: - for alergico a losartana ou a qualquer outro componente deste medicamento (veja o item composicao); bula do paciente bula losartana potassica 50mg                                                          vitamedic 2016 -  xxxxxx  03/16a  - sua funcao hepatica estiver seriamente prejudicada; - voce estiver com mais de 3 meses de gestacao. o uso de losartana potassica tambem deve ser evitado no \tamido,losartana,etilico,potassica,silicio,dioxido,magnesio,macrogol,hipromelose,croscarmelose,titanio,sodica,estearato,lactose\thipertensao,losartana,vascular,coracao,renal,cardiaco,insuficiencia,infarto,cardiaca,acidente,ventriculo,cerebral,ventricular,potassica,derrame,hipertrofia,ataque,alta,diabetes,pressao,proteinuria,receitou\tlosartana,potassica,gestacao,seriamente,hepatica\t: losartana potassica.........................................................................................................50mg \tlosartana,potassica\n/home/altieris/datascience/data/bulario/bulas-txt/551/551-7715722018-10714874.txt\t                                                                                                                                             losartana potassica 50 mg                   losartana potassica  comprimidos revestidos  50 mg                                                                                                                                           modelo de bula  paciente                                                                                                                                              losartana potassica 50 mg     i) identificacao do medicamento   losartana potassica  medicamento generico  lei no 9.787 de 1999.  forma farmaceutica e apresentacoes losartana potassica 50 mg: embalagens com 30, 60 ou 500 comprimidos revestidos  uso oral uso adulto                composicao cada comprimido revestido de losartana potassica de 50 mg contem: losartana potassica...................................................................................................................50 mg excipientes.........................................................................................................q.s.p. 1 comprimido  excipientes: celulose microcristalina, lactose, estearato de magnesio, amido (pre-gelatinizado), talco e componentes de opadry branco  hiprolose, hipromelose, dioxido de titanio e agua.  ii) informacoes ao paciente  \t o seu medico receitou losartana potassica para tratar a sua hipertensao (pressao alta) ou por voce ter uma doenca conhecida como insuficiencia cardiaca (enfraquecimento do coracao). em pacientes com pressao alta e hipertrofia ventricular esquerda, losartana potassica reduziu o risco de derrame (acidente vascular cerebral) e de ataque cardiaco (infarto do miocardio) e ajudou esses pacientes a viverem mais (veja o item 4. o que devo saber antes de usar este medicamento?  uso em pacientes de raca negra com pressao alta e hipertrofia do ventriculo esquerdo). o seu medico tambem pode ter receitado losartana potassica por voce ter diabetes tipo 2 e proteinuria; nesse caso, losartana potassica pode retardar a piora da doenca renal.  \tvoce nao deve tomar losartana potassica se:  - for alergico a losartana ou a qualquer outro componente deste medicamento (veja o item composicao);  - sua funcao hepatica estiver seriamente prejudicada;  - voce estiver com mais de 3 meses de gestacao. o uso de losartana potassica tambem deve ser evitado no inicio da \tamido,losartana,potassica,dioxido,magnesio,hiprolose,talco,opadry,hipromelose,titanio,estearato,lactose\thipertensao,losartana,vascular,coracao,renal,cardiaco,insuficiencia,infarto,cardiaca,acidente,ventriculo,cerebral,ventricular,potassica,derrame,hipertrofia,ataque,alta,diabetes,pressao,proteinuria,receitou\tlosartana,potassica,gestacao,seriamente,hepatica\t: losartana potassica...................................................................................................................50 mg \tlosartana,potassica\n/home/altieris/datascience/data/bulario/bulas-txt/551/551-6840202018-10673133.txt\t         losartana potassica        bula para paciente comprimido revestido 50 mg       losartana potassica_bula_vp_v4                                                  versao 04  esta versao altera a versao 03   losartana potassica medicamento generico lei no 9.787, de 1999.  comprimido revestido  forma farmaceutica e apresentacoes:  embalagens com 30 ou 60 comprimidos revestidos contendo 50 mg de losartana potassica.  uso oral  uso adulto   composicao: cada comprimido revestido contem: losartana potassica ............................................................................................................................................. 50 mg excipientes q.s.p. .................................................................................................................................  1 comprimido excipientes: lactose monoidratada, celulose microcristalina, amido, croscarmelose sodica, dioxido de silicio, estearato de magnesio, oleo vegetal hidrogenado, hipromelose, macrogol e dioxido de titanio.  informacoes ao paciente  \to seu medico receitou losartana potassica para tratar a sua hipertensao (pressao alta) ou por voce ter uma doenca conhecida como insuficiencia cardiaca (enfraquecimento do coracao). em pacientes com pressao alta e hipertrofia ventricular esquerda, losartana potassica reduziu o risco de derrame (acidente vascular cerebral) e de ataque cardiaco (infarto do miocardio) e ajudou esses pacientes a viverem mais (vide itens 4. o que devo saber antes de usar este medicamento? e uso em pacientes de raca negra com pressao alta e hipertrofia do ventriculo esquerdo). o seu medico tambem pode ter receitado losartana potassica por voce ter diabetes tipo 2 e proteinuria; nesse caso, losartana potassica pode retardar a piora da doenca renal.  \tvoce nao deve tomar losartana potassica se: - for alergico a losartana ou a outro componente deste medicamento (vide item composicao);  - sua funcao hepatica estiver seriamente prejudicada; - voce estiver com mais de 3 meses de gestacao. o uso de losartana potassica tambem deve ser evitado no inicio da \thidrogenado,amido,monoidratada,losartana,potassica,silicio,dioxido,magnesio,macrogol,vegetal,hipromelose,croscarmelose,oleo,titanio,sodica,estearato,lactose\thipertensao,losartana,vascular,coracao,renal,cardiaco,insuficiencia,infarto,cardiaca,acidente,ventriculo,cerebral,ventricular,potassica,derrame,hipertrofia,ataque,alta,diabetes,pressao,proteinuria,receitou\tlosartana,potassica,gestacao,seriamente,hepatica\t: losartana potassica ............................................................................................................................................. 50 mg \tlosartana,potassica\n/home/altieris/datascience/data/bulario/bulas-txt/551/551-23294642016-3916216.txt\t               losartana potassica   cristalia prod. quim. farm. ltda.   comprimido revestido 50 mg   bula para o paciente   i - identificacao do medicamento  losartana potassica medicamento generico lei no 9.787, de 1999.  apresentacoes embalagens contendo 30 comprimidos revestidos de losartana potassica 50 mg.  uso oral uso adulto   composicao cada comprimido revestido de 50 mg contem: losartana potassica ....................................................................................50 mg excipiente qsp .......................................................................................... 1 comprimido excipientes: celulose microcristalina, dioxido de silicio, lactose monoidratada, povidona, estearato de magnesio, crospovidona, hipromelose, dioxido de titaneo, polietilenoglicol 400, polissorbato 80, polietilenoglicol 6000. losartana potassica 50 mg contem potassio na seguinte quantidade: 4,24 mg (0,108 meq)   ii - informacoes ao paciente  \to seu medico receitou losartana potassica para tratar a sua hipertensao (pressao alta) ou por voce ter uma doenca conhecida como insuficiencia cardiaca (enfraquecimento do coracao). em pacientes com pressao alta e hipertrofia ventricular esquerda, losartana potassica reduziu o risco de derrame (acidente vascular cerebral) e de ataque cardiaco (infarto do miocardio) e ajudou esses pacientes a viverem mais (vide o que devo saber antes de usar este medicamento?  uso em pacientes de raca negra com pressao alta e hipertrofia do ventriculo esquerdo). o seu medico tambem pode ter receitado losartana potassica por voce ter diabetes tipo 2 e proteinuria; nesse caso, losartana potassica pode retardar a piora da doenca renal.  \tcontraindicacoes  voce nao deve tomar losartana potassica se: - for alergico a losartana ou a qualquer outro componente deste medicamento (veja o item composicao); - sua funcao hepatica estiver seriamente prejudicada; - voce estiver com mais de 3 meses de gestacao. o uso de losartana potassica tambem deve ser evitado no inicio \tlosartana,monoidratada,potassica,silicio,dioxido,magnesio,crospovidona,cristalia,titaneo,polietilenoglicol,polissorbato,potassio,hipromelose,povidona,estearato,lactose\thipertensao,losartana,vascular,coracao,renal,cardiaco,insuficiencia,infarto,cardiaca,acidente,ventriculo,cerebral,ventricular,potassica,derrame,hipertrofia,ataque,alta,diabetes,pressao,proteinuria,receitou\tlosartana,potassica,gestacao,seriamente,hepatica\t: losartana potassica ....................................................................................50 mg excipiente qsp .......................................................................................... 1 comprimido \tlosartana,potassica\n/home/altieris/datascience/data/bulario/bulas-txt/551/551-7691372018-10713796.txt\t     losartana potassica  merck s/a  comprimidos revestidos 50 mg    losartana potassica  medicamento generico lei no 9.787, de 1999   apresentacoes comprimidos revestidos de 50 mg em embalagens com 30 comprimidos.  uso oral uso adulto   composicao cada comprimido revestido contem:  losartana potassica .............................................................. 50 mg excipientes: celulose microcristalina, lactose, amido, estearato de magnesio, dioxido de silicio, hipromelose, dioxido de titanio, macrogol, polissorbato 80 e azul de indigotina 132 laca de aluminio.  cada comprimido de losartana potassica de 50 mg contem 4,24 mg (0,108 meq) de potassio.  informacoes ao paciente \to seu medico receitou losartana potassica para tratar a sua hipertensao (pressao alta) ou por voce ter uma doenca conhecida como insuficiencia cardiaca (enfraquecimento do coracao). em pacientes com pressao alta e hipertrofia ventricular esquerda, a losartana potassica reduziu o risco de derrame (acidente vascular cerebral) e de ataque cardiaco (infarto do miocardio) e ajudou esses pacientes a viverem mais (veja o item 4 o que devo saber antes de usar este medicamento? - uso em pacientes de raca negra com pressao alta e hipertrofia do ventriculo esquerdo).  o seu medico tambem pode ter receitado losartana potassica por voce ter diabetes tipo 2 e proteinuria; nesse caso, a losartana potassica pode retardar a piora da doenca renal.  \tvoce nao deve tomar losartana potassica se:  - for alergico a losartana ou a qualquer outro componente deste medicamento (veja o item composicao);  - sua funcao hepatica estiver seriamente prejudicada;  - voce estiver com mais de 3 meses de gestacao. o uso de losartana potassica tambem deve ser evitado no inicio da gestacao (veja o item 4. o que devo saber antes de usar este medicamento?  gravidez e amamentacao);  - voce tiver diabetes ou insuficiencia renal e estiver tomando algum medicamento para reduzir a pressao arterial que contenha alisquireno.  \tamido,losartana,potassica,silicio,dioxido,magnesio,indigotina,macrogol,polissorbato,aluminio,merck,hipromelose,potassio,titanio,estearato,lactose\thipertensao,losartana,vascular,coracao,renal,cardiaco,insuficiencia,infarto,cardiaca,acidente,ventriculo,cerebral,ventricular,potassica,derrame,hipertrofia,ataque,alta,diabetes,pressao,proteinuria,receitou\tlosartana,potassica,gestacao,arterial,alisquireno,seriamente,pressao,renal,hepatica,diabetes,insuficiencia\t:  losartana potassica .............................................................. 50 mg \tlosartana,potassica\n/home/altieris/datascience/data/bulario/bulas-txt/45/45-12669702018-10942197.txt\t         amlovasc  (besilato de anlodipino)  bula do paciente  sandoz do brasil ind. farm. ltda.  comprimidos  5 mg e 10 mg           amlovasc (besilato de anlodipino) 5 mg e 10 mg  comprimidos  vp10 i) identificacao do medicamento    amlovasc besilato de anlodipino  medicamento similar equivalente ao medicamento de referencia.  apresentacoes  amlovasc comprimido 5 mg. embalagem contendo 30 comprimidos. amlovasc comprimido 10 mg. embalagem contendo 30 comprimidos.  uso oral uso adulto   composicao cada comprimido de 5 mg contem: besilato de anlodipino  ............................................................................................................................ 6,936 mg (equivalente a 5 mg de anlodipino) excipientes q.s.p. ............................................................................................................................. 1 comprimido (amidoglicolato de sodio, fosfato de calcio dibasico, celulose microcristalina, estearato de magnesio)  cada comprimido de 10 mg contem: besilato de anlodipino  ........................................................................................................................... 13,872  mg (equivalente a 10 mg de anlodipino) excipientes q.s.p. ................................................................................................................................ 1 comprimido (amidoglicolato de sodio, fosfato de calcio dibasico, celulose microcristalina, estearato de magnesio)   ii) informacoes ao paciente  \t amlovasc e  indicado  como  medicamento   de  primeira  escolha  no  tratamento  da hipertensao (pressao alta) e angina de peito (dor no peito, por doenca do coracao) devido a isquemia miocardica (falta de sangue no coracao). amlovasc pode  ser usado  isoladamente  ou em combinacao  com outros medicamentos  para tratar  as mesmas indicacoes acima.  \t nao use amlovasc se voce tem hipersensibilidade  as diidropiridinas*  (classe de medicamentos  a que pertence o anlodipino, principio ativo do medicamento) ou a qualquer componente da formula. *o amlovasc e um bloqueador do canal de calcio diidropiridino.  \tamlovasc,calcio,magnesio,dibasico,anlodipino,estearato,besilato,sodio,amidoglicolato,fosfato\tmiocardica,hipertensao,pressao,coracao,angina,peito,alta,amlovasc\tcanal,calcio,anlodipino,hipersensibilidade,amlovasc,diidropiridino\t: besilato de anlodipino  ............................................................................................................................ 6,936 mg (equivalente a 5 mg de anlodipino) \tanlodipino,besilato\n/home/altieris/datascience/data/bulario/bulas-txt/31/31-7456452018-10706006.txt\t        aldactone  (espironolactona)  wyeth industria farmaceutica ltda. comprimidos 25 mg, 50,mg e 100 mg   ll-pld_bra_cdsv9.0_01jun2018_v1_adncom_12_vp  1 07/jun/2018 aldactone espironolactona   i - identificacao do medicamento nome comercial: aldactone nome generico: espironolactona  apresentacoes aldactone 25 mg ou 50 mg em embalagens contendo 30 comprimidos. aldactone 100 mg em embalagem contendo 16 comprimidos.  via de administracao: uso oral  uso adulto e pediatrico   composicao cada comprimido de aldactone 25 mg ou 50 mg contem o equivalente a 25 mg ou 50 mg de espironolactona, respectivamente. excipientes: dioxido de silicio coloidal, aroma hortela-pimenta, amido de milho, lactose monoidratada, celulose microcristalina, estearato de magnesio.  cada comprimido de aldactone 100 mg contem o equivalente a 100 mg de espironolactona. excipientes: sulfato de calcio diidratado, amido de milho, povidona, estearato de magnesio.   ll-pld_bra_cdsv9.0_01jun2018_v1_adncom_12_vp  2 07/jun/2018 ii - informacoes ao paciente  \taldactone (espironolactona) e indicado no tratamento da hipertensao essencial (aumento da pressao arterial sem causa determinada), disturbios edematosos (relacionados a inchaco), tais como: edema e ascite (acumulo de liquido dentro do abdome) relacionados a insuficiencia cardiaca congestiva (quando o coracao torna-se incapaz de bombear sangue em quantidade suficiente para suprir as necessidades do corpo), cirrose hepatica (perda importante de celulas do figado e comprometimento de suas funcoes) e sindrome nefrotica (doenca renal que leva a perda de proteina na urina), edema idiopatico (inchaco sem causa aparente); como terapia auxiliar na hipertensao maligna (tipo grave de pressao arterial elevada). aldactone e indicado na prevencao da hipopotassemia (diminuicao dos niveis sanguineos de potassio) e hipomagnesemia (diminuicao dos niveis sanguineos de magnesio) em pacientes tomando diureticos. aldactone e indicado para o diagnostico e tratamento do hiperaldosteronismo primario (aumento dos niveis sanguineos de aldosterona  hormonio renal  sem causa aparente) e tratamento pre-operatorio de pacientes com hiperaldosteronismo primario.  \taldactone e contraindicado a pacientes que apresentam hipersensibilidade a espironolactona ou a qualquer componente da formula; a pacientes com insuficiencia renal aguda (diminuicao aguda da funcao dos rins), diminuicao significativa da funcao renal, anuria (perda da capacidade de urinar), hiperpotassemia (aumento dos niveis sanguineos de potassio) ou doenca de addison, hipercalemia (aumento dos niveis sanguineos de potassio) ou com uso concomitante de eplerenona.  \tamido,monoidratada,espironolactona,calcio,silicio,coloidal,dioxido,magnesio,sulfato,diidratado,milho,aldactone,povidona,estearato,lactose\thipertensao,hipomagnesemia,incapaz,primario,comprometimento,hiperaldosteronismo,coracao,renal,aldosterona,insuficiencia,proteina,edema,auxiliar,cardiaca,cirrose,potassio,espironolactona,edematosos,magnesio,idiopatico,ascite,leva,arterial,aparente,pressao,aldactone,hipopotassemia,hepatica,abdome,nefrotica,suprir,elevada,figado\thipercalemia,espironolactona,eplerenona,significativa,renal,hipersensibilidade,anuria,urinar,aldactone,rins,potassio,addison,hiperpotassemia,insuficiencia\t o equivalente a 25 mg ou 50 mg de espironolactona, respectivamente. \tespironolactona\n/home/altieris/datascience/data/bulario/bulas-txt/31/31-15937892016-3350490.txt\t       aldactone   laboratorios pfizer ltda. comprimidos 25 mg, 50 mg e 100 mg       ll-pld_bra_cdsv8.0_12jun2014_v3_adncom_09_vp   01/mar/2016   aldactone espironolactona   i - identificacao do medicamento nome comercial: aldactone nome generico: espironolactona  apresentacoes aldactone 25 mg ou 50 mg em embalagens contendo 30 comprimidos. aldactone 100 mg em embalagem contendo 16 comprimidos.  via de administracao: uso oral  uso adulto e pediatrico   composicao: cada comprimido de aldactone 25 mg ou 50 mg contem o equivalente a 25 mg ou 50 mg de espironolactona, respectivamente. excipientes: dioxido de silicio coloidal, aroma hortela-pimenta, amido de milho, lactose monoidratada, celulose microcristalina, estearato de magnesio.  cada comprimido de aldactone 100 mg contem o equivalente a 100 mg de espironolactona. excipientes: sulfato de calcio diidratado, amido de milho, povidona, estearato de magnesio.      ll-pld_bra_cdsv8.0_12jun2014_v3_adncom_09_vp   01/mar/2016   ii - informacoes ao paciente  \taldactone (espironolactona) e indicado no tratamento da hipertensao essencial (aumento da pressao arterial sem causa determinada), disturbios edematosos (relacionados a inchaco), tais como: edema e ascite (acumulo de liquido dentro do abdome) relacionados a insuficiencia cardiaca congestiva (quando o coracao torna-se incapaz de bombear sangue em quantidade suficiente para suprir as necessidades do corpo), cirrose hepatica (perda importante de celulas do figado e comprometimento de suas funcoes) e sindrome nefrotica (doenca renal que leva a perda de proteina na urina), edema idiopatico (inchaco sem causa aparente); como terapia auxiliar na hipertensao maligna (tipo grave de pressao arterial elevada). aldactone e indicado na prevencao da hipopotassemia (diminuicao dos niveis sanguineos de potassio) e hipomagnesemia (diminuicao dos niveis sanguineos de magnesio) em pacientes tomando diureticos. aldactone e indicado para o diagnostico e tratamento do hiperaldosteronismo primario (aumento dos niveis sanguineos de aldosterona  hormonio renal  sem causa aparente) e tratamento pre-operatorio de pacientes com hiperaldosteronismo primario.  \taldactone e contraindicado a pacientes que apresentam hipersensibilidade a espironolactona ou a qualquer componente da formula; a pacientes com insuficiencia renal aguda (diminuicao aguda da funcao dos rins), diminuicao significativa da funcao renal, anuria (perda da capacidade de urinar), hiperpotassemia (aumento dos niveis sanguineos de potassio) ou doenca de addison, hipercalemia (aumento dos niveis sanguineos de potassio) ou com uso concomitante de eplerenona.  \tamido,monoidratada,espironolactona,calcio,silicio,coloidal,dioxido,magnesio,sulfato,diidratado,milho,aldactone,povidona,estearato,lactose\thipertensao,hipomagnesemia,incapaz,primario,comprometimento,hiperaldosteronismo,coracao,renal,aldosterona,insuficiencia,proteina,edema,auxiliar,cardiaca,cirrose,potassio,espironolactona,edematosos,magnesio,idiopatico,ascite,leva,arterial,aparente,pressao,aldactone,hipopotassemia,hepatica,abdome,nefrotica,suprir,elevada,figado\thipercalemia,espironolactona,eplerenona,significativa,renal,hipersensibilidade,anuria,urinar,aldactone,rins,potassio,addison,hiperpotassemia,insuficiencia\t o equivalente a 25 mg ou 50 mg de espironolactona, respectivamente. \tespironolactona\n/home/altieris/datascience/data/bulario/bulas-txt/31/31-6683352018-10668124.txt\t                             aldomet (metildopa)   aspen pharma industria farmaceutica ltda.   comprimidos revestidos   250mg 500mg          bula do paciente  aldomet_bu_pac_001 07.1.02.10  05  pagina 2 de 10 i - identificacao do medicamento  aldomet metildopa  apresentacoes aldomet 250 mg: embalagens contendo blisteres com 30 comprimidos revestidos. aldomet 500 mg: embalagens contendo blisteres com 30 comprimidos revestidos.  via oral uso adulto   composicao aldomet 250 mg cada comprimido revestido contem: metildopa-----------------------------------------------250 mg   aldomet 500 mg metildopa-----------------------------------------------500 mg   excipientes: etilcelulose, acido citrico, edetato dissodico de calcio, goma guar, dioxido de silicio, celulose microcristalina, estearato de magnesio, alcool etilico, agua purificada, cera de carnauba, opadry amarelo (hipromelose, dioxido de titanio, propilenoglicol, talco, amarelo quinolina laca de aluminio (corante amarelo d\u0026c no 10), oxido de ferro vermelho e acido citrico monoidratado).  ii - informacoes ao paciente  \taldomet (metildopa) e destinado para o tratamento da hipertensao (pressao alta).  informacoes ao paciente com pressao alta o que e pressao arterial? e a pressao gerada pelo seu coracao ao bombear o sangue para todas as partes do corpo; sem a pressao arterial, o sangue nao circula pelo corpo. uma pressao arterial normal e essencial para uma boa saude.   bula do paciente  aldomet_bu_pac_001 07.1.02.10  05  pagina 3 de 10 a pressao arterial sofre alteracoes durante o dia, dependendo da atividade, do estresse e da excitacao a que as pessoas estao expostas. a leitura da pressao arterial e composta de dois numeros, por exemplo, 120/80 (le-se: cento e vinte por oitenta). o numero mais alto representa a forca medida enquanto seu coracao esta bombeando sangue, enquanto o numero mais baixo representa a forca medida em repouso, entre os batimentos cardiacos.  o que e pressao alta (ou hipertensao)? uma pessoa tem pressao alta ou hipertensao quando sua pressao arterial e alta mesmo quando se esta calmo e relaxado. observa-se pressao alta quando os vasos sanguineos se estreitam e dificultam o fluxo do sangue pelo corpo.  como saber se tenho pressao alta (ou hipertensao)? em geral, a pressao alta nao causa sintomas. a unica maneira de saber se voce tem hipertensao e medindo sua pressao arterial; por isso, voce deve medir sua pressao arterial regularmente.  por que a pressao alta (ou hipertensao) deve ser tratada? se nao for tratada, a pressao alta pode causar danos a orgaos essenciais para a vida, tais como o coracao e os rins. voce pode estar se sentindo bem e nao apresentar sintomas, mas a hipertensao pode causar derrame (acidente vascular cerebral), ataque cardiaco (infarto do miocardio), insuficiencia cardiaca, insuficiencia renal ou perda da visao. seu medico pode lhe dizer qual a pressao arterial ideal para voce. memorize o valor estipulado por ele e siga suas recomendacoes para atingir a pressao arterial ideal para voce.  \tvoce nao deve tomar aldomet se: - for alergico a qualquer um de seus ingredientes (veja o item ingredientes ativo e inativos); - tiver doenca do figado, tais como hepatite aguda ou cirrose ativa; - estiver tomando medicamentos inibidores da monoaminoxidase (mao).   bula do paciente  aldomet_bu_pac_001 07.1.02.10  05  pagina 4 de 10 este medicamento e contraindicado para o uso em criancas.  procure seu medico se voce nao tem certeza se deve iniciar o tratamento com aldomet.  \td,silicio,aldomet,aluminio,edetato,citrico,titanio,propilenoglicol,metildopa,calcio,dioxido,talco,quinolina,monoidratado,aspen,acido,etilico,magnesio,ferro,carnauba,hipromelose,dissodico,cera,oxido,etilcelulose,estearato,opadry\testipulado,expostas,hipertensao,aldomet,vascular,coracao,renal,medir,cardiaco,relaxado,insuficiencia,metildopa,estreitam,infarto,dizer,acidente,cardiaca,oitenta,repouso,cerebral,derrame,ataque,alta,rins,ideal,danos,circula,orgaos,arterial,bombeando,pressao,excitacao,vinte,estresse,calmo\thepatite,aldomet,monoaminoxidase,cirrose,figado\t: metildopa-----------------------------------------------250 mg   aldomet 500 mg metildopa-----------------------------------------------500 mg   \taldomet,metildopa"
          },
          {
            "type": "HTML",
            "data": "\u003cdiv class\u003d\"result-alert alert-warning\" role\u003d\"alert\"\u003e\u003cbutton type\u003d\"button\" class\u003d\"close\" data-dismiss\u003d\"alert\" aria-label\u003d\"Close\"\u003e\u003cspan aria-hidden\u003d\"true\"\u003e\u0026times;\u003c/span\u003e\u003c/button\u003e\u003cstrong\u003eOutput is truncated\u003c/strong\u003e to 102400 bytes. Learn more about \u003cstrong\u003eZEPPELIN_INTERPRETER_OUTPUT_LIMIT\u003c/strong\u003e\u003c/div\u003e"
          }
        ]
      },
      "apps": [],
      "jobName": "paragraph_1549110528108_1150576025",
      "id": "20190202-102848_798724029",
      "dateCreated": "2019-02-02 10:28:48.108",
      "dateStarted": "2019-02-02 17:26:29.462",
      "dateFinished": "2019-02-02 17:26:31.167",
      "status": "FINISHED",
      "progressUpdateIntervalMs": 500
    },
    {
      "text": "%neo4j\nmatch(p:Patologia {nome:\u0027hipertensao\u0027})-[r:active_principle_indication]-(i:ItemPrincipioAtivo)-[r1:counter_indication_term_associated]-(p1:Patologia {nome:\u0027diabetes\u0027}) return distinct i.term as indicado_para,p.nome as tratamento_patologia,p1.nome as contra_indicado\n",
      "user": "anonymous",
      "dateUpdated": "2019-02-02 11:17:30.710",
      "config": {
        "colWidth": 12.0,
        "fontSize": 9.0,
        "enabled": true,
        "results": {
          "0": {
            "graph": {
              "mode": "table",
              "height": 300.0,
              "optionOpen": false,
              "setting": {
                "table": {
                  "tableGridState": {},
                  "tableColumnTypeState": {
                    "names": {
                      "indicado_para": "string",
                      "tratamento_patologia": "string",
                      "contra_indicado": "string"
                    },
                    "updated": false
                  },
                  "tableOptionSpecHash": "[{\"name\":\"useFilter\",\"valueType\":\"boolean\",\"defaultValue\":false,\"widget\":\"checkbox\",\"description\":\"Enable filter for columns\"},{\"name\":\"showPagination\",\"valueType\":\"boolean\",\"defaultValue\":false,\"widget\":\"checkbox\",\"description\":\"Enable pagination for better navigation\"},{\"name\":\"showAggregationFooter\",\"valueType\":\"boolean\",\"defaultValue\":false,\"widget\":\"checkbox\",\"description\":\"Enable a footer for displaying aggregated values\"}]",
                  "tableOptionValue": {
                    "useFilter": false,
                    "showPagination": false,
                    "showAggregationFooter": false
                  },
                  "updated": false,
                  "initialized": false
                }
              },
              "commonSetting": {}
            }
          }
        },
        "editorSetting": {
          "language": "scala",
          "editOnDblClick": false,
          "completionKey": "TAB",
          "completionSupport": true
        },
        "editorMode": "ace/mode/scala"
      },
      "settings": {
        "params": {},
        "forms": {}
      },
      "results": {
        "code": "SUCCESS",
        "msg": [
          {
            "type": "TABLE",
            "data": "indicado_para\ttratamento_patologia\tcontra_indicado\n\"arginina\"\t\"hipertensao\"\t\"diabetes\"\n\"hidroclorotiazida\"\t\"hipertensao\"\t\"diabetes\"\n\"lisinopril\"\t\"hipertensao\"\t\"diabetes\"\n\"indapamida\"\t\"hipertensao\"\t\"diabetes\"\n\"perindopril\"\t\"hipertensao\"\t\"diabetes\"\n\"micardis\"\t\"hipertensao\"\t\"diabetes\"\n\"telmisartana\"\t\"hipertensao\"\t\"diabetes\"\n\"irbesartana\"\t\"hipertensao\"\t\"diabetes\"\n\"aprozide\"\t\"hipertensao\"\t\"diabetes\"\n\"potassica\"\t\"hipertensao\"\t\"diabetes\"\n\"besilato\"\t\"hipertensao\"\t\"diabetes\"\n\"losartana\"\t\"hipertensao\"\t\"diabetes\"\n\"anlodipino\"\t\"hipertensao\"\t\"diabetes\"\n\"cilexetila\"\t\"hipertensao\"\t\"diabetes\"\n\"candesartana\"\t\"hipertensao\"\t\"diabetes\"\n\"maleato\"\t\"hipertensao\"\t\"diabetes\"\n\"enalapril\"\t\"hipertensao\"\t\"diabetes\"\n"
          }
        ]
      },
      "apps": [],
      "jobName": "paragraph_1549107652108_51317831",
      "id": "20190202-094052_2130659747",
      "dateCreated": "2019-02-02 09:40:52.108",
      "dateStarted": "2019-02-02 11:17:29.202",
      "dateFinished": "2019-02-02 11:17:29.220",
      "status": "FINISHED",
      "progressUpdateIntervalMs": 500
    },
    {
      "text": "%neo4j\nmatch(i:ItemPrincipioAtivo {term:\u0027perindopril\u0027})-[r:active_principle_linked_term]-(i1:ItemPrincipioAtivo) return distinct i.term,i.drugbank_id, i1.term, i1.drugbank_id",
      "user": "anonymous",
      "dateUpdated": "2019-02-02 11:30:16.996",
      "config": {
        "colWidth": 12.0,
        "fontSize": 9.0,
        "enabled": true,
        "results": {
          "0": {
            "graph": {
              "mode": "table",
              "height": 300.0,
              "optionOpen": false,
              "setting": {
                "table": {
                  "tableGridState": {},
                  "tableColumnTypeState": {
                    "names": {
                      "i.term": "string",
                      "i.drugbank_id": "string",
                      "i1.term": "string",
                      "i1.drugbank_id": "string"
                    },
                    "updated": false
                  },
                  "tableOptionSpecHash": "[{\"name\":\"useFilter\",\"valueType\":\"boolean\",\"defaultValue\":false,\"widget\":\"checkbox\",\"description\":\"Enable filter for columns\"},{\"name\":\"showPagination\",\"valueType\":\"boolean\",\"defaultValue\":false,\"widget\":\"checkbox\",\"description\":\"Enable pagination for better navigation\"},{\"name\":\"showAggregationFooter\",\"valueType\":\"boolean\",\"defaultValue\":false,\"widget\":\"checkbox\",\"description\":\"Enable a footer for displaying aggregated values\"}]",
                  "tableOptionValue": {
                    "useFilter": false,
                    "showPagination": false,
                    "showAggregationFooter": false
                  },
                  "updated": false,
                  "initialized": false
                }
              },
              "commonSetting": {}
            }
          }
        },
        "editorSetting": {
          "language": "scala",
          "editOnDblClick": false,
          "completionKey": "TAB",
          "completionSupport": true
        },
        "editorMode": "ace/mode/undefined"
      },
      "settings": {
        "params": {},
        "forms": {}
      },
      "results": {
        "code": "SUCCESS",
        "msg": [
          {
            "type": "TABLE",
            "data": "i.term\ti.drugbank_id\ti1.term\ti1.drugbank_id\n\"perindopril\"\t\"DB00790\"\t\"indapamida\"\t\"DB00808\"\n\"perindopril\"\t\"DB00790\"\t\"arginina\"\t\"\"\n"
          }
        ]
      },
      "apps": [],
      "jobName": "paragraph_1549109762537_-1214122336",
      "id": "20190202-101602_1920713781",
      "dateCreated": "2019-02-02 10:16:02.537",
      "dateStarted": "2019-02-02 11:30:16.569",
      "dateFinished": "2019-02-02 11:30:16.615",
      "status": "FINISHED",
      "progressUpdateIntervalMs": 500
    },
    {
      "text": "%python\n\nimport pandas as pd\n\nbulas_df \u003d pd.read_csv(\"/data/bulario/cleansed/bulas-tagged.csv\", sep\u003d\u0027;\u0027)\nz.show(bulas_df.head())",
      "user": "anonymous",
      "dateUpdated": "2019-02-17 08:56:26.385",
      "config": {
        "colWidth": 12.0,
        "fontSize": 9.0,
        "enabled": true,
        "results": {
          "0": {
            "graph": {
              "mode": "table",
              "height": 300.0,
              "optionOpen": false,
              "setting": {
                "table": {
                  "tableGridState": {},
                  "tableColumnTypeState": {
                    "names": {
                      "filename": "string",
                      "composicao": "string",
                      "indicacao": "string",
                      "contraindicacao": "string",
                      "composicao_keywords": "string",
                      "indicacao_keywords": "string",
                      "contraindicacao_keywords": "string",
                      "principio_ativo": "string",
                      "principio_ativo_keywords": "string"
                    },
                    "updated": false
                  },
                  "tableOptionSpecHash": "[{\"name\":\"useFilter\",\"valueType\":\"boolean\",\"defaultValue\":false,\"widget\":\"checkbox\",\"description\":\"Enable filter for columns\"},{\"name\":\"showPagination\",\"valueType\":\"boolean\",\"defaultValue\":false,\"widget\":\"checkbox\",\"description\":\"Enable pagination for better navigation\"},{\"name\":\"showAggregationFooter\",\"valueType\":\"boolean\",\"defaultValue\":false,\"widget\":\"checkbox\",\"description\":\"Enable a footer for displaying aggregated values\"}]",
                  "tableOptionValue": {
                    "useFilter": false,
                    "showPagination": false,
                    "showAggregationFooter": false
                  },
                  "updated": false,
                  "initialized": false
                }
              },
              "commonSetting": {}
            }
          }
        },
        "editorSetting": {
          "language": "python",
          "editOnDblClick": false,
          "completionKey": "TAB",
          "completionSupport": true
        },
        "editorMode": "ace/mode/python"
      },
      "settings": {
        "params": {},
        "forms": {}
      },
      "results": {
        "code": "SUCCESS",
        "msg": [
          {
            "type": "TABLE",
            "data": "filename\tcomposicao\tindicacao\tcontraindicacao\tcomposicao_keywords\tindicacao_keywords\tcontraindicacao_keywords\tprincipio_ativo\tprincipio_ativo_keywords\n/data/bulario/bulas-txt/179/179-3200592017-5138453.txt\tcetoprofeno medicamento generico, lei no 9.787, de 1999  cristalia prod. quim. farm. ltda.  solucao injetavel 50 mg/ml  modelo de bula para o paciente   cetoprofeno_bula paciente i - identificacao do medicamento  cetoprofeno  medicamento generico, lei no 9.787, de 1999   apresentacoes  embalagens contendo 6, 25 ou 48 ampolas de 2 ml de solucao injetavel de cetoprofeno 50 mg/ml.  uso intramuscular uso adulto  composicao  cada ml da solucao injetavel contem:  cetoprofeno........................................................................50 mg  veiculo qsp..........................................................................1 ml  excipientes: arginina, acido citrico, alcool benzilico, acido cloridrico, hidroxido de sodio e agua para injetaveis.   ii - informacoes ao paciente    \to cetoprofeno e um medicamento anti-inflamatorio, analgesico e antitermico, sendo indicado para o tratamento de inflamacoes e dores decorrentes de processos reumaticos (doencas que podem afetar musculos, articulacoes e esqueleto), traumatismos (lesao interna ou externa resultante de um agente externo) e de dores em geral.   \tcetoprofeno nao deve ser utilizado nos seguintes casos:   - pacientes com historico de reacoes de hipersensibilidade (alergia ou intolerancia) ao cetoprofeno, como crises asmaticas (doenca pulmonar caracterizada pela contracao das vias respiratorias ocasionando falta de ar) ou outros tipos de reacoes alergicas ao cetoprofeno, ao acido acetilsalicilico ou a outros anti-inflamatorios nao esteroidais -aines (como diclofenaco, ibuprofeno, indometacina, naproxeno). nestes pacientes foram relatados casos de reacoes anafilaticas severas (reacao alergica grave e imediata), raramente fatais (vide quais os males que este medicamento pode me causar?).   - pacientes que ja tiveram ou tem ulcera peptica/hemorragica (lesao localizada no estomago e/ou intestino).   - pacientes que ja tiveram sangramento ou perfuracao gastrintestinal (estomago e/ou intestino), relacionada ao uso de aines).   - paciente com hemorragia gastrintestinal, cerebrovascular ou qualquer outro sangramento ativo.   - hemostasia ou terapia anticoagulante em curso (contraindicacao relacionada com a via intramuscular).   - pacientes com insuficiencia severa (reducao acentuada da funcao do orgao) do coracao, do figado e/ou dos rins.   - mulheres no terceiro trimestre da gravidez.   cetoprofeno_bula paciente  este medicamento e contraindicado para uso por pacientes com insuficiencia do coracao, do figado e/ou dos rins severas, pacientes com historico de reacoes de hipersensibilidade ao cetoprofeno, ao acido acetilsalicilico ou a outros anti-inflamatorios nao esteroidais -aines e por pacientes que ja tiveram ou tem ulcera peptica/hemorragica.   este medicamento e contraindicado na faixa etaria pediatrica.   este medicamento nao deve ser utilizado por mulheres gravidas (3o trimestre gestacional) sem orientacao medica ou do cirurgiao-dentista. informe imediatamente seu medico ou cirurgiao-dentista em caso de suspeita de gravidez.   \tcontem,apresentacoes,cada,sodio,injetavel,quim,bula,hidroxido,modelo,generico,veiculo,arginina,paciente,farm,lei,prod,ii,alcool,injetaveis,embalagens,informacoes,benzilico,uso,composicao,ampolas,contendo,cloridrico,adulto,agua,cetoprofeno,mg,medicamento,ml,i,identificacao,qsp,cristalia,excipientes,citrico,intramuscular,ltda,acido,solucao\tdecorrentes,geral,agente,analgesico,podem,indicado,resultante,tratamento,reumaticos,dores,sendo,esqueleto,afetar,interna,doencas,processos,externa,articulacoes,cetoprofeno,externo,lesao,medicamento,musculos,inflamacoes,traumatismos,antitermico\tibuprofeno,ulcera,acetilsalicilico,pulmonar,aines,estomago,gravidez,intestino,diclofenaco,tipos,curso,paciente,hemorragia,faixa,esteroidais,intolerancia,imediatamente,lesao,seguintes,contracao,gestacional,outros,fatais,grave,vide,caso,severas,terapia,historico,acentuada,nestes,utilizado,anafilaticas,caracterizada,relacionada,etaria,perfuracao,ativo,uso,orgao,vias,pode,gravidas,ocasionando,falta,intramuscular,suspeita,acido,mulheres,cerebrovascular,anticoagulante,funcao,reacoes,causar,gastrintestinal,relatados,naproxeno,orientacao,males,trimestre,ser,indometacina,pacientes,localizada,imediata,cetoprofeno,deve,insuficiencia,qualquer,contraindicado,crises,doenca,figado,reducao,medico,casos,contraindicacao,alergicas,quais,ja,pediatrica,rins,hemostasia,hipersensibilidade,informe,medica,reacao,raramente,coracao,ar,respiratorias,nao,severa,asmaticas,alergica,outro,medicamento,sangramento,terceiro,alergia,via\t:  cetoprofeno........................................................................50 mg  veiculo qsp..........................................................................1 ml  \tml,veiculo,qsp,cetoprofeno,mg\n/data/bulario/bulas-txt/179/179-3814822017-5285132.txt\t    cetoprofeno  medley farmaceutica ltda.  capsula  50 mg       cetoprofeno medicamento generico, lei no 9.787, de 1999  apresentacao capsulas de 50 mg: embalagem com 24 capsulas.  uso oral  uso adulto   composicao cada capsula contem: cetoprofeno.......................................................................50 mg excipientes q.s.p...........................................................1 capsula (carbomer 934p, lactose monoidratada, estearato de magnesio, talco).  informacoes ao paciente   \to cetoprofeno e um medicamento anti-inflamatorio, analgesico e antitermico, sendo indicado para o tratamento de inflamacoes e dores decorrentes de processos reumaticos (doencas que podem afetar musculos, articulacoes e esqueleto), traumatismos (lesao interna ou externa resultante de um agente externo) e de dores em geral.  \to cetoprofeno capsulas nao deve ser utilizado nos seguintes casos: - pacientes com historico de reacoes de hipersensibilidade (alergia ou intolerancia) ao cetoprofeno, como crises asmaticas (doenca pulmonar caracterizada pela contracao das vias respiratorias ocasionando falta de ar) ou outros tipos de reacoes alergicas ao cetoprofeno, ao acido acetilsalicilico ou a outros anti-inflamatorios nao esteroidais - aines (ex: diclofenaco, ibuprofeno, indometacina, naproxeno). nestes pacientes foram relatados casos de reacoes anafilaticas severas (reacao alergica grave e imediata), raramente fatais (vide quais os males que este medicamento pode me causar?). - pacientes que ja tiveram ou tem ulcera peptica/hemorragica (lesao localizada no estomago e/ou intestino).       - pacientes que ja tiveram sangramento ou perfuracao gastrintestinal (estomago e/ou intestino), relacionada ao uso de aines.  - pacientes com insuficiencia severa (reducao acentuada da funcao do orgao) do coracao, do figado e/ou dos rins. - mulheres no terceiro trimestre da gravidez.  este medicamento e contraindicado para uso por pacientes com insuficiencia do coracao, do figado e/ou dos rins severas, pacientes com historico de reacoes de hipersensibilidade ao cetoprofeno, ao acido acetilsalicilico ou a outros anti-inflamatorios nao esteroidais - aines e por pacientes que ja tiveram ou tem ulcera peptica/hemorragica.  este medicamento e contraindicado na faixa etaria pediatrica.  este medicamento nao deve ser utilizado por mulheres gravidas (3 trimestre gestacional) sem orientacao medica. informe imediatamente seu medico em caso de suspeita de gravidez.   \tcontem,talco,cada,generico,lactose,embalagem,capsula,carbomer,paciente,capsulas,lei,informacoes,oral,uso,monoidratada,composicao,estearato,adulto,farmaceutica,cetoprofeno,mg,medicamento,magnesio,excipientes,apresentacao,medley,ltda\tdecorrentes,geral,agente,analgesico,podem,indicado,resultante,tratamento,reumaticos,dores,sendo,esqueleto,afetar,interna,doencas,processos,externa,articulacoes,cetoprofeno,externo,lesao,medicamento,musculos,inflamacoes,traumatismos,antitermico\tibuprofeno,ulcera,acetilsalicilico,pulmonar,aines,estomago,gravidez,intestino,diclofenaco,tipos,capsulas,esteroidais,intolerancia,imediatamente,lesao,seguintes,contracao,gestacional,outros,fatais,grave,vide,caso,severas,acentuada,historico,nestes,utilizado,anafilaticas,caracterizada,relacionada,etaria,perfuracao,uso,orgao,vias,pode,gravidas,ocasionando,falta,suspeita,acido,mulheres,funcao,reacoes,causar,gastrintestinal,relatados,naproxeno,orientacao,males,trimestre,ser,indometacina,pacientes,localizada,imediata,cetoprofeno,deve,insuficiencia,contraindicado,crises,doenca,figado,reducao,medico,casos,alergicas,quais,alergia,ja,pediatrica,rins,hipersensibilidade,informe,medica,reacao,raramente,coracao,ar,respiratorias,nao,severa,asmaticas,alergica,medicamento,sangramento,terceiro,ex,faixa\t: cetoprofeno.......................................................................50 mg \tcetoprofeno,mg\n/data/bulario/bulas-txt/179/179-10381032018-10830025.txt\t             cetoprofeno ems s/a  comprimido de liberacao prolongada 150mg               i  identificacao do medicamento cetoprofeno medicamento generico lei n 9.787, de 1999.  apresentacoes comprimido de liberacao prolongada de 150 mg. embalagem contendo 4, 10, 20, 30, 60, 100 e 200  comprimidos de liberacao prolongada. embalagem fracionavel  embalagem hospitalar  uso oral uso adulto  composicao cada comprimido de liberacao prolongada contem: cetoprofeno..........................................................................................................................................150 mg  excipientes qsp..........................................................................................................................1 com lib prol povidona, croscarmelose sodica, lactose monoidratada, amido pre-gelatinizado, dioxido de silicio, estearato de magnesio, oxido de ferro amarelo, hietelose e fosfato de calcio di-basico di-hidratado.  ii - informacoes ao paciente  \tcetoprofeno e um medicamento anti-inflamatorio, analgesico e antitermico, sendo indicado para o tratamento de inflamacoes e dores decorrentes dos seguintes casos: - processos otorrinolaringologicos: sinusites (inflamacao da mucosa nasal), otites (inflamacao do ouvido), faringites (inflamacao da faringe), laringites (inflamacao da laringe), amigdalites (inflamacao da garganta); - processos ginecologicos-obstetricos: anexites (processo inflamatorio que envolve o trato genital feminino), parametrites (inflamacao do parametrio  pelvico), endometrites (inflamacao do endometrio), dismenorreia (dor menstrual);  - processos urologicos: colica nefretica (dor lombar decorrente de obstrucao total ou parcial dos rins e ureteres), orquiepididimites (inflamacao do testiculo), prostatites (inflamacao da prostata); - processos odontologicos: periodontites (inflamacao e perda dos tecidos conjuntivos que envolvem e sustentam os dentes), pulpites (inflamacao da polpa dentaria), abscessos (acumulo de pus em tecidos, orgaos ou espacos circunscritos normalmente associado com sinais de infeccao), extracoes dentarias; - processos reumaticos: artrite reumatoide (inflamacao cronica das articulacoes), espondilite anquilosante (inflamacao de uma ou mais vertebras), gota (doenca reumatica caracterizada pelo acumulo de cristais de acido urico junto a articulacoes e/ou em outros orgaos), condrocalcinose (deposito de sais de calcio nas articulacoes), reumatismo psoriatico (tipo de artrite associada a alteracao da pele), sindrome de reiter (um tipo de artrite), pseudo-artrite, lupus eritematoso sistemico (doenca que apresenta manifestacoes na pele, coracao, rins, articulacoes, entre outras), esclerodermia (doenca auto-imune que pode ter varias manifestacoes, entre elas o endurecimento da pele), periarterite nodosa (tipo de inflamacao que ocorre nas arterias), osteoartrite (doenca articular degenerativa e progressiva), periartrite escapulo-umeral (inflamacao de tecidos ao redor da articulacao do ombro), bursites (inflamacao da bursa, pequena bolsa contendo liquido que envolve as articulacoes), capsulite adesiva (inflamacao caracterizada por perda de movimentos do ombro), sinovites (inflamacao da membrana que envolve as articulacoes), tenossinovites (inflamacao da bainha de um tendao), tendinites (inflamacao dos tendoes), epicondilites (doenca resultante de um esforco nao usual do braco); - lesoes ortopedicas: contusoes e esmagamentos (lesao causada por trauma direto ou pressao), fraturas, entorses (lesao de ligamento e musculo, sem deslocamento ou fratura), luxacoes (deslocamento de qualquer parte do corpo, normalmente uma articulacao, de sua posicao normal); - dores diversas: nevralgia cervico-braquial (dor associada a lesao de nervos da regiao do pescoco a axila), cervicalgia (dor na regiao do pescoco), lombalgia (dor na regiao lombar), dor ciatica (dor causada pela compressao do nervo ciatico), pos-operatorios diversos, enxaqueca (dor de cabeca intensa) com ou sem aura (sintomas que precedem a enxaqueca e que variam consideravelmente entre os pacientes afetando principalmente, a visao e a audicao).  \tcetoprofeno nao deve ser utilizado nos seguintes casos: - pacientes com historico de reacoes de hipersensibilidade (alergia ou intolerancia) ao cetoprofeno, como crises asmaticas (doenca pulmonar caracterizada pela contracao das vias respiratorias ocasionando falta de ar) ou outros tipos de reacoes alergicas ao cetoprofeno, ao acido acetilsalicilico ou a outros anti-inflamatorios nao esteroidais - aines (ex: diclofenaco, ibuprofeno, indometacina, naproxeno). nestes pacientes foram relatados casos de reacoes anafilaticas severas (reacao alergica grave e imediata), raramente fatais (vide quais os males que este medicamento pode me causar?). - pacientes que ja tiveram ou tem ulcera peptica/ hemorragica (lesao localizada no estomago e/ou intestino). - pacientes que ja tiveram sangramento ou perfuracao gastrintestinal (estomago ou intestino), relacionada ao uso de aines. - pacientes com insuficiencia severa (reducao acentuada da funcao do orgao) do coracao, do figado e dos rins. - mulheres no terceiro trimestre da gravidez.  este medicamento e contraindicado para uso por pacientes com insuficiencia do coracao, do figado ou dos rins severas, pacientes com historico de reacoes de hipersensibilidade ao cetoprofeno, ao acido acetilsalicilico ou a outros anti-inflamatorios nao esteroidais - aines e por pacientes que ja tiveram ou tem ulcera peptica/hemorragica.  este medicamento e contraindicado na faixa etaria pediatrica.  este medicamento nao deve ser utilizado por mulheres gravidas (3 trimestre gestacional) sem orientacao medica ou do cirurgiao-dentista. informe imediatamente seu medico ou cirurgiao-dentista em caso de suspeita de gravidez  \tcontem,apresentacoes,hospitalar,cada,silicio,comprimido,povidona,croscarmelose,generico,ferro,oxido,lactose,embalagem,sodica,n,paciente,hietelose,lei,ii,calcio,informacoes,oral,ems,lib,uso,monoidratada,composicao,estearato,contendo,adulto,cetoprofeno,mg,fosfato,medicamento,amido,i,identificacao,fracionavel,comprimidos,amarelo,qsp,prolongada,prol,dioxido,magnesio,excipientes,liberacao\tdecorrentes,deslocamento,pressao,visao,pelvico,dismenorreia,ter,principalmente,bursa,precedem,sinusites,sais,resultante,polpa,sindrome,sintomas,variam,genital,pele,reiter,fratura,calcio,ciatico,trato,arterias,esclerodermia,luxacoes,pescoco,processos,inflamacao,tendao,esforco,ligamento,otorrinolaringologicos,lesao,seguintes,dentaria,regiao,pus,outros,sistemico,reumatica,articular,feminino,ureteres,prostatites,tendinites,reumatoide,ouvido,lupus,osteoartrite,ortopedicas,corpo,nasal,tendoes,fraturas,nervo,garganta,audicao,bolsa,analgesico,outras,sustentam,pequena,indicado,mucosa,enxaqueca,varias,nervos,testiculo,artrite,posicao,sinovites,reumaticos,caracterizada,capsulite,ciatica,membrana,dor,total,envolvem,processo,alteracao,cristais,dentes,endurecimento,degenerativa,articulacoes,pode,faringe,gota,lombar,reumatismo,ocorre,parcial,obstrucao,inflamacoes,espondilite,condrocalcinose,epicondilites,inflamatorio,adesiva,acido,nefretica,parametrites,laringe,associada,anexites,apresenta,ombro,causada,anquilosante,acumulo,tenossinovites,progressiva,endometrites,circunscritos,axila,cabeca,endometrio,nevralgia,extracoes,cervicalgia,bainha,intensa,orgaos,movimentos,odontologicos,diversos,normal,pulpites,sinais,contendo,pacientes,cronica,cetoprofeno,bursites,qualquer,braco,infeccao,doenca,diversas,laringites,associado,prostata,orquiepididimites,deposito,periartrite,usual,casos,vertebras,redor,periodontites,dentarias,entorses,manifestacoes,periarterite,decorrente,tipo,tecidos,lesoes,musculo,compressao,rins,urico,tratamento,otites,direto,dores,trauma,espacos,sendo,normalmente,coracao,lombalgia,faringites,liquido,nao,abscessos,conjuntivos,menstrual,perda,esmagamentos,aura,medicamento,psoriatico,nodosa,colica,eritematoso,parte,urologicos,amigdalites,articulacao,consideravelmente,afetando,envolve,contusoes,junto,antitermico,parametrio\tibuprofeno,ulcera,acetilsalicilico,pulmonar,aines,estomago,gravidez,intestino,diclofenaco,tipos,esteroidais,intolerancia,imediatamente,lesao,seguintes,contracao,gestacional,outros,fatais,grave,vide,caso,severas,acentuada,historico,nestes,utilizado,anafilaticas,caracterizada,relacionada,etaria,perfuracao,uso,orgao,vias,pode,gravidas,ocasionando,falta,suspeita,acido,mulheres,funcao,reacoes,causar,gastrintestinal,relatados,naproxeno,orientacao,males,trimestre,ser,indometacina,pacientes,localizada,imediata,cetoprofeno,deve,insuficiencia,contraindicado,crises,doenca,figado,reducao,medico,casos,alergicas,quais,alergia,ja,pediatrica,rins,hipersensibilidade,informe,medica,reacao,raramente,hemorragica,coracao,ar,respiratorias,nao,severa,asmaticas,alergica,medicamento,sangramento,terceiro,ex,faixa\t: cetoprofeno..........................................................................................................................................150 mg  \tcetoprofeno,mg\n/data/bulario/bulas-txt/179/179-6266992018-10648841.txt\t1            cetoprofeno    hipolabor farmaceutica ltda  solucao injetavel  50mg/ml            2 cetoprofeno medicamento generico lei n 9.787, de 1999 nome generico: cetoprofeno forma farmaceutica: solucao injetavel apresentacoes: 50mg/ml - caixa contendo 50 ampolas ambar x 2ml 50mg/ml - caixa contendo 100 ampolas ambar x 2ml uso adulto  uso i.m. composicao cada ml de solucao injetavel contem: cetoprofeno.................................................................................................................................................................... ...........50mg veiculo q.s.p ..............................................................................................................................................................................1ml (alcool benzilico, arginina, hidroxido de sodio, acido citrico anidro, agua de osmose reversa) informacoes ao paciente  \to cetoprofeno solucao injetavel e um medicamento anti-inflamatorio, analgesico e antitermico, sendo indicado para o tratamento de inflamacoes e dores decorrentes de processos reumaticos (doencas que podem afetar musculos, articulacoes e esqueleto), traumatismos (lesao interna ou externa resultante de um agente externo) e de dores em geral.\to cetoprofeno solucao injetavel nao deve ser utilizado nos seguintes casos: - pacientes com historico de reacoes de hipersensibilidade (alergia ou intolerancia) ao cetoprofeno, como crises asmaticas(doenca pulmonar caracterizada pela contracao das vias respiratorias ocasionando falta de ar) ou outros tipos de reacoesalergicas ao cetoprofeno, ao acido acetilsalicilico ou a outros anti-inflamatorios nao esteroidais - aines (como diclofenaco,ibuprofeno, indometacina, naproxeno). nestes pacientes foram relatados casos de reacoes anafilaticas severas (reacao alergicagrave e imediata), raramente fatais (vide quais os males que este medicamento pode me causar?).- pacientes que ja tiveram ou tem ulcera peptica/hemorragica (lesao localizada no estomago e/ou intestino).- pacientes que ja tiveram sangramento ou perfuracao gastrintestinal (estomago e/ou intestino), relacionada ao uso de aines).- paciente com hemorragia gastrintestinal, cerebro-vascular ou qualquer outro sangramento ativo.- hemostasia ou terapia anticoagulante em curso (contraindicacao relacionada com a via intramuscular).- pacientes com insuficiencia severa (reducao acentuada da funcao do orgao) do coracao, do figado e/ou dos rins.- mulheres no terceiro trimestre da gravidez.este medicamento e contraindicado para uso por pacientes com insuficiencia do coracao, do figado e/ou dos rinsseveras, pacientes com historico de reacoes de hipersensibilidade ao cetoprofeno, ao acido acetilsalicilico ou a outrosanti-inflamatorios nao esteroidais - aines e por pacientes que ja tiveram ou tem ulcera peptica/hemorragica.este medicamento e contraindicado na faixa etaria pediatrica.este medicamento nao deve ser utilizado por mulheres gravidas (3o trimestre gestacional) sem orientacao medica ou docirurgiao-dentista. informe imediatamente seu medico ou cirurgiao-dentista em caso de suspeita de gravidez.\tcontem,apresentacoes,cada,sodio,injetavel,anidro,hipolabor,hidroxido,generico,veiculo,osmose,nome,arginina,n,paciente,lei,reversa,alcool,informacoes,benzilico,ambar,uso,caixa,composicao,ampolas,contendo,agua,adulto,farmaceutica,cetoprofeno,medicamento,ml,x,forma,citrico,ltda,acido,solucao\tdecorrentes,geral,agente,injetavel,analgesico,podem,indicado,resultante,tratamento,reumaticos,dores,sendo,esqueleto,afetar,interna,doencas,processos,externa,articulacoes,cetoprofeno,externo,lesao,medicamento,musculos,inflamacoes,traumatismos,antitermico,solucao\tibuprofeno,ulcera,acetilsalicilico,pulmonar,aines,estomago,gravidez,intestino,diclofenaco,tipos,curso,paciente,hemorragia,faixa,esteroidais,intolerancia,imediatamente,lesao,seguintes,contracao,gestacional,outros,fatais,vide,caso,severas,terapia,historico,acentuada,nestes,utilizado,reacoesalergicas,anafilaticas,caracterizada,relacionada,etaria,perfuracao,uso,orgao,vias,pode,gravidas,ocasionando,falta,intramuscular,suspeita,acido,solucao,rinsseveras,mulheres,anticoagulante,funcao,reacoes,causar,gastrintestinal,relatados,naproxeno,orientacao,males,trimestre,ser,alergicagrave,indometacina,pacientes,localizada,imediata,cetoprofeno,deve,insuficiencia,qualquer,contraindicado,crises,doenca,figado,reducao,medico,casos,contraindicacao,injetavel,quais,ja,hemostasia,hipersensibilidade,informe,medica,reacao,raramente,coracao,ar,respiratorias,nao,severa,asmaticas,outro,medicamento,sangramento,terceiro,alergia,via\t: cetoprofeno.................................................................................................................................................................... ...........50mg \tcetoprofeno\n/data/bulario/bulas-txt/179/179-7350312014-2192394.txt\t               cetop airela industria farmaceutica ltda xampu 20 mg/g        cetop cetoconazol  apresentacoes cartucho contendo frasco de plastico com 100 ml.  uso topico uso adulto  composicao cada 1 g do xampu contem: cetoconazol...........................................................................................................................20 mg excipientes q.s.p.........................................................................................................................1 g (metilparabeno, propilparabeno, edetato dissodico, butilidroxitolueno, acido cloridrico, dietanolamina de acido graxo de coco, cocoamidopropilbetaina, hidroxido de sodio, laurilpoliglucosideo, lauriletersulfato de sodio, fragrancia herba mar plus, corante rosa brilhante e agua purificada).  informacoes ao paciente  \to cetop xampu e indicado para tratamento da dermatite seborreica (seborreia) do couro cabeludo em adultos.  \to cetop xampu e contraindicado para pacientes com hipersensibilidade (alergia) conhecida a qualquer componente da formulacao. os sintomas de maior sensibilidade sao a coceira e a vermelhidao da pele apos o uso do medicamento.  \tcontem,apresentacoes,rosa,purificada,cada,sodio,fragrancia,lauriletersulfato,topico,herba,hidroxido,plus,brilhante,airela,coco,xampu,graxo,dietanolamina,mar,paciente,metilparabeno,cocoamidopropilbetaina,g,laurilpoliglucosideo,edetato,informacoes,dissodico,cartucho,uso,composicao,cetop,propilparabeno,contendo,cloridrico,adulto,agua,farmaceutica,mg,cetoconazol,plastico,ml,frasco,industria,butilidroxitolueno,excipientes,ltda,acido,corante\tadultos,xampu,dermatite,seborreia,couro,cabeludo,cetop,tratamento,seborreica,indicado\tcoceira,vermelhidao,maior,formulacao,sao,xampu,apos,sintomas,hipersensibilidade,pele,conhecida,uso,sensibilidade,cetop,pacientes,medicamento,qualquer,contraindicado,componente,alergia\t: cetoconazol...........................................................................................................................20 mg \tmg,cetoconazol\n"
          }
        ]
      },
      "apps": [],
      "jobName": "paragraph_1549110053508_774290735",
      "id": "20190202-102053_1442547649",
      "dateCreated": "2019-02-02 10:20:53.508",
      "dateStarted": "2019-02-17 08:56:26.423",
      "dateFinished": "2019-02-17 08:56:26.898",
      "status": "FINISHED",
      "progressUpdateIntervalMs": 500
    },
    {
      "text": "%python\ndisease_df \u003d bulas_df[(bulas_df[\u0027indicacao_keywords\u0027].str.contains(\u0027diabetes\u0027) \u003d\u003d True) \u0026 (bulas_df[\u0027contraindicacao_keywords\u0027].str.contains(\u0027diabetes\u0027) \u003d\u003d False)]\nz.show(disease_df.head())",
      "user": "anonymous",
      "dateUpdated": "2019-02-17 08:56:19.564",
      "config": {
        "colWidth": 12.0,
        "fontSize": 9.0,
        "enabled": true,
        "results": {},
        "editorSetting": {
          "language": "python",
          "editOnDblClick": false,
          "completionKey": "TAB",
          "completionSupport": true
        },
        "editorMode": "ace/mode/python"
      },
      "settings": {
        "params": {},
        "forms": {}
      },
      "results": {
        "code": "ERROR",
        "msg": [
          {
            "type": "TEXT",
            "data": "Traceback (most recent call last):\n  File \"/tmp/zeppelin_python-3932238126661643528.py\", line 307, in \u003cmodule\u003e\n    exec(code, _zcUserQueryNameSpace)\n  File \"\u003cstdin\u003e\", line 1, in \u003cmodule\u003e\n  File \"/home/altieris/tools/anaconda3/lib/python3.7/site-packages/pandas/core/generic.py\", line 4372, in __getattr__\n    return object.__getattribute__(self, name)\n  File \"/home/altieris/tools/anaconda3/lib/python3.7/site-packages/pandas/core/accessor.py\", line 133, in __get__\n    accessor_obj \u003d self._accessor(obj)\n  File \"/home/altieris/tools/anaconda3/lib/python3.7/site-packages/pandas/core/strings.py\", line 1895, in __init__\n    self._validate(data)\n  File \"/home/altieris/tools/anaconda3/lib/python3.7/site-packages/pandas/core/strings.py\", line 1917, in _validate\n    raise AttributeError(\"Can only use .str accessor with string \"\nAttributeError: Can only use .str accessor with string values, which use np.object_ dtype in pandas\n\nDuring handling of the above exception, another exception occurred:\n\nTraceback (most recent call last):\n  File \"/tmp/zeppelin_python-3932238126661643528.py\", line 319, in \u003cmodule\u003e\n    raise Exception(traceback.format_exc())\nException: Traceback (most recent call last):\n  File \"/tmp/zeppelin_python-3932238126661643528.py\", line 307, in \u003cmodule\u003e\n    exec(code, _zcUserQueryNameSpace)\n  File \"\u003cstdin\u003e\", line 1, in \u003cmodule\u003e\n  File \"/home/altieris/tools/anaconda3/lib/python3.7/site-packages/pandas/core/generic.py\", line 4372, in __getattr__\n    return object.__getattribute__(self, name)\n  File \"/home/altieris/tools/anaconda3/lib/python3.7/site-packages/pandas/core/accessor.py\", line 133, in __get__\n    accessor_obj \u003d self._accessor(obj)\n  File \"/home/altieris/tools/anaconda3/lib/python3.7/site-packages/pandas/core/strings.py\", line 1895, in __init__\n    self._validate(data)\n  File \"/home/altieris/tools/anaconda3/lib/python3.7/site-packages/pandas/core/strings.py\", line 1917, in _validate\n    raise AttributeError(\"Can only use .str accessor with string \"\nAttributeError: Can only use .str accessor with string values, which use np.object_ dtype in pandas\n\n"
          }
        ]
      },
      "apps": [],
      "jobName": "paragraph_1550403836987_-1913287531",
      "id": "20190217-084356_270446629",
      "dateCreated": "2019-02-17 08:43:56.987",
      "dateStarted": "2019-02-17 08:56:19.620",
      "dateFinished": "2019-02-17 08:56:19.632",
      "status": "ERROR",
      "progressUpdateIntervalMs": 500
    },
    {
      "text": "%python\n",
      "user": "anonymous",
      "dateUpdated": "2019-02-17 08:56:19.566",
      "config": {},
      "settings": {
        "params": {},
        "forms": {}
      },
      "apps": [],
      "jobName": "paragraph_1550404579564_1864723832",
      "id": "20190217-085619_1023603176",
      "dateCreated": "2019-02-17 08:56:19.564",
      "status": "READY",
      "progressUpdateIntervalMs": 500
    }
  ],
  "name": "DATAMINING/VII - NEO4J",
  "id": "2E3CZ695B",
  "noteParams": {},
  "noteForms": {},
  "angularObjects": {
    "python:shared_process": [],
    "neo4j:shared_process": [],
    "sh:shared_process": [],
    "spark:shared_process": []
  },
  "config": {
    "isZeppelinNotebookCronEnable": false
  },
  "info": {}
}